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ABSTRACT 
Damages to the genetic materials arise throughout the lifespan of a cell, and elicit 
upregulation of DNA repair factors. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is part of 
a DNA repair protein complex that specialises in the repair of DNA base modifications 
and single-strand breaks (SSBs). TDP1 removes a broad spectrum of chemical 
adducts from the 3’ end of a DNA strand break, including topoisomerase 1 (TOP1) 
peptide, during DNA transcription and replication. Inactivation or deletion of TDP1 is 
associated with cerebellar dysfunction and degeneration, with remarkably little extra-
neurological manifestation. The reason for the selective dependence of the cerebellar 
neurons on TDP1 activity is not clear. It was hypothesised that the TDP1 activity is 
upregulated in tissues with high levels of SSBs, either from DNA transcriptional activity, 
or reactive oxygen species (ROS)-induced damage.  
The aim of this doctoral project was therefore to identify and characterise the cellular 
mechanisms that regulate TDP1 activity. Our lab has previously shown that the N-
terminus domain (NTD) of TDP1 covalently interacts with DNA ligase 3α. In this thesis, 
evidence has been presented to show that this interaction is regulated by the putative 
ATM/ATR/DNA-PK phosphorylation site, serine 81, to prolong TDP1 half-life, and 
enhance cellular survival after genotoxic stress. A second post-translational 
modification in the NTD by SUMOylation of the K111 residue was identified, 
enlightening a mechanism by which TDP1 is recruited to sites of transcription-mediated 
SSBs.  
To investigate the requirement for TDP1 in cells under high levels of oxidative stress, I 
have developed a mouse cellular model whereby the levels of endogenous ROS can 
be modulated by overexpression of the human anti-oxidant enzyme superoxide 
dismutase 1 (SOD1) or its toxic mutant SOD1G93A. Overexpression of SOD1G93A in 
Tdp1-/- MEFs induces accumulation of chromosomal SSBs and decreases survival after 
H2O2 challenge, while overexpression of SOD1 has a protective effect. Besides repair 
of ROS-induced TOP1-cc in the nucleus, TDP1 also repairs mitochondrial 
topoisomerase 1-mediated DNA breaks. This role is required during transcription and 
assembly of mitochondrial subunits of the electron transfer chain complexes, and has 
direct impact on mitochondrial respiration and ROS production. Collectively, these data 
provide mechanistic insights into regulation of TDP1-mediated chromosomal and 
mitochondrial DNA repair. 
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1.1 Genome stability 
Inside each living cell, the genetic material is constantly being altered everyday 
(Lindahl, 1993), either by programmed biological processes, or by environmental 
stimuli. Programmed biological processes that introduce genetic alterations include 
DNA transcription and replication, mitosis and meiosis. The intracellular environment 
can generate molecules that lead to spontaneous DNA damage, such as reactive 
oxygen and nitrogen species. Environmental stimuli originate from outside the 
organism, such as UV radiation, chemical compounds with high-energy state or high 
nucleic acid binding affinity, and reprogramming by viral species.  
The process of permanent alteration of genetic material is a driving force of biological 
evolution. However, in multicellular organisms, particularly those with highly specialised 
organ-systems, genetic mutations must be kept under check during the reproductive 
lifespan of the particular organism, to ensure transfer of accurate genetic information to 
the next generation. Otherwise, it may result in deleterious outcomes to the somatic 
cells such as developmental failure (loss of programmed developmental stages), 
premature aging (loss of cellular functions), and tumourigenesis (loss of cellular 
specialisation and co-ordination), to name but a few.  
The importance of maintaining genome stability is apparent in the array of DNA 
damage response and repair pathways conserved in all living cells. As our 
understanding of each pathway expands, new players and layers of regulation will 
emerge and challenge our assumptions. But for the purpose of this introduction, a 
broad classification of the DNA repair pathways according to the types of DNA lesions 
is described below, with an emphasis placed on higher eukaryotic model organisms. 
But first, a classification of the types of DNA damage is required. 
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1.2 Types of DNA damage 
The types of DNA damage can be classified according to the site and nature of the 
alteration to the molecule. For example, 1) the nucleobases, 2) the glycosidic bonds 
between a base and the deoxyribose sugar, or 3) the sugar phosphate backbone. 
Lesions on the backbone can further be classified into single-stranded breaks, and 
double-stranded breaks (Fig. 1.1). In reality, one form of DNA lesion is often 
transformed into another over time either spontaneously, or in concert with DNA 
replication, transcription or repair.  
1.2.1 Base modifications/loss 
1.2.1.1 Oxidation 
In aerobic organisms, the most abundant source of base damaging agent is from 
reactive oxygen species (ROS), a by-product of oxidative phosphorylation in the 
mitochondria. About 109 ROS species are generated per human cell per hour, a 
proportion of the more stable species can cross the nuclear pore and damage 
chromosomal DNA (Lieber, 2010). Other endogenous sources of ROS include lipid 
peroxidation and the Fenton reaction through ferrous ions (Haber and Weiss, 1934;  
Goldstein et al., 1993). Exogenous sources of ROS include UV and ionising radiation. 
ROS include hydrogen peroxide (H2O2), hydroxyl radical (•OH), hydroxide (¯OH), 
superoxide (O2¯) and singlet O2 (1O2). Numerous forms of oxidised bases have been 
documented (Evans et al., 2004), the most well-characterised being 8-hydroxyguanine 
(8-oxo-G). It has been estimated that ~ 180 8-oxo-G lesions are generated per 
mammalian cell per day (Lindahl, 1993). 8-oxo-G is mutagenic as it can pair with 
adenine or cytosine during DNA replication, and potentially introduce permanent 
mutation to thymine in the next round of replication (G->T transversion) (Shibutani et 
al., 1991;  Maki and Sekiguchi, 1992). DNA oxidation is associated with aging, 
neurodegeneration, cardiovascular diseases, and cancers (Cooke et al., 2003). 
Figure 1.1 Types of common DNA damage. Modifications to the bases include alkylation,
methylation, oxidation most commonly due to ROS or toxic chemicals. Non-Watson-Crick
pairing of bases (transversions, transitions) can occur during translesion synthesis.
Hydrolysis of a base from the phosphate backbone can occur due to physical stress (heat,
low pH), oxidation, or action of a glycosidase, leading to an abasic site. Intercalating agents
such as cisplatin causes intra- and inter-strand crosslinks (“ICL”). UVB and UVC radiation
induce binding of adjacent bases, forming stable photochemical products. Spontaneous or
enzymatic degradation of the sugar phosphate backbone generates single-strand breaks
(“SSBs”). Abortive topoisomerase reactions lead to protein-DNA breaks (“PDBs”). Double-
strand breaks (“DSBs”) occur when two SSBs on anti-parallel strands occur in proximity to
each other, or when high energy electromagnetic waves disrupt right across the DNA double
helix structure. Adapted from Hoeijmakers, 2001.
Transversion
OxidationAlkylation/
Methylation
Hydrolysis
Photochemical products
Transition SSB DSBPDB
ICL
Abasic site
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1.2.1.2 Alkylation/methylation 
Covalent modifications of bases by alkyl/methyl carbon groups can disrupt base pairing 
thereby promote mutagenesis, block DNA replication and transcription. Alkylating 
agents are ubiquitous, including environmental pollutants (fuel combustion wastes and 
tobacco smoke), biological by-products (methyl chloride from algae, bacterial 
nitrosation), or endogenously from oxidative damage or aberrant methylation by S-
adensylmethione, 30 % of which originate in the mitochondria (Fu et al., 2012).  
Two common products of DNA alkylation are 7-methylguanine (7meG) and 3-
methyladenine (3meA) (Fu et al., 2012). The N-glycosidic bond between the 
deoxyribose backbone and 7meG is unstable and spontaneously transforms into 
potentially mutagenic abasic site (Park and Ames, 1988), while 3meA is a bulky adduct 
that can block replication. (Rydberg and Lindahl, 1982;  Sedgwick et al., 2006). Both 
7meG and 3meA have been associated methyl methanesulfonate (MMS)-induced 
transversions in mouse model lacking Alkylpurine-DNA-N-glycosylase (APNG) (Elder 
et al., 1998). O6-methylguanine (O6meG) can cause G->A transition, activate DNA 
recombination, and induce apoptosis (Margison et al., 2002).  
Alkylating agents therefore have been widely used as anti-cancer drugs. 7meG, 3meA 
and O6meG are the primary lesions induced by the monofunctional type of alkylating 
agents such as dacarbazone and temozolomide; while bifunctional alkylating agents 
such as nitrogen mustards, mitomycin C and cisplatin induce crosslinks between two 
alkylated bases from two DNA strands (inter-strand crosslinks) (Fu et al., 2012).  
1.2.1.3 Hydrolysis 
The N-glycosidic bond between a base and the sugar backbone can be enzymatically 
cleaved by glycosylases as part of the process to repair damaged bases, or non-
enzymatically by alkylation or heat, leaving an intermediate abasic site (AP-site) 
(Lindahl and Nyberg, 1972;  Lindahl and Karlström, 1973). The lesion can be 
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potentially mutagenic or block DNA replication and transcription (Loeb et al., 1986;  
Guillet and Boiteux, 2002;  Yu et al., 2003). 
Spontaneous or ROS-induced hydrolysis of the -NH2 group of cytosine forms 5-
hydroxycytosine, 5-hydroyxuracil and uracil glycol, the latter two can cause C->T 
transitions (Duncan and Miller, 1980). Activation-induced deaminase (AID)-mediated 
deamination of cytosine is physiologically important in B-cell antibody diversification 
through somatic hypermutation (SHM), but can also induce oncogenic transformation  
(Liu and Schatz, 2009). Deamination of thymine to thymine glycol can give rise to T->C 
transitions (Basu et al., 1989); the bulky thymine glycol also distorts the DNA structure 
and can stall replication (Ide et al., 1985;  Clark and Beardsley, 1986;  Clark et al., 
1987).  
1.2.1.4 Photochemical products 
Characteristic of UV irradiation, UV-photoproducts are formed when two opposing 
pyrimidines on anti-parallel strands of the DNA absorb the electromagnetic energy from 
the UV ray and form a 4-ring structure with stabilised bonds between C5 and C6 (in the 
case of cyclobutane pyrimidine dimers, or CPD), or between adjacent C6 and C4 of the 
same strand (in the case of (6-4) photoproducts, or (6-4) PP) (Pfeifer, 1997). Besides 
distorting the DNA helical structure and inhibiting DNA replication, UV-photoproducts 
can spontaneously deaminate, causing transitions and transversions (Ikehata and Ono, 
2011).  
1.2.1.5 Spontaneous base substitution  
In the eukaryotes, replicative DNA polymerases (Polα, Polδ and Polε) have high 
selectivity for the Watson-Crick pairing of complementary bases. However, it is 
estimated that one in 3.3 x 108 bases can undergo spontaneous misincorporation per 
cell division (Lynch et al., 2008). Polδ and Polε have additional exonuclease activity to 
excise mismatched bases, and mice lacking the Polδ and Polε exonuclease activity 
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have 10-fold higher mutation rates and develop cancers prematurely (Goldsby et al., 
2002;  Uchimura et al., 2009;  Albertson et al., 2009).  
1.2.2 Single-stranded breaks (SSBs)  
SSBs occur on the phosphate backbone of one strand of the DNA, and an estimated 
10,000 SSBs are formed per cell per day (Lindahl and Nyberg, 1972;  Lindahl, 1993;  
Beckman and Ames, 1997;  Ward, 1998). SSBs can arise directly from oxidised sugars 
that spontaneously degrade, leaving a one-base gap with damaged 3’ termini; or as an 
intermediate product of base excision repair, which can form either a one- or multiple-
base gap. Most SSBs from ROS damage have 3’-phosphate or 3’-phosphoglycolate 
ends, with intact 5’ ends (Ward, 1998;  Caldecott, 2008). A small proportion has 5’ 
hydroxyl group (Nakamura et al., 2000). Additionally, transient SSBs with no gaps are 
generated in the phosphodiester bond linking the sugar phosphate backbone by type I 
topoisomerases to facilitate unwinding of the DNA duplex, as well as to remove 
torsional stress built-up during replication and transcription (Wang, 2002).  
Although SSBs are not mutagenic per se, they can inhibit transcription or transform into 
unstable double-stranded breaks (DSBs) during replication, or deplete NAD+ by 
excessive PARP1 activation, leading to mitochondria-mediated apoptosis (Caldecott, 
2008) (Fig. 1.2). Defective repair of SSBs have been linked to several 
neurodegenerative diseases, which will be discussed in Section 1.3.2.5.  
1.2.3 Double-stranded breaks (DSBs) 
DSBs occur when two SSBs are closely spaced on antiparallel strands so that the 
strands are not sufficiently held together by base-pairing and the nucleosome structure. 
It has been estimated that ten DSBs arise per cell per day in mammalian fibroblasts 
(Martin et al., 1985;  Lieber et al., 2003;  Lieber and Karanjawala, 2004).  DNA 
replication across an unrepaired SSB nick or an inter-strand crosslink lesion is a major 
source of endogenous DSBs (Pfeiffer et al., 2000); while programmed DSBs arise in 
germline cells during meiosis (Keeney and Neale, 2006), and in early development 
Figure 1.2 Consequences unrepaired SSBs. (A) Persistent SSBs can stall transcription
elongation, triggering transcription-coupled repair (TCR). Failing that, premature termination
of transcription may result, while annealing of the nascent mRNA to the DNA template
exposes the single-stranded anti-sense strand (forming a R-loop) susceptible to genotoxic
stressors. (B) In replicating cells, a persistent SSB or R-loop can impede progression of the
replication fork, causing a one-sided DSB which may cause fork reversal if not repaired, or
eventually collapse into frank DSB, a strong trigger for checkpoint activation. (C) In non-
replicating cells, persistent or excessive SSBs following oxidative stress can deplete
mitochondrial NAD+ by excessive activation of PARP1, leading to reduced ATP production
and cell death. Adapted from Caldecott, 2008.
PARP1
(A) Transcription (B) Replication (C) Viability
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lymphocytes for immunoglobulin class switch recombination (CSR) and somatic 
hypermutation (SHM) (Dudley et al., 2005). DSBs can also be generated from the 
activity of type II topoisomerases (Adachi et al., 2003;  Haffner et al., 2011). TOP2B-
induced DSBs have been found to play a critical role in transcription initiation of a 
subset of oestrogen and androgen responsive transcription factors (Ju et al., 2006;  
Wong et al., 2009;  Haffner et al., 2010).  
Reactive oxygen species (ROS) is another major source of DSBs. It is estimated that 
~ 109 ROS are generated per hour per cell (Lieber, 2010). Mitochondrial genome 
sustains more DNA damage than the nuclear genome due to its close proximity to the 
source of ROS production (Yakes and Van Houten, 1997;  Salazar and Van Houten, 
1997;  Ballinger et al., 1999;  Ballinger et al., 2000;  Mandavilli et al., 2000;  Jin et al., 
2001;  Sawyer et al., 2001). Exogenous source of ROS can come in the form of 
ionising radiation (IR), when the electromagnetic energy is transferred to the water 
molecules surrounding the DNA (Riley, 1994). DSBs account for only < 5 % of the 
lesions caused by IR (Ward, 1990;  Friedberg et al., 2006). However, persistent DSBs 
are highly cytotoxic due to their potential to cause gross chromosomal aberrations, 
such as deletions, translocations, and mis-segregations during mitosis, or activation of 
apoptosis (Hoeijmakers, 2001).  
1.3 The DNA Damage Response (DDR) 
Given the amount of DNA damage that continually arises from exogenous and 
endogenous sources, a cell must be well-equipped with an array of coordinated 
responses to preserve genome stability and prevent passing on deleterious genetic 
material to future generations. In a eukaryotic cell, these responses entail activation of 
cell cycle checkpoints, DNA repair, and apoptosis or senescence when repair is not 
possible. Defective DDR factors are associated with developmental defects, 
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neurodegeneration, immunodeficiency, radiosensitivity, sterility, and cancer 
predisposition (Jackson and Bartek, 2009).  
1.3.1 Cell cycle checkpoints 
Eukaryotic cells undergo four phases of cell cycle: G1, whereby all cell contents, 
except the chromosomes, are duplicated; S, whereby the chromosomes are duplicated 
(forming sister chromatids); G2, whereby cytoplasmic contents are assembled and 
errors in duplicated DNA are checked; and M, whereby chromosomes are divided 
between daughter cells during mitosis. After mitosis a cell returns to G1-phase, or exits 
the cell cycle (G0-phase) (Sclafani and Holzen, 2007).  
Progression through the cell cycle is dependent on expression of cyclin-dependent 
kinases (CDKs) (Norbury and Nurse, 1992). Arrest of cell cycle progression can occur 
at four checkpoints: G1 (which prevents initiation of DNA replication), intra-S (which 
prevents firing of late replication origins and activates DNA repair), G2/M (which 
prevents entry into mitosis) (Vermeulen et al., 2003), and M-phase (also known as the 
“spindle assembly checkpoint”, which prevents progression of cytokinesis). Inhibition of 
activities of CDKs is achieved through highly interlinked but cell cycle-dependent 
signalling cascades via DNA damage sensors, signal transducers, and downstream 
effectors. The major factors in cell cycle checkpoint activation are described below. 
1.3.1.1 Phosphaditylinositol 3-kinase-like kinases (PIKKs)  
The phosphaditylinositol 3-kinase-like kinases (PIKKs) – ATM, ATR and DNA-PK, are 
the central signal transducers in the DDR pathways. ATM and DNA-PK are primarily 
recruited to sites of IR-induced DSBs, while ATR is primarily activated at sites of 
ssDNA associated with replication fork stalling by bulky base lesions and UV 
photoproducts, as well as resected DSBs during homologous recombination (HR) 
(Wright et al., 1998;  Hekmat-Nejad et al., 2000;  Lowndes and Murguia, 2000;  Pandita 
et al., 2000;  Abraham, 2001;  Andegeko et al., 2001;  Cortez et al., 2001). Recruitment 
of the PIKKs is mediated by interactions with DNA repair factors with affinity for 
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damaged DNA. Recruitment of ATM to DSBs is mediated by the MRN complex 
(MRE11, RAD50 and NBS1) (Section 1.3.2.9); and recruitment of DNK-PK is 
dependent on Ku70/Ku80 (Section 1.3.2.8); while ATR is recruited to RPA-coated 
ssDNA via its interacting partner ATRIP (Cortez et al., 2001;  Unsal-Kaçmaz et al., 
2002;  Zou and Elledge, 2003;  Unsal-Kaçmaz and Sancar, 2004;  Ball et al., 2005).  
Through phosphorylation of a vast number of downstream effectors, the PIKKs initiate 
multiple responses to DNA damage, including cell cycle arrest, chromatin remodelling, 
upregulation of DNA repair, and apoptosis (Shiloh, 2003). ATM, ATR and DNA-PK 
preferentially phosphorylate their target substrates at a serine or a threonine residue 
followed by a glutamine (SQ or TQ motif), and there is considerable overlap in their 
substrates (Anderson and Lees-Miller, 1992;  Bannister et al., 1993;  Kim et al., 1999;  
Rathbun et al., 1999;  Kastan and Lim, 2000). CHK1 and CHK2 are two substrates of 
ATM and ATR with prominent roles in the checkpoint pathways 
1.3.1.2 G1 checkpoint 
DNA damage sustained in G1-phase cells induces phosphorylation of tumour 
suppressor protein, p53, by ATM, CHK2 and ATR (Abraham, 2001). p53 
phosphorylation stabilises the protein (Chehab et al., 2000;  Hirao et al., 2000;  Shieh 
et al., 2000;  Maya et al., 2001), and promotes transcription of p21 (el-Deiry et al., 
1994;  Dumaz and Meek, 1999), which inhibits cyclin E and cyclin A-associated CDK2 
activities required for initiation of replication (Xiong et al., 1993;  Waga et al., 1994;  
Brugarolas et al., 1999;  Donaldson and Blow, 1999) 
1.3.1.3 Intra-S checkpoint 
In S-phase cells, to ensure timely repair of DSBs during DNA replication, and to 
prevent stalled replication forks from collapsing into DSBs, there are multiple pathways 
in operation. In addition to the ATM, CHK2 and ATR mediated upregulation of p53 
stability and transcription activity, there are several pathways that inhibit DNA 
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synthesis. Firstly, ATM, ATR, CHK2 and CHK1 phosphorylate the cdc25A phosphatase 
(Sanchez et al., 1997;  Falck et al., 2001) which in turn downregulates the activity of 
cyclin A/CDK2 and inhibits progression of replication (Falck et al., 2001). Secondly, 
ATM also phosphorylates SMC1 (Kim et al., 2002;  Yazdi et al., 2002;  Kitagawa et al., 
2004), NBS1 (Gatei et al., 2000b;  Lim et al., 2000;  Wu et al., 2000) and BRCA1 
(Cortez et al., 1999;  Gatei et al., 2000a;  Xu et al., 2001). This pathway has been 
shown to promote proper activation of the intra-S checkpoint, DSBR by HR (Section 
1.3.2.9), and genome stability (Falck et al., 2002;  Wakeman et al., 2004;  Kitagawa 
and Kastan;  Antoccia et al., 2008;  Bauerschmidt et al., 2011). In response to 
replication-blocking lesions, ATR-ATRIP, together with the checkpoint clamp loader 
Rad17, recruits the 9-1-1 complex (Rad9-Hus1-Rad1) (Kondo et al., 2001;  Melo et al., 
2001;  Zou et al., 2002;  Jones et al., 2003), which phosphorylates and activates CHK1 
(Weiss et al., 2002;  Jones et al., 2003;  Roos-Mattjus et al., 2003). 
1.3.1.4 G2/M checkpoint 
The G2/M checkpoint is the final point whereby unrepaired or newly-arisen DNA 
damage can be resolved before mitosis, therefore is especially important in preventing 
genomic instability. Activation of the ATM/CHK2 and ATR/CHK1 pathways results in 
degradation of Cdc25A and upregulation of Wee1, which together inhibit Cdc2/Cyclin B 
activity required for entry into mitosis (Zhao and Piwnica-Worms, 2001;  Xu et al., 
2001;  Yarden et al., 2002;  Zhao et al., 2002;  Brown and Baltimore, 2003). The 
ATM/CHK2 pathway also contributes to the maintenance of the G2/M checkpoint by 
p53-mediated transcriptional activation of GADD45 (Papathanasiou et al., 1991;  
Artuso et al., 1995;  Wang et al., 1999) and 14-3-3 (Hermeking et al., 1997), both of 
which inhibit cdc25A and Cyclin B activities (Kumagai and Dunphy, 1999;  Wang et al., 
1999;  Zhan et al., 1999;  Forrest and Gabrielli, 2001;  Jin et al., 2002;  Chen et al., 
2003;  Dalal et al., 2004). 
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1.3.2 DNA repair 
Based on the type of DNA damage sustained and the cell cycle stage it is in, a cell will 
attempt to repair the damage using a multitude of repair pathways. For each pathway, 
the mechanism of lesion detection, removal and repair are described, followed by the 
consequences of in case of dysfunction.  
1.3.2.1 Direct reversal 
There is a small proportion of DNA lesions that can be directly repaired without altering 
the structure of the molecule, simply by cleaving off the aberrant bond(s). For example, 
photolyases utilise the energy from light to break the bonds between the pyrimidines in 
UV products CPDs and (6-4) PPs (Weber, 2005). Another example is the O6-
methylguanine-DNA methyltransferase (MGMT)-encoded protein, O6-alkylguinine-DNA 
alkyltransferase (AGT), which removes the alkyl groups from O6-methylguanine and 
O4-methylthymine to restore the normal guanine structure (Gerson, 2004).  
Methylation of the MGMT promoter is associated with both tumourigenesis and 
sensitization to anti-tumour alkylating agents such as temozolamide, while 
overexpression in normal tissues confers protection against the cytotoxic effects of 
these alkylating agents (Soejima et al., 2005). 
1.3.2.2 Mismatch repair (MMR) 
DNA mismatches can arise through modification of bases (Section 1.2.1) or slippage 
of the DNA replication machinery at regions of tandem repeats (microsatellite 
instability). The mutagenic nature of these lesions requires prompt removal before 
completion of DNA replication, this pathway is therefore highly conserved from bacteria 
to human (Li, 2008).  
In mammals, detection and binding of structure-distorting lesions by the MutS 
heterodimer MutSα (MSH2/MSH6) or MutSβ (MSH2/MSH3) (Drummond et al., 1995;  
Palombo et al., 1995;  Palombo et al., 1996) results in the recruitment of MutL 
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heterodimer MutLα (MLH1/PMS2) (Li and Modrich, 1995), MutLβ (MLH1/PMS1) 
(Räschle et al., 1999) or MutLγ (MLH1/MLH3) (Cannavo et al., 2005). The replication 
clamp PCNA and clamp loader replication factor C (RFC) physically interact with MSH2 
(Clark et al., 2000;  Flores-Rozas et al., 2000;  Lau and Kolodner, 2003) and MLH1 to 
promote localisation of MutSα to the mismatch site (Umar et al., 1996;  Gu et al., 1998) 
and activation of the endonuclease activity of MutLα (Kadyrov et al., 2006;  Pluciennik 
et al., 2010). MutLα then makes a nick on the discontinuous daughter strand, either 5’ 
or 3’ of the mismatch site (Kadyrov et al., 2006). 5’ to 3’ excision of the daughter strand 
from the nick to past the mismatch site is dependent on the activity of Exo1 (Umar et 
al., 1996;  Gu et al., 1998), while 3’ to 5’ excision requires both Exo1 and PCNA (Guo 
et al., 2004). The resected DNA is then coated with single-stranded DNA binding 
protein RPA, which displaces MutSα and MutLα and promote gap-filling by DNA 
polymerase δ (Polδ) (Ramilo et al., 2002;  Zhang et al., 2005;  Guo et al., 2006). The 
nick is then sealed by DNA ligase 1 (Lig1) (Zhang et al., 2005).  
The MMR factors play a significant role in the DDR pathways through interactions with 
ATM (Brown et al., 2003;  Adamson et al., 2005), ATR (Wang and Qin, 2003) CHK1 
and CHK2 (Adamson et al., 2005), p53 (Chen and Sadowski, 2005), and p73 
(Shimodaira et al., 2003). MMR factors also play a role in antibody diversification by 
class switch recombination (CSR) of immunoglobulin genes (Martin and Scharff, 2002).  
In humans, defective MMR is associated with increased risk of tumourigenesis, typified 
by Lynch syndrome (Sijmons and Hofstra, 2016), which is characterised by hereditary 
non-polyposis colorectal cancer (HNPCC), amongst other cancers (OMIM #120435).  
1.3.2.3 Nuclear excision Repair (NER)
The NER pathway repairs a wide range of bulky DNA distorting lesions that impede 
replication and transcription, such as UV photoproducts CPDs, (6-4) PPs, inter-strand 
crosslinks induced by cisplatin, or ROS-induced bulky base modifications such as 
cyclopurines (Gillet and Schärer, 2006).  
 
13 
There are two pathways in NER: global genome NER (GG-NER) and transcription-
coupled NER (TC-NER) (Fig. 1.3). They differ in that TC-NER is specialised in 
detection of lesions within the proximity of a stalled transcription machinery, while GG-
NER can detect lesions in the whole genome irrespective of the transcription status. In 
GG-NER, the XPC-RAD23B-Centrin2 complex (Masutani et al., 1994;  Shivji et al., 
1994;  Nishi et al., 2005) scans the genome (Sugasawa et al., 1998;  Wood, 1999) and 
binds the strand opposite the lesion (Min and Pavletich, 2007;  Maillard et al., 2007;  
Schärer, 2007), then recruits the transcription factor II H (TFIIH) complex (Coin et al., 
2007;  Oksenych et al., 2009). Within the complex, the helicase activity by subunits 
XPB (3’ – 5’) and XPD (5’ – 3’) forms a bubble ~ 30 nucleotides around the lesion 
(Evans et al., 1997;  Coin et al., 2007;  Mathieu et al., 2010), which is coated and 
stabilised by RPA (De Laat et al., 1998;  Hermanson-Miller and Turchi, 2002). XPA, 
which is also recruited to the bubble platform, displaces the TFIIH and RPA (Coin et 
al., 2008), and promotes recruitment of the endonuclease complexes XPF-ERCC1 and 
XPG to resect the 5’ and 3’ ends, respectively, of the strand containing the bulky lesion 
(De Laat et al., 1998;  Fagbemi et al., 2011). The gap is then filled by replicative DNA 
polymerases δ, ε, or κ with the aid of PCNA and RFC (Ogi and Lehmann, 2006;  
Mocquet et al., 2008;  Ogi et al., 2010). Finally, the nick is repaired by XRCC1-Lig3α 
(Moser et al., 2007;  Paul-Konietzko et al., 2015) or FEN1-Lig1 during S-phase 
(Mocquet et al., 2008). 
In TC-NER, the lesion detection step is carried out by Cockayne syndrome proteins 
CSA and CSB by interaction with stalled RNA polymerase II (RNAP II) (Henning et al., 
1995;  Van Gool et al., 1997;  Lee et al., 2002). CSA and CSB promote recruitment of 
the NER machinery (Fousteri et al., 2006), and further repair is thought to proceed 
similar to the GG-NER pathway (Hanawalt and Spivak, 2008). 
In humans, defective NER has been historically associated with xeroderma 
pigmentosum (XP) (Cleaver, 1978), Cockayne syndrome (CS) (Schmickel et al., 1977;  
Centrin
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XPF
RNAP II
RNAP II
CSB
CSA
hR23B
XPC
XPB XPD
XPA
XPA
RPA
ERCC1 XPG
Lig1/3
Polε/δ
PCNA
Recruitment of BER factors
In mitochondria
Repair by BER
GG-NER TC-NER
Figure 1.3 The nucleotide excision repair pathway. (A) A bulky lesion that distorts the
DNA helix is (B) detected by the XPC-RAD23B-Centrin complex, or (C) stalls an elongating
RNAP II transcription complex, which (D) recruits the CSA/CSB complex that recognises the
lesion. (E) Both XPC and CSA/B can recruit the multiprotein transcription factor TFIIH. The
XPB and XPD helicase subunits separate the strands surrounding the lesion, (F) forming a ~
30-nucleotide bubble, which is stabilised by coating with RPA. XPA then displaces TFIIH and
RPA, recruits exonucleases XPF/ERCC1 and XPG to excise the lesion-containing strand,
and PCNA, which mediates the polymerase switch for subsequent gap repair. (G) Gap-filling
is carried out by DNA Pol ε and δ, with the help of PCNA and RFC. (H) Ligase 1 or 3 seals
the nick to complete the repair. (I) Notably, in the mitochondria, where GG-NER factors are
absent, repair is carried out through the BER pathway. Adapted from Diderich et al., 2011.
TFIIH
(A)
(B) (C)
(E) (D)
(F)
(G)
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(H)
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Andrews et al., 1978;  Mayne and Lehmann, 1982;  Venema et al., 1990), and 
trichothiodystrophy (TTD) (Stefanini et al., 1993a;  Stefanini et al., 1993b;  Vermeulen 
et al., 1994). Clinical symptoms of these syndromes are diverse, characterised by skin 
and eye manifestations of UV hypersensitivity, cancers of the skin and internal organs, 
neurological and skeletal abnormalities and premature aging (Lehmann, 2003). The 
variability in symptoms likely reflects the wide spectrum of lesions that accumulate in 
NER-deficient individuals.  
Notably, XP patients with defective TC-NER display more severe neurological 
symptoms (Lehmann, 2003), which possibly reflect the role of TC-NER in repair of 
oxidised bases such as thymine glycols (Cooper et al., 1997) and 8-oxo-G, 8-oxo-A 
(Reardon et al., 1997;  Le Page et al., 1999). Increasing evidence suggests an overlap 
in the TC-NER and BER pathways for repair of oxidative DNA damage, which will be 
discussed in Section 1.3.2.6. 
1.3.2.4 Base excision repair (BER) 
Non-bulky base modifications and AP-site lesions (Section 1.2.1) are generally 
repaired by the BER pathway (Lindahl and Wood, 1999). Given the frequent 
occurrence of these lesions, BER is another crucial pathway for maintaining genome 
stability. 
The steps involved in BER are: damage recognition, base excision, end processing, 
gap filling, and ligation (Fig. 1.4).  
Recognition of damaged bases depends on the glycosylases. There are 11 known 
glycosylases, each specific to the altered base structure that it recognises (Jacobs and 
Schär, 2012). For example, OGG1 recognises 8-oxo-G and Fapy-G (Boiteux and 
Radicella, 2000). They can be classified as monofunctional or bifunctional. 
Monofunctional glycosylases simply excise the base to be repaired, while bifunctional 
glycosylases also generate a nick in the phosphodiester bond in the backbone (Jacobs 
Gly Gly
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Polβ
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Figure 1.4 The base excision repair and SSB repair pathways. (A) A non-bulky base
lesion is (B) excised by a bifunctional glycosylase, or (C) a monofunctional glycosylase,
followed by (D) cleavage of the phosphodiester backbone by APE1. APE1 associates with
the scaffold protein XRCC1, (E) which recruits PARP1 to stabilise the break ends and
activate downstream repair factors. (F) The end-processing factors restore the chemistry
around the nick. (G) In SP-BER, Pol β fills in the missing nucleotide and (H) Lig3 seals the
nick. (I) If the 5’-dRP end is oxidised, repair is carried out by LP-BER. Outside S-phase,
repair is achieved through coordinated gap filling and strand displacement up to 2 nt by Polβ
and FEN1, followed by steps (G) to (H). (J) During S-phase, switching to replicative
polymerase allows insertion 2 – 10 nucleotides past the break end, generating a short flap,
which is excised by FEN1. (K) Lig1 seals the nick to complete the repair. Part highlighted in
blue indicates overlap with the single-strand break repair pathway. Adapted from Caldecott,
2008.
PNKP
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and Schär, 2012). Upon binding with the damaged base, the glycosylase cleaves the 
C1-N-glycosidic bond, leaving an AP-site (Brooks et al., 2013). AP-sites arising from 
spontaneous deamination of bases are further processed in an identical manner. 
To initiate repair of the AP-site, the phosphodiester bond is hydrolysed either by a 
bifunctional glycosylase (Sun et al., 1995;  Nash et al., 1997;  Takao et al., 2002), or by 
apurine/apyrimidine endonuclease 1 (APE1) (Demple et al., 1991;  Robson and 
Hickson, 1991). APE1 is recruited to the AP-site by a monofunctional glycosylase, 
along with x-ray cross complementing protein 1 (XRCC1), a scaffold protein required 
for assembly of the repair machinery (Parikh et al., 1998;  Waters et al., 1999;  
Hardeland et al., 2000;  Hill et al., 2001;  Pope et al., 2002;  Marsin et al., 2003;  
Campalans et al., 2005). APE1 cleaves the phosphodiester bond 5’ to the AP-site to 
generate a 5’-deoxyribosephosphate (5-dRP) end and 3’-hydroxyl (3’-OH) end (Demple 
and Harrison, 1994;  Barzilay and Hickson, 1995;  Parikh et al., 1998;  Waters et al., 
1999;  Hill et al., 2001). This lesion is then rapidly detected by Poly(ADP-ribose) 
polymerase 1 (PARP1), which forms poly(ADP-ribose) chains on itself (to amplify the 
signal) (Ogata et al., 1981;  Huletsky et al., 1989;  D'Amours et al., 1999), as well as 
surrounding histones (to promote chromatin relaxation) (Beneke, 2012) and BER 
scaffold protein XRCC1 (Masson et al., 1998;  Pleschke et al., 2000;  El-Khamisy et al., 
2003). XRCC1 provides a platform for the assembly of downstream BER factors such 
as PNKP, DNA polymerase β (Polβ) and DNA ligase 3α (Lig3α) required for further 
processing of the base lesion (Caldecott, 2001). 
To insert a new nucleotide into the gap, the 5’ and 3’ ends of the phosphodiester bond 
must be restored to a 5’-phosphate and 3’-hydroxyl moiety, which are often altered by 
the actions of glycosylases and APE1. Bifunctional glycosylases with β-lyase activity 
generate 3’-α,β unsaturated aldehyde ends (Mazumder et al., 1991) that are repaired 
by APE1 (Izumi et al., 2000). Bifunctional glycosylases with β,σ-lyase activity such as 
NEIL1, NEIL2 and NEIL3 generate 3’-phosphate ends that are repaired by 
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polynucleotide kinase-phosphatase (PNKP) or APE1 (Habraken and Verly, 1988;  
Jilani et al., 1999;  Wiederhold et al., 2004). The 5’-dRP ends generated by APE1 is 
removed by Polβ (Allinson et al., 2001;  Podlutsky et al., 2001).  
Further repair of the nick on the DNA backbone proceeds as in the case of single-
strand break repair (SSBR), with modifications in the steps of damage recognition and 
DNA end-processing. 
1.3.2.5 Single-strand break repair (SSBR) 
The recognition step of SSBs starts with binding and PARylation by PARP1, which 
protects the site from further damage (Parsons et al., 2005), and recruits downstream 
repair machinery (Caldecott et al., 1996;  Pleschke et al., 2000;  El-Khamisy et al., 
2003;  Okano et al., 2003;  Das et al., 2014). The steady-state of 
PARylation/dePARylation is regulated by poly(ADP-ribose) glycohydrolase (PARG) 
and terminal ADP-ribose protein glycohydrolase (TARG1), which catabolise the PAR 
chains to allow access of the repair factors (Zahradka and Ebisuzaki, 1982;  Oka et al., 
1984;  Lin et al., 1997;  Davidovic et al., 2001;  Fisher et al., 2007;  Gao et al., 2007;  
Chen et al., 2011;  Slade et al., 2011;  Zaja et al., 2012). 
The end-processing factors in BER can also repair similar ends generated by other 
means (Fig. 1.4). For example, 3’-phosphate termini arising from spontaneous 
disintegration of oxidised bases or processing of TOP1-cc are repaired by PNKP (Jilani 
et al., 1999;  Karimi-Busheri et al., 1998;  Inamdar et al., 2002). 3’-phosphoglycolate 
termini from ROS damage are efficiently repaired by APE1 (Suh et al., 1997;  Parsons 
et al., 2004). However, there are several additional SSBR end-processing factors to 
fine-tune the repair. For example, tyrosyl-DNA-phosphodiesterase 1 (TDP1) can 
accurately remove 3’ moieties such as phosphoglycolate (Zhou et al., 2005), dRP 
(Lebedeva et al., 2011), or a tyrosyl group (from the active site of TOP1) (Davies et al., 
2003;  Interthal et al., 2005a), leaving an ungapped nick with 5’-OH and 3’-phosphate 
terminus for further processing by PNKP (Inamdar et al., 2002). Similarly, 5’-AMP 
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termini (resulting from abortive DNA ligase activity near 5’-phosphate ends) can be 
accurately removed by aprataxin (APTX), leaving a 5’-phosphate terminus (Ahel et al., 
2006). Several DNA polymerases besides Polβ have also been shown to process dRP 
termini from oxidative damage, such as Polλ and Polι (García-Díaz et al., 2001;  
Bebenek et al., 2001;  Braithwaite et al., 2005a;  Braithwaite et al., 2005b). When a 5’-
dRP or 5’ sugar phosphate is oxidised, it becomes resistant to the lyase activity of 
Polβ. These lesions need to be repaired by the long-patch BER (LP-BER) pathway.  
The next step is to fill in the missing nucleotide(s) by DNA polymerases. Depending on 
the efficiency of the end-processing step, and the cell cycle status, short-patch BER 
(SP-BER) or long-patch BER (LP-BER) (during S-phase, or if either of the nicked 
termini cannot be correctly restored) may be chosen. In SP-BER, Polβ inserts one 
nucleotide in the gap (if necessary) and Lig3α seals the nick to complete the repair 
(Caldecott, 2008).  
LP-BER, in its most efficient form, entails one nucleotide gap filling by Polβ, followed by 
excision of one nucleotide flap at the 5’ end containing the oxidised lesion by Flap 
endonuclease 1 (FEN1) (Liu et al., 2005). Lig3α seals the nick and completes the 
repair. Alternatively, during DNA replication, polymerase switching can occur when a 
replisome approaches, resulting in Polε and Polδ mediated extension past the break 
point and generation of 5’ flap of a 3 – 10 nucleotides. The 5’ flap is excised by the 
concerted action of flap endonuclease 1 (FEN1), PCNA and PARP1 (Prasad et al., 
2000). Lig1 reseals the nick between the newly synthesised strand and the 5’ end to 
complete the repair (Mortusewicz et al., 2006).  
As the “housekeeping” DNA repair pathway, deficiency of the BER pathway is 
associated with tumourigenesis, neurodegeneration and aging, and in some cases, is 
incompatible with life (Wilson and Bohr, 2007;  Caldecott, 2008;  Maynard et al., 2009). 
Both reduction and overexpression of some BER factors have been associated with 
cancers (Mohan and Madhusudan, 2013). As BER plays a role in preventing 
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mutagenesis, as well as promoting tumour resistance to radio- and chemotherapeutic 
agents, it is unclear whether the aberrant expression patterns reflect the cause or the 
consequence of tumourigenesis. Regulation of BER factors is therefore an important 
area of cancer research. 
Intriguingly, defects in three of the SSBR-specific end-processing factors, APTX, TDP1 
and PNKP, all show exclusively neurological phenotypes with little signs of systemic 
involvement. Mutations in APTX are associated with ataxia-oculomotor apraxia 1 
(AOA1) (OMIM #208920) (Date et al., 2001;  Moreira et al., 2001); a single catalytic 
mutation in TDP1 is linked to spinocerebellar axonal neuropathy 1 (SCAN1) 
(OMIM #607250) (Takashima et al., 2002;  El-Khamisy et al., 2005;  Interthal et al., 
2005b); and mutations in PNKP are found in patient with MCSZ syndrome 
(microcephaly, early-onset, intractable seizures and developmental delay) (OMIM 
#613402) (Shen et al., 2010;  Reynolds et al., 2012), cerebellar degeneration and 
polyneuropathy (Poulton et al., 2013) and AOA4 (OMIM #616267) (Bras et al., 2015). 
1.3.2.6 Transcription-coupled base excision repair (TC-BER) 
Although the role of TC-NER in repair of bulky lesions in actively transcribed gene is 
well-characterised (Section 1.3.2.3), there is increasing evidence supporting the notion 
of a transcription-associated sub-pathway of BER (TC-BER). It has been shown that 
TC-NER factors confer protection against oxidative DNA damage. CSB promotes BER 
by stimulating the activities of PARP1 (Flohr et al., 2003;  Thorslund et al., 2005) and 
APE1 (Wong et al., 2007); XPC stimulates activity of OGG1 and APE1 (Errico et al., 
2006;  Kassam and Rainbow, 2007;  Melis et al., 2011;  de Melo et al., 2016); and XPG 
promotes binding of NTH1 to thymine glycols for repair by BER (Klungland et al., 
1999). It is not clear though, if non-bulky lesions such as 8-oxo-G can stall RNA Pol II 
per se (Tornaletti, 2005;  Charlet-Berguerand et al., 2006;  Guo et al., 2013). It has 
been suggested that the sequence complexity and the chromatin structure surrounding 
the lesion may affect whether TC-NER or BER is utilised for repair (Yu et al., 2000;  
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Allgayer et al., 2013). Interestingly, in the mitochondria, CSA and CSB promote repair 
of 8-oxo-G lesions via the BER, as core components of the NER pathway are not 
identified in the mitochondria (Dianov et al., 1999;  Stevnsner et al., 2002). Therefore, 
the neurological and premature aging phenotype of CS patients could be attributed to 
excessive damage to the mitochondrial genome (Stevnsner et al., 2008). 
Protein-linked SSBs, such as TOP1-cc, are also known to block the transcription 
machinery (Bendixen et al., 1990;  Ljungman and Hanawalt, 1996;  Wu and Liu, 1997). 
Repair by TDP1 is specific to actively transcribed region of the genome, as in TDP1-
deficient cells, inhibition of RNAP II elongation by α-amanitin abrogated accumulation 
of TOP1-cc, while inhibition of replication by aphidicolin showed no such response (El-
Khamisy et al., 2005;  Miao et al., 2006). Another BER factor, NEIL2, has also been 
shown to preferentially interact with active RNAP II and the transcriptional regulator 
heterogeneous nuclear ribonucleoprotein-U (hnRNP-U) (Banerjee et al., 2011).  
1.3.2.7 Double-strand break repair (DSBR) 
DSBs, although less frequent than base modifications or SSBs, pose serious threat to 
genome stability, as they can lead to chromosomal rearrangements, deletions, 
duplications, and activation of cell death mechanisms (Jackson, 2002). DSBs are 
inevitably generated during DNA replication and cell division. It is therefore not 
surprising that many factors in DSBR are also involved in cell cycle checkpoints, as 
mentioned in Section 1.3.1. 
There two main DSBR pathways – homologous recombination (HR) and non-
homologous end-joining (NHEJ). The two pathways are mechanistically distinct and 
result in different repair outcomes. The pathway choice is dependent on factors such 
as the cell cycle status, the complexity of the DNA damage, and the chromatin 
structure surrounding the damage (Symington and Gautier, 2011). 53BP1 (Tumour 
suppressor p53-binding protein 1) is considered an important mediator in the DDR 
following DSB, as well as on the repair pathway choice. Following its recruitment to a 
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DSB site by ubiquitinated H2A and H2AX (Doil et al., 2009;  Stewart et al., 2009), 
53BP1 promotes relaxation of heterochromatin to allow the repair machinery to access 
the break (Noon et al., 2010;  Goodarzi et al., 2011). Furthermore, phosphorylation of 
53BP1 by ATM recruits RIF1 (Replication Timing Regulatory Factor 1) to the damage 
site, which have been shown to inhibit BRCA1-mediated end resection during G1-
phase (Bunting et al., 2010;  Bothmer et al., 2011;  Chapman et al., 2013;  Di Virgilio et 
al., 2013;  Escribano-Diaz et al., 2013;  Feng et al., 2013;  Zimmermann et al., 2013). 
During S/G2 phase, where the chromatin is likely already relaxed, 53BP1 plays a less 
crucial role in DSBR. BRCA1 displaces 53BP1 from the DSB site (Chapman et al., 
2012;  Kakarougkas et al., 2013) and recruits the E3 Ubiquitin ligase UHRF1 
(Ubiquitin-like, with PHD and RING finger domains 1) to polyubiquitinates RIF1, 
promoting its dissociation from 53BP1 (Zhang et al., 2016). 
1.3.2.8 Non-homologous end-joining (NHEJ) 
NHEJ is the DSBR pathway utilised throughout the cell cycle, but predominantly in G1- 
and G2-phases of the cell cycle, where homologous sister chromatids are not available 
(Beucher et al., 2009).  
NHEJ involves tethering of the two ends of the DSB, various degree of end-processing, 
and ligation of the ends to complete the repair, with or without loss of some nucleotide 
sequences at the ends (Fig. 1.5). It has been estimated that ~ 80 % of DSBs induced 
by IR are efficiently repaired by NHEJ within 30 minutes (Beucher et al., 2009). 
In its simplest form, canonical/classical NHEJ (c-NHEJ) is initiated by binding and 
stabilisation of the DSB ends to the heterodimer Ku70/Ku80, which aligns the ends of 
the break (Yoo and Dynan, 1999;  Walker et al., 2001) and recruits and activates the 
DDR kinase DNA-PK (Gottlieb and Jackson, 1993;  Suwa et al., 1994;  Jin et al., 1997; 
Uematsu et al., 2007). DNA-PK binds to the two ends and forms a bridging “synaptic 
complex” to stabilise the break (DeFazio et al., 2002) and prevents initiation of 
resection by HR factors such as Exo1 (Mimitou and Symington, 2010). DNA-PK also 
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Figure 1.5 The non-homologous end-joining pathway. (A) A double strand break arising
outside S-phase elicits (B) ATM-mediated phosphorylation of 53BP1 and H2A histones,
promoting chromatin relaxation and binding of Ku70/80 to the DSB ends. (C) Ku70/80 recruits
and activates DNA-PK, which in turn recruits (D) end-processing factors Artemis, PNKP,
APTX, TDP2 and TDP1 to clean up the ends. (E) PARylation of the scaffold protein APLF by
PARP3 promotes recruitment of the Lig4/XRCC4/XLF complex to join the break ends.
Adapted from Hartlerode & Scully, 2009; Heo et al., 2015; Xu et al., 2012.
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promotes assembly of downstream NHEJ repair factors including end-processing 
enzymes, XRCC4-Ligase 4 (Lig4), and XRCC4-like factor (XLF) (Critchlow et al., 1997;  
Ahnesorg et al., 2006;  Costantini et al., 2007). PARP3 and APLF also promote the 
retention and activity of XRCC4-Lig4-XLF (Rulten et al., 2011;  Grundy et al., 2013).  
In c-NHEJ, where minimal end-processing is required, XRCC4-Lig4 stabilises the break 
ends (Grawunder et al., 1997;  Grawunder et al., 1998), and Lig4 seals the ends 
(Schar et al., 1997;  Teo and Jackson, 1997;  Wilson et al., 1997;  Tomkinson et al., 
2006). XLF is important in completion of the Lig4 catalytic cycle and recycling Lig4 for 
further use (Riballo et al., 2009). 
With more complex DNA ends, like in SSBR, end-processing requires several 
structural-specific nucleases. Artemis is a well-characterised endonuclease with hairpin 
processing, 5’ exonuclease, and 3’-PG processing activity (Ma et al., 2002;  Ma et al., 
2005;  Povirk et al., 2007;  Li et al., 2014). Together with ATM, it is required for V(D)J 
recombination of immunoglobulin genes (Ma et al., 2002;  Riballo et al., 2004). PNKP, 
the 5’ and 3’ phosphatase required in BER/SSBR, has also been shown to play a 
similar role in NHEJ (Ward, 1998;  Chappell et al., 2002;  Bernstein et al., 2005;  Koch 
et al., 2004;  Karimi-Busheri et al., 2007;  Mani et al., 2010;  Segal-Raz et al., 2011). 
Similarly, APTX (Section 1.3.2.5) has also been implicated in NHEJ (Rass et al., 
2007). The more recently characterised TOP2-DSB repair factor, TDP2, also functions 
in the NHEJ pathway (Gómez-Herreros et al., 2013). TDP2 cleaves the 5’-
phosphotyrosyl bond in TOP2-cc, leaving re-ligatable 5’-OH ends (Cortes Ledesma et 
al., 2009).  
There is also an alternative end-joining (A-EJ) pathway that is slower and more error-
prone (Kabotyanski et al., 1998;  DiBiase et al., 2000;  Wang et al., 2003;  Iliakis et al., 
2004;  Terzoudi et al., 2008). It has been observed in c-NHEJ and HR-deficient cells 
(Audebert et al., 2004;  Audebert et al., 2006;  Geuting et al., 2013). The trigger and 
mechanism of this pathway is less well-understood. It is postulated that PARP1 is the 
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DSB sensing factor in the absence of Ku70/80 (Wang et al., 2006), and the ligation 
step is carried out by XRCC1-Lig3α or Lig1 (Audebert et al., 2004;  Wang et al., 2005;  
Liang et al., 2008;  Simsek et al., 2011;  Della-Maria et al., 2011;  Paul et al., 2013). 
Components of the HR pathway such as the MRE11 and CtIP have also been shown 
to promote A-EJ (Ma et al., 2003;  Lee and Sang, 2007;  Bennardo et al., 2008;  
Deriano et al., 2009;  Rass et al., 2009;  Xie et al., 2009;  Yun and Hiom, 2009;  
Zhuang et al., 2009;  Lee-Theilen et al., 2010;  Zhang and Jasin, 2011), which could 
explain the characteristic generation of microhomologies (short stretch of homologous 
sequences) at the junction of repair indicative of end-resection. 
Defects in NHEJ core components such as Ku70/80, DNA-PK, Lig4, Artemis and XLF 
result in with gross genomic instability, immunodeficiency, tumourigenesis, 
radiosensitivity, and neurodevelopmental defects (O'Driscoll and Jeggo, 2006).  
1.3.2.9 Homologous recombination (HR) 
The HR pathway depends on using a sister chromatid with homologous sequence as 
the template for repairing both strands of the damaged DNA, therefore it should only be 
activated in cycling cells, in the late S- and G2 phases of the cell cycle, for repair of 
lesions that have already undergone replication. HR has a slower repair kinetic, but is 
virtually error-free (Kasparek and Humphrey, 2011). Fig. 1.6 illustrates how SSBs 
arising during early S-phase can be converted to one-ended DSBs, or two-ended 
DSBs in late S-phase, and require repair by HR (Caldecott, 2008). 
In the HR pathway, the MRN complex (MRE11, RAD50 and NBS1) is the early sensor 
of DSBs (D'Amours and Jackson, 2002;  Tauchi et al., 2002). Upon binding it stabilises 
the DSB ends, MRE11 initiates 5’ – 3’ resection and displaces Ku from the ends, 
inhibiting repair by NHEJ (Petrini et al., 2001;  D'Amours and Jackson, 2002). NBS1 
activates ATM through autophosphorylation and monomerisation (Uziel et al., 2003;  
Lee and Paull, 2004;  Lee and Paull, 2005). ATM phosphorylates a multitude of 
substrates involved in the DDR (Section 1.3.1.1), including the histone variant H2AX 
Figure 1.6 Replication-coupled repair of SSBs. (A) Collision of the replication machinery
with a SSB results in (B) a one-ended DSB formed by the sister chromatid (green box) and a
residual SSB (blue box). (C) Repair of the DSB is initiated by 3’ to 5’ excision by CtIP in
conjunction with MRN, while the SSB ends are processed by SSBR factors, or structure-
specific nucleases such as ERCC1-XPF at 3'-termini, FEN1 at 5'-flapped termini, or the MRN
complex at 5'- and possibly 3'-termini. Gap filling is then carried out by the replicative
polymerases Pol ε and/or Pol δ and associated factors, and the nick ligated by Lig1. (D)
Homologous recombination (HR) by RAD51-mediated template switching completes repair of
the excised DSB ends. (E) In the case of CPT-induced SSB, increased torsional stress
promotes reversal of the replication fork by annealing of the daughter strands, essentially
formation a double Holliday junction (HJ). (F) action of HJ resolvase Mus81/Eme1 (red
arrows) and ERCC1/XPF (purple arrows) and subsequent repair by Lig1 results in (G) a one-
ended DSB (green box) and a TOP1-associated SSB (blue box). Further repair follows steps
(B) – (D). (H) If the SSB or one-sided DSB is not repaired in a timely manner, a converging
replication fork or new origin firing past the SSB result in a two-sided DSB (green box). (I)
End resection by CtIP and MRN allows further repair by HR. Adapted from Caldecott, 2008;
Kim et al., 2013.
MRN, CtIP
SSBR factors, 
ERCC1 (FEN1, 
MRN)
PCNA, Pol ε/δ, Lig1
Template 
switching
MRN,
CtIP
MRN, CtIP, 
ERCC1
(A)
(B)
(C)
(D)
(H)
(I)
(J)
HJ resolvase
TOP1
TOP1
Mus81/EME1, 
Slx1/4
TOP1
(E)
(F)
(G)
ERCC1/XPF, 
Slx1/4
Lig1
 
23 
on ser139 (γH2AX) (Rogakou et al., 1998;  Burma et al., 2001) and BRCA1 (Cortez et 
al., 1999;  Kim et al., 1999;  Gatei et al., 2000a), which initiates the chromatin 
relaxation process (Hu et al., 1999;  Bochar et al., 2000;  Ye et al., 2001), and 53BP1, 
which is crucial in maintaining the ATM signalling through the G2/M checkpoint (You et 
al., 2005;  Noon et al., 2010;  Shibata et al., 2010).  
The ends are then more extensively resected by nucleases Exo1, DNA2 and BLM 
(Gravel et al., 2008;  Liao et al., 2008;  Nimonkar et al., 2008;  Zhu et al., 2008;  
Mimitou and Symington, 2009;  Cejka et al., 2010a;  Nimonkar et al., 2011;  
Sturzenegger et al., 2014), generating ssDNAs with 3’ overhangs, which are rapidly 
coated by RPA which prevents formation of secondary structures (Sung and Klein, 
2006). With the help of BRCA2/PALB2, RAD51 nucleofilament then displaces RPA to 
promote homology search by strand invasion of the sister chromatid (Sharan et al., 
1997;  Wong et al., 1997;  Pellegrini et al., 2002;  San Filippo et al., 2006;  Sung and 
Klein, 2006;  Carreira et al., 2009;  Sy et al., 2009;  Dray et al., 2010;  Holthausen et 
al., 2010;  Jensen et al., 2010;  Liu et al., 2010;  Thorslund et al., 2010). This results in 
the formation of the D-loop, within which RAD51 is gradually dissociated by RAD54, 
allowing access of DNA polymerases for DNA synthesis on the invading strand 
(Petukhova et al., 1998;  Petukhova et al., 1999;  Solinger et al., 2002;  Li and Heyer, 
2009;  Wright and Heyer, 2014).  
The invading strand then can either be displaced back and anneal with its antiparallel 
(non-sister chromatid) strand, and the nick sealed by Lig1 (Goetz et al., 2005), 
resulting in non-crossover; or it can be stabilized in the D-loop by ligating to the 3’ end 
of the DSB on the same strand, allowing repair synthesis on the antiparallel strand, 
forming a double Holliday junction structure (Pâques et al., 1999). The structure can 
then be processed by resolvases such as GEN1, Mus81 and SLX1 into crossover and 
non-crossover products (Chen et al., 2001;  Constantinou et al., 2002;  Andersen et al., 
2009;  Fekairi et al., 2009;  Munoz et al., 2009;  Svendsen et al., 2009;  Wechsler et al., 
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2011), or converted to a hemi-catenone by BLM then resolved by topoisomerase 3 
(TOP3) into non-crossover products (Ira et al., 2003;  Wu and Hickson, 2003;  Cejka et 
al., 2010b;  Hickson and Mankouri, 2011). Mutations in key HR components such as 
BRCA1, BRCA2, RAD51, RAD54, PALB2 and p53 are associated with tumourigenesis. 
In addition, mutations in BLM helicase that suppresses illegitimate crossovers are 
associated with developmental delay (OMIM #210900). Defective meiosis-specific 
recombination (e.g. DMC1) is associated with male infertility (Bannister et al., 2007). 
1.3.2.10 The Fanconi anaemia (FA) pathway 
So-called due to the clinical presentation of patients with genetic mutations in factors 
involved in this pathway, the FA pathway is important for repair of ICLs during S-phase. 
It does this by co-ordinating factors of NER, HR and translesion synthesis (TLS) 
polymerases, although the molecular mechanisms of many of the FA factors are 
currently unknown. 
The FA factors can be divided into: 1) the FA core complex (consisting of FANCA, 
FANCB, FANCC, FANCE, FANCG, FANCF, FANCL and FANCM); 2) the ID2 complex 
(FANCD2, FANCI); and the downstream repair proteins (BRCA2/FANCD1, Rad51, 
PALB2/FANCN, BACH1) (Moldovan and D'Andrea, 2009). 
Upon replication fork stalling by an ICL, DDR is triggered when ATR phosphorylates 
and recruits HR factors including Rad51 and BRCA1 (Taniguchi et al., 2002;  Pichierri 
and Rosselli, 2004;  Zhu and Dutta, 2006). ATR also recruits the core FA complex to 
the damage site through FANCM and FAAP24 (Collis et al., 2008;  Kim et al., 2008;  
Huang et al., 2010;  Schwab et al., 2010;  Wang et al., 2013). FANCL then mono-
ubiquitinates FANCD2-FANCI to stabilise it at the damage site (Seki et al., 2007;  Alpi 
et al., 2008;  Longerich et al., 2009). Monoubiquitinated FANCD2/FANCI (ID2 complex) 
then recruits FAN1 (Fanconi anaemia associated nuclease 1) (Kratz et al., 2010;  
MacKay et al., 2010;  Smogorzewska et al., 2010) and XPF/ERCC1 nucleases to 
incise the DNA backbone on the leading strand and unhook the ICL (De Silva et al., 
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2000;  Kuraoka et al., 2000;  Niedernhofer et al., 2004). The ubiquitin signalling 
pathway is also important in the polymerase switching during translesion synthesis 
(TLS). At stalled replication forks, the replication clamp PCNA is ubiquitinated by 
Rad18 and Rad6 (Hoege et al., 2002;  Stelter and Ulrich, 2003;  Kannouche et al., 
2004;  Davies et al., 2008), to switch its affinity for replicative DNA polymerases to 
bypass polymerases (Polη, Polκ, Polι, Polξ and Rev1), which are able to use the 
damaged base as template and allow replication to proceed past the lesion (Waters et 
al., 2009). The unhooked ICL is then excised by the NER machinery (reviewed by 
Wood, 2011), and finally the DSB formed by Mus81 and the replication runoff is 
repaired by HR (Hinz, 2010). 
Genetic defects in the FA pathway present clinically early in life, with very diverse 
features including bone marrow failure, acute myeloid leukaemia, head and neck 
cancers, skin and skeletal abnormalities, microcephaly, and multiple organ 
abnormalities (Neveling et al., 2009). Defective TLS is associated with increased 
genomic instability, as exemplified by the human disease xeroderma pigmentosum 
variant (XPV) (Masutani et al., 1999;  Johnson et al., 1999). It can be inferred that a 
degree of tolerance to some mutagenic lesions is preferable to the consequences of 
DSBs such as chromosomal rearrangement and translocations. 
1.3.3 Apoptosis, senescence and autophagy 
When a cell fails to restore genome stability due to the quantity or complexity of the 
DNA damage sustained, it is still possible to prevent malignant transformation by 
undergoing apoptosis, senescence or autophagy. The choice between these outcomes 
depends on many factors, such as the cell cycle status and the severity of the damage, 
although many factors overlap in all three pathways. 
Apoptosis is programmed cell death closely linked to the DDR. The process is 
intrinsically linked to the release of mitochondrial inner membrane proteases such the 
cytochrome c and caspases, under the regulation of BCL-2 protein family (Czabotar et 
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al., 2014). In the context of DNA damage and cell cycle checkpoint activation, 
sustained p53 hyper-accumulation increases expression of pro-apoptotic factors such 
as BAX, NOXA, PUMA, and FAS receptor (Lane, 1992), which promotes cell death 
through activation of the caspase cascade (Haupt et al., 2003). There is also a p53-
independent pathway of initiating apoptosis through CHK1/CHK2-dependent activation 
of transcription factor E2F1, which promotes expression of factor p73 (another member 
of the p53 protein family), which activates pro-apoptotic factors such as BAX, PUMA 
and SCOTIN, as well as its anti-apoptotic isoform like ΔNp73 (Ramadan et al., 2005). 
In addition, DNA damage can also trigger the NF-κB-dependent activation of caspases 
through the IKK (IκB kinase) complex (Janssens and Tschopp, 2006).  
Senescence refers to a permanent arrest in cell cycle progression in normally cycling 
cells. DNA damage and oxidative stress are well-characterised triggers of cellular 
senescence (Campisi and d'Adda di Fagagna, 2007;  van Heemst et al., 2007). Not 
surprisingly, p53 plays a very similar role in maintaining cell cycle arrest as during the 
G1/S checkpoint activation, through activation of p21 and inhibition of CDK2 function 
(Section 1.3.1.2). Another pathway involves the retinoblastoma protein (pRB) 
activation by p16, and subsequent inhibition of E2F-dependent transcription of pro-
proliferation factors (Becker and Haferkamp, 2013). 
In postmitotic cells such as neurons and cardiomyocytes, where senescence is not 
feasible, autophagy becomes an important mechanism to systematically remove 
protein aggregates, dysfunctional organelles, or intracellular microbes through 
lysosome-mediated degradation (Cuervo, 2004;  Klionsky et al., 2007). The formation 
of autophagosomes is regulated by multiple factors such as nutritional deprivation 
(Lum et al., 2005;  Bergamini et al., 2007;  Mörck and Pilon, 2007;  Bishop and 
Guarente, 2007), oxidative stress (Filomeni et al., 2015), as well as endothelial 
reticulum (ER) stress (Ogata et al., 2006;  Yorimitsu et al., 2006;  Høyer-Hansen and 
Jäättelä, 2007). Autophagy usually promotes cellular viability but can lead to 
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accelerated cell death when apoptosis is inhibited (Shimizu et al., 2004;  Levine and 
Yuan, 2005), and conversely, inhibition of autophagy in the presence of nutritional 
deprivation promotes cell death by apoptosis (Maiuri et al., 2007). 
1.4 DNA topoisomerases 
DNA topoisomerases resolve topological stresses in the DNA double helix as it 
unwinds during processes such as DNA replication, transcription, DNA recombination, 
and chromatin remodelling. During these processes, positive or negative supercoils 
can build up in the still annealed double strands on either side of the separated 
strands, as the DNA double helix folds back onto itself and becomes entangled, 
preventing any further DNA unwinding. Therefore, supercoils must be removed as they 
arise. Topoisomerases are thus indispensable for life and are conserved from 
prokaryotes to all eukaryotes (Forterre et al., 2007).  
Topoisomerases modulate DNA topology by transiently breaking the backbone of the 
DNA, allowing movement of the DNA strand relative to itself or to another DNA strand, 
resealing the break, and then dissociating from the DNA. They can be broadly 
classified as type I or type II topoisomerases. The former breaks the backbone on one 
strand of the DNA, while the latter breaks both strands (Wang, 2002). Type I 
topoisomerases can further be divided into type IA, which forms covalent linkage to the 
5’-phosphate group of the phosphodiester bond of the backbone, and IB, which 
covalently links to the 3’-phosphate group (Wang, 2002). Type II topoisomerases can 
similarly be divided into type IIA and IIB. There are six known topoisomerases in 
humans: TOP1 (type IB), TOP1mt (type IB), TOP2α (type IIA), TOP2β (type IIA), 
TOP3α (type IA), and TOP3β (type IA) (Wang, 2002) (Fig. 1.7). 
1.4.1 Catalytic cycle 
Upon non-covalent binding around the DNA strand, a topoisomerase utilises a tyrosine 
residue in the catalytic site to deprotonate the scissile phosphate of the DNA backbone 
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Figure 1.7 Types of vertebrate topoisomerases. Topoisomerases can be classified
according to their modes of action. (A) A type 1B topoisomerase (TOP1 and TOP1mt in
humans) incises one strand of the DNA while being covalently attached to the 3’ end of the
nick. It can cleave both in front of a polymerase (positively supercoiled “Sc+”) or behind a
RNA polymerase (negatively supercoiled “Sc-”), and allow controlled rotation of the cleaved
strand around its own axis to relieve the supercoiling. (B) A type 2A topoisomerase (TOP2α
and TOP2β in humans) incises both strands of the DNA simultaneously, while being
covalently attached to the 5’ ends of the nick. TOP2 enzymes can cleave both positively and
negatively supercoiled DNA, but they are especially important in separating sister chromatids
post-replication. The strand passage reaction is ATP-dependent. (C) A type 1A
topoisomerase (TOP3α and TOP3β in humans) incises one strand of the DNA where the two
strands are separated by negative supercoiling. It attaches to the 5’ end of the nick and
passes the intact strand through the broken strand. The process is also ATP dependent.
Adapted from Pommier et al., 2016.
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(a nucleophilic reaction), breaking the phosphodiester bond of the DNA backbone and 
creating a covalent phosphotyrosine bond between the topoisomerase and the 
backbone (Champoux, 2001). The nick on the backbone then allows another DNA 
strand to pass through (in the case of type IA and type II topoisomerases), or the 
nicked strand can swivel around the intact strand (type IB) to release the torsional 
tension (Champoux, 2001). To reseal the nick, the hydroxyl group generated by 
breaking of the phosphodiester bond deprotonates the phosphotyrosine, thus restoring 
the phosphodiester bond and releasing the topoisomerase from the DNA backbone 
(Champoux, 2001). 
1.4.2 Cellular functions 
As topoisomerases are required wherever topological stress arises in the genome, they 
can bind supercoiled DNA with low sequence specificity (Spitzner and Muller, 1988;  
Porter and Champoux, 1989;  Capranico et al., 1990;  Jaxel et al., 1991). Type IB and 
type II topoisomerases preferentially bind supercoiled dsDNAs (Wang, 2002), reflecting 
their ability to resolve positive and negative supercoils. Type IA topoisomerases, as 
necessitated by their mechanism of action, require a short stretch of ssDNA for binding 
(Wang, 1971;  Srivenugopal et al., 1984;  Wilson et al., 2000;  Wang, 2002). Their 
supercoiling relaxing property is also less efficient than that of type II topoisomerases 
(change of one linking number per catalytic cycle instead of two), therefore they were 
predicted to be inefficient for resolving positive supercoils (Kirkegaard and Wang, 
1985;  Plank et al., 2005). 
1.4.2.1 Chromatin remodelling 
DNA transactions such as replication, transcription, recombination and damage repair 
that require modification or displacement of the nucleosomes to allow access for the 
involved proteins also often require changes in DNA topology. It is therefore not 
surprising that topoisomerases are required during chromatin remodelling. For 
example, it has been shown in yeast that the chromatin remodelling activity of the 
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Switch/Sucrose Non-Fermentable (SWI/SNF) complex is dependent on the activities of 
TOP1 and TOP2 (Gavin et al., 2001). Conversely, TOP1 and TOP2 are targeted to 
sites of active transcription or replication through interaction with the catalytic subunit of 
SWI/SNF, SMARCA4 (Dykhuizen et al., 2013;  Husain et al., 2016).  
In general, TOP1 is more closely associated with transcription-mediated chromatin 
remodelling, while TOP2 is more specific for replication-mediated remodelling. For 
instance, TOP1 has been shown to displace nucleosomes at transcription initiation 
sites (Khobta et al., 2006;  Durand-Dubief et al., 2011;  Baranello et al., 2010;  
Baranello et al., 2016); while TOP2α has an established role in postmitotic chromatid 
decatenation and nucleosome assembly (Hirano and Mitchison, 1993;  Dykhuizen et 
al., 2013;  Farr et al., 2014;  Broderick et al., 2015;  Nielsen et al., 2015;  Shintomi et 
al., 2015). 
1.4.2.2 DNA replication 
During DNA replication, as the replication fork progresses, positive supercoils 
accumulate ahead of the replication bubble. As the replication machinery rotates 
around the replication fork along the DNA helical axis, the tension in the positive 
supercoils is redistributed toward the back of the replication machinery and cause the 
newly synthesised DNA to intertwine (Peter et al., 1998). The activities of type IB and 
type IIA topoisomerases are therefore required: type IB to remove the positive 
supercoils and type IIA to separate the tangled replicated strands (Brill et al., 1987;  
Kim and Wang, 1989;  Strumberg et al., 2000). 
As two replication forks converge, the short piece of parental strands in between 
(termed “hemicatenane”) becomes too short for a type IB topoisomerase to bind to. In 
this case, type IA topoisomerase could resolve the tension in the single-stranded 
region of the parental strands, converting two replication forks into one (DiGate and 
Marians, 1988;  Nurse et al., 2003;  Suski and Marians, 2008). Type II topoisomerase 
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can then resolve the supercoiling in the two double-stranded replicated strands (Lucas 
et al., 2001;  Cebrián et al., 2015).  
Type IB and II topoisomerases have also been implicated in initiation of replication 
(Rampakakis et al., 2010), as they localise to a subset of replication origins 
(Abdurashidova et al., 2007;  Falaschi et al., 2007;  Falaschi, 2009;  Rampakakis and 
Zannis-Hadjopoulos, 2009;  Hu et al., 2009).   
Interestingly, in mammalian cells, TOP2 appears to negatively regulate replication 
initiation (Gonzalez et al., 2011;  Gaggioli et al., 2013), which could be important for 
suppression of aberrant replication initiation at sites of RNA:DNA hybrids (R-loops) 
(Kaguni and Kornberg, 1984).  
At completion of DNA replication, the daughter chromosomes must separate to allow 
proper segregation during mitosis. The centromeres play an important role in the 
process. Type II topoisomerases have been shown to associate with centromeric 
proteins like Aurora kinase B and Polo-like kinase 1 (PLK1), supporting its role in 
unlinking (decatenating) daughter chromosomes at the centromeres during mitosis 
(Holm et al., 1985;  Uemura and Yanagida, 1986;  Nitiss, 2009;  Coelho et al., 2008;  
Baxter et al., 2011;  Edgerton et al., 2016). 
1.4.2.3 Transcription 
During transcription, it has been observed that positive supercoiling is generated ahead 
of the transcription machinery; in addition, negative supercoils build up behind it (Liu 
and Wang, 1987). The formation of negative supercoils has been proposed to be due 
to the inability of the transcription machinery to rotate around the DNA helical axis, thus 
the DNA rotates instead (Maaløe, 1966). As transcription of most mRNAs is confined in 
the nucleolar “transcription factories”, anchorage of the DNA loop to the nuclear 
membrane and to the ribosomes (in the case of transcription-coupled translation) likely 
impede the mobility of the DNA and the transcription machinery relative to each other.  
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Although in transcription, there is no problem of formation of intertwined daughter 
strands, negatively supercoiled strands have the propensity to hybridise to the 
elongating nascent RNA strand, forming stable R-loops, especially in long genes with 
highly repetitive sequences such as rDNAs (Aguilera and García-Muse, 2012).  
Both type IB and II topoisomerase have been shown to reduce R-loop formation in 
rDNA genes (El Hage et al., 2010), with TOP1 primarily responsible for removal of 
negative supercoils and TOP2 more important for resolving positive supercoils (French 
et al., 2011).  
It is worth noting that TOP1 has an additional kinase activity unrelated to its DNA-
relaxation activity. TOP1 phosphorylates the splicing factor ASF/SF2 to promote RNA 
maturation (Rossi et al., 1996), thereby preventing annealing of the nascent RNA to the 
ssDNA template (Tuduri et al., 2009). 
Other than removing supercoils, topoisomerases also play a role in regulating gene 
expression at promoter and enhancer regions. For example, TOP1 interacts with the 
TATA-binding protein (TBP) subunit of the transcription activator, TFIID complex, and 
promotes its binding to TATA box (Kretzschmar et al., 1993;  Merino et al., 1993;  
Shykind et al., 1997). TOP1 also interacts with RNA Pol II paused near transcription 
initiation sites to promote transcription elongation (Baranello et al., 2016). In some but 
not all cases, the DNA cleaving activity of TOP1 is required, such as at androgen 
receptor-regulated enhancers (Puc et al., 2015). Similarly, TOP2β has been shown to 
induce DSBs at the sites of several ligand-dependent promoters (Ju et al., 2006;  
Haffner et al., 2010;  Williamson and Lees-Miller, 2011;  Trotter et al., 2015), as well as 
a subset of neuron-specific early response genes (Madabhushi et al., 2015).  
Pharmacological inhibition of TOP1 and TOP2 showed differing effect on transcription, 
with TOP1 stalling occurring mainly along elongating transcripts, while TOP2 stalling 
mainly at promoter regions (Collins et al., 2001). The response was also highly variable 
amongst genes of different lengths and chromosomal and episomal promoters, 
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suggesting the importance of chromosomal architecture in transcription. More 
specifically, in human cancer cell lines HCT116, MCF7 and MDA-MB-231, CPT 
downregulated transcription of long genes that were highly expressed, such as genes 
involved in RNA degradation, cell cycle, basal transcription factors and ubiquitin-
proteasome pathways, while activating transcription of short inactive genes in the 
oxidative phosphorylation, ribosome and p53 signalling pathways (Solier et al., 2013). 
It was proposed that CPT-induced TOP1-cc downregulate transcription at long genes 
through arresting RNA Pol II (Ljungman and Hanawalt, 1996;  Desai et al., 2003); 
inhibiting RNA splicing (Solier et al., 2004;  Solier et al., 2010); and upregulation of 
p53-dependent miRNA-142-3p (Solier et al., 2013). 
1.4.2.4 DNA recombination 
DSBR by HR can give rise to double Holliday junctions (dHJs) (Section 1.3.2.9). This 
is resolved by the HJ resolvosome, which consists of the RecQ helicase BLM, RPA-like 
factors RecQ-mediated genome instability proteins 1 and 2 (RMI1 and RMI2), and 
TOP3α (Wu et al., 2006;  Hartung et al., 2008;  Kaur et al., 2015). The helicase activity 
of BLM forces the two HJs to converge, making the dHJ resemble the structure of two 
colliding replication forks. TOP3α, stabilised by RMI1 and RMI2, binds the 
hemicatenane region and gradually decatenates the crossover strands, until they are 
completely separated and non-crossover products are generated (Wu and Hickson, 
2003;  Plank et al., 2006).   
On the other hand, during meiosis, DSBs are generated by the TOP4-like protein 
SPO11, which promotes recombination by recruiting the MRN complex, RAD51, CtIP, 
and DMC1-like factors (Baudat et al., 2000;  Neale et al., 2005;  Li and Ma, 2006;  
Keeney, 2008;  Hartsuiker et al., 2009), thus promoting genetic diversity in the 
daughter cells. 
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1.4.2.5 Mitochondrial DNA replication and transcription 
In the mitochondria, mtDNA replication and transcription also require the action of 
topoisomerases. TOP1mt, TOP2α, TOP2β, and TOP3α have all been found in the 
mitochondria (Zhang et al., 2001;  Wang, 2002;  Zhang et al., 2004a;  Plank et al., 
2005), although their mechanisms of action are less well-characterised.  
1.4.3 Cellular response to TOP1-cc 
Given the DNA-nicking property of the topoisomerases, the potential of introducing 
genomic instability increases if their catalytic cycle fails to complete, resulting in 
polymerase-blocking protein-DNA adducts. It has been shown that TOP1 can become 
trapped on the DNA backbone if it incises near endogenous DNA lesions such as base 
modifications, AP sites, nicks and mis-incorporated RNA (Pommier et al., 2003), which 
lack the 5’ hydroxyl group required for the re-ligation step. Trapped TOP1 (TOP1-cc) 
per se do not elicit DDR associated with DNA breaks, which is masked by the bulk of 
the protein. Fig. 1.2 illustrates that during DNA replication, collision with the replication 
machinery or excessive build-up of positive supercoiling in front inhibits progression of 
the replication fork, causing cytotoxic DSBs (Sordet et al., 2009). During transcription, 
stalling by TOP1-cc promotes formation of stable RNA/DNA hybrids (R-loops) that 
inhibit replication fork progression and associated ssDNA’s that are prone to 
spontaneous degradation or mutagenesis (Aguilera, 2002;  Li and Manley, 2006;  
Aguilera and García-Muse, 2012).   
The most well-characterised repair pathway of TOP1-cc to date, as mentioned in 
Section 1.3.2.5, involves the PARP1-TDP1-PNKP-XRCC1-Lig3α branch of SSBR 
(Pommier et al., 2006;  Ashour et al., 2015). APE1 has also been shown to process 3’-
phosphotyrosyl ends (Harrigan et al., 2007). PARP1 is known to accumulate in actively 
transcribing sites (Kraus and Lis, 2003;  Krishnakumar et al., 2008) and also physically 
interacts with TOP1 (Bauer et al., 2000). It has been shown that trapped TOP1 is 
rapidly ubiquinated and proteasomally degraded (Lin et al., 2008;  Lin et al., 2009), 
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together with the stalled RNAPII if present (Ratner et al., 1998); and that degraded 
TOP1-DNA adduct is the preferred substrate of TDP1 (Desai et al., 2003;  Lin et al., 
2009). Degradation of TOP1 has been shown to be dependent the E3 Ub ligases Cullin 
3 (Cul3) (Zhang et al., 2004b) and Cullin 4B (Cul4B) (Kerzendorfer et al., 2010). 
It is interesting that trapped TOP1 is also modified by SUMOylation (Mao et al., 2000;  
Horie et al., 2002), but the intended effect is not yet defined. It has been proposed to 
play a role in translocating TOP1-cc from the nucleolus to the nucleoplasm (Mo et al., 
2002;  Rallabhandi et al., 2002;  Christensen et al., 2004), inhibiting ubiquitination of 
TOP1 (Horie et al., 2002), or signalling recruitment of more free TOP1 (Horie et al., 
2002), or TDP1 (Hudson et al., 2012) to the damage sites. 
Given that most the genome is transcriptionally silent, it is likely that transcription-
independent pathways to repair TOP1-cc exist. Furthermore, in replicating cells, 
excessive accumulation of TOP1-cc would saturate the SSBR machinery, leading to 
collision of TOP1-cc with replication forks and formation of DSBs (Pouliot et al., 2001). 
Indeed, it has been demonstrated in yeast and mammalian cells that both HR and 
NHEJ pathways confer resistance against CPT in the absence of Tdp1 (Pommier et al., 
2003). Mre11/Rad50/Sae2 and Mus81/Mms4 (Mus81/EME1 in humans), together with 
Slx1/Slx4 can resect several nucleotides 5’ of the TOP1-cc end, leaving a 3’-hydroxyl 
end for gap repair (Deng et al., 2005;  Hamilton and Maizels, 2010;  Sacho and 
Maizels, 2011;  Regairaz et al., 2011). As these endonucleases do not require access 
to the phosphotyrosine bond like TDP1, degradation of TOP1 might not a prerequisite 
for this mode of repair.  
The NER pathway is also implicated in the repair of TOP1-cc. CSB defective patient 
cells show sensitivity to CPT, and in yeast the 3’ endonuclease Rad1/Rad10 
(XPF/ERCC1 in humans) possess activity against single-stranded 3’-phosphotyrosyl 
moieties similar to TDP1 (Vance and Wilson, 2002;  Zhang and Jasin, 2011;  Takahata 
 
35 
et al., 2015). Multiple NER factors such as RPA, pol δ, FEN1 and Lig1 catalyse the 
downstream repair in vitro (Takahata et al., 2015), suggesting repair during S-phase.   
Notably, since lower eukaryotes lack several key SSBR factors such as PARP1, 
XRCC1 and Lig3α (Kelley et al., 2003), it is likely that the SSBR pathway of TOP1-cc 
repair evolved later to manage the larger genome size and/or the higher transcriptional 
activity in specialised postmitotic tissues such as neurons. More recently, experiments 
in yeast and in vitro human cell extracts also suggest a role of TDP1 in the NHEJ 
pathway (Bahmed et al., 2010;  Heo et al., 2015), likely of functional significance in G2 
or postmitotic cells.  
1.4.4 Clinical relevance of TOP1 poisons 
Given the multiple pathways available to repair TOP1-cc, it is unlikely that TOP1-cc 
arising endogenous DNA lesions would elicit a dramatic DDR response such as 
checkpoint arrest or apoptosis, except in the case of cells under unusually high 
oxidative or replicative stresses. This differential DDR response between fast- and 
slow-growing cells forms the basis of several new classes of anti-cancer therapeutics. 
For example, PARP1 inhibitors are highly selective against fast-growing tumours, 
especially those defective in DSBR (Helleday, 2011). By compromising SSBR, more 
SSBs are converted to DSBs in fast-replicating cells, and if DSBR is defective, can 
undergo cell cycle arrest (Section 1.3.1) and apoptosis (Section 1.3.3).  
Topoisomerase poisons, unlike most enzymatic inhibitors, rely on the catalytic activity 
to form cleavage complexes, which then trigger DDR and apoptosis (Liu et al., 2000). 
Camptothecin was the original TOP1 poison discovered in the Chinese plant 
Camptotheca Accumulata (Wall and Wani, 1995). It had been used as an anti-cancer 
drug long before its mechanism of action was understood. Structural work by the 
Pommier group and others have later shown that it stabilises TOP1 on the DNA 
backbone nick by forming hydrogen bonds with the TOP1 catalytic residues and the -1 
T and +1 G bases surrounding the nick (Staker et al., 2002;  Staker et al., 2005;  
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Ioanoviciu et al., 2005;  Marchand et al., 2006). Therefore, CPT is specific to TOP1 
both in a sequence- and structural manner.  
However, the effects of TOP1 inhibitors on DNA transcription and replication also 
target haematopoietic stem cells and postmitotic cells, leading to immunosuppression, 
cardiotoxicity and neurotoxicity over time (Moertel et al., 1972;  Muggia et al., 1972). 
Due to its potent cytotoxicity, CPT is no longer used in the clinical setting. Currently, 
CPT analogues such as topotecan (TPT) and irinotecan (CPT-11) are FDA-approved 
for use in advanced colorectal, ovarian, cervical, and small-cell lung cancers (Pommier, 
2006). CPT and non-CPT analogues currently in clinical trials are summarized in Table 
1.1 (Xu and Her, 2015). 
Besides the unwanted cytotoxicity, the main challenges to develop next-generation 
TOP1 inhibitors lie with improving compound stability and overcoming development of 
resistance (Beretta et al., 2013). As over time, even a single point mutation in TOP1 
can potentially confer resistance. The rationale of combination therapy is that, by 
simultaneously generating TOP1-cc and inhibiting TOP1-cc repair, synthetic lethality 
can be achieved at lower or non-cytotoxic doses. For example, combination of a 
PARP1 (Delaney et al., 2000;  Thomas et al., 2007;  Zander et al., 2010;  Kummar et 
al., 2011;  Patel et al., 2012;  Samol et al., 2012;  LoRusso et al., 2016) or TDP1 
inhibitor and TOP1 poison would inhibit TOP1-cc repair by SSBR; while combination 
with ATM, ATR, CHK2 or TDP2 inhibitors would hinder repair by DSBR (Shao et al., 
1997;  Tse and Schwartz, 2004;  Flatten et al., 2005;  Pommier et al., 2005;  Elsayed et 
al., 2016). Alternatively, TOP1 poisons can be used as a neo-adjuvant drug to sensitize 
localized solid tumours such as glioblastomas to radiotherapy (Vredenburgh et al., 
2009).   
Name Trial phase Indications
Belotecan (CKD-602) Approved
(South Korea)
Advanced metastatic 
cancer, SCLC
Diflomotecan
(BN80915)
Phase II
(Ipsen)
Advanced solid tumors
Gimatecan
(ST-1481, LBQ707)
Phase I/II
(Sigma-Tau, Novartis)
SCLC, Ovarian
Lurtotecan
(Liposomal OSI-211, NX 
211)
Phase II
(Astellas, NCLC)
Exatecan mesylate
(DX-8951f)
Phase II/III
(Daiichi)
Sarcoma, Pancreatic, 
Gastric, Liver
Indenoisoquinolines 
(LMP400, LMP776)
Phase I
Table 1.1: Topoisomerase 1 inhibitors in clinical trials and their indications
(Adapted from Hu & Her, 2015. Biomolecules, 5, 1652-70)
 
37 
1.5 TDP1   
TDP1 is one of the more recently discovered member of the SSBR pathway. Its activity 
to resolve TOP1-cc is conserved from yeast to human (Yang et al., 1996;  Pouliot et 
al., 1999;  Interthal et al., 2001;  El-Khamisy et al., 2005), highlighting its evolutionary 
importance. This activity has also been implicated in resistance against anti-cancer 
TOP1 and TOP2 poisons (Barthelmes et al., 2004;  Nivens et al., 2004;  Liu et al., 
2007;  Meisenberg et al., 2014b), and therefore has been under investigation as a 
candidate for combination therapy with topoisomerase poisons. 
1.5.1 Structure and substrates 
Human TDP1 is a 68.5 kDa (608 amino acids) enzyme that belongs to the 
phospholipase D (PLD) superfamily and contains two distinct HKD motifs 
(HXK(X)4D(X)6GSXN) essential for its catalytic activity (Interthal et al., 2001). The N-
terminus domain (first 150 amino acids in human TDP1) is poorly conserved and only 
present in higher eukaryotes (Davies et al., 2002). The crystal structure of the C-
terminus domain of human TDP1 reveals two symmetrical α-β-α domains each 
consisting of seven beta sheets and two alpha helices, and a central catalytic site 
(Davies et al., 2002). Perpendicular to the boundary between the two domains, a 
narrow, positively-charged cleft of 8 Å runs through one side of the active site, while a 
widening cone-shaped cleft of up to 20 Å of mixed charge runs through the other side 
(Davies et al., 2002). This conformation allows binding of ssDNA in the narrow cleft 
and a TOP1 peptide moiety in the cone-shaped cleft (Davies et al., 2002;  Debéthune 
et al., 2002;  Davies et al., 2004;  Interthal and Champoux, 2011).  
Further structural and mutational studies revealed that TDP1 resolves TOP1-cc in a 
two-step reaction, firstly nucleophilic attack of the scissile phosphate by the H263 
residue and protonation of the tyrosyl residue by the H493 residue cleave the TOP1 
peptide from the DNA backbone, while forming a covalent phosphohistidine bond 
between TDP1 H263 and the 3’ phosphate end of the DNA backbone; the second step 
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involves activation of a water molecule by H493, which catalyses hydrolysis of the 
phosphohistidine bond and release of TDP1 (Interthal et al., 2001;  Davies et al., 
2003). Mutation of H493 therefore has a dominant negative effect, leading to formation 
of covalent TDP1-DNA intermediates similar to TOP1 (Interthal et al., 2005a;  Hirano et 
al., 2007). Resolution of these TDP1-DNA intermediates has been proposed to be 
carried out by TDP1 itself (Interthal et al., 2005a), as TDP1 has been shown to process 
the 3’- phosphoamide bond in the TDP1-DNA intermediate in vitro (Interthal et al., 
2005a); and that heterozygous carriers of H493R mutation do not develop SCAN1 
(Takashima et al., 2002). 
TDP1 has also been shown to process a variety of physiologically relevant 3’ termini, 
such as 3’-phosphoglycolate from oxidative damage and 3’-dRP from monofunctional 
alkylating agents (Inamdar et al., 2002;  Interthal et al., 2005a;  Zhou et al., 2009).  
Besides its 3’ phosphodiesterase activity, TDP1 also has limited 3’ exonuclease 
activity, which removes one nucleoside from DNA or RNA with 3’-hydroxyl ends 
(Interthal et al., 2005a;  Dexheimer et al., 2010). This activity has been linked to repair 
of lesions induced in the nucleus and mitochondria by chain-terminating anti-cancer 
and anti-viral nucleoside analogues (Huang et al., 2013;  Tada et al., 2015). 
1.5.2 Cellular functions 
TDP1 is ubiquitously expressed in most human and mouse tissues, both in the nuclear 
and mitochondrial compartments (Hirano et al., 2007;  Das et al., 2010;  Fam et al., 
2013a).   
Cell lines established from SCAN1 patients, Tdp1-/- mice, and TDP1-/- DT40 cells all 
show hypersensitivity to CPT (El-Khamisy et al., 2005;  Interthal et al., 2005b;  Miao et 
al., 2006;  Hirano et al., 2007;  Katyal et al., 2007;  Das et al., 2009;  El-Khamisy et al., 
2009;  Hawkins et al., 2009;  Murai et al., 2012), while overexpression of TDP1 
increases resistance to CPT (Barthelmes et al., 2004;  Nivens et al., 2004), confirming 
the role of TDP1 in repair of TOP1-cc in higher eukaryotes. Physical interaction of 
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TDP1 with XRCC1/Lig3α of the BER/SSBR pathway in mammalian cell lines (Plo et al., 
2003;  El-Khamisy et al., 2005) supports the prediction based on the crystal structure 
that TDP1 participates in the repair of single-stranded TOP1-linked DNA breaks in 
higher eukaryotes.  
However, accumulation of DSBs with 3’-PG ends was also detected in SCAN1 patient-
derived LCLs and Tdp1-/- MEFs (Zhou et al., 2005;  Hawkins et al., 2009). Moreover, 
Tdp1-/- MEFs and DT40 cells are sensitive to 3’-PG DSB-inducing drug bleomycin 
(Hirano et al., 2007;  Murai et al., 2012), while SCAN1 LCLs and TDP1-deficient HeLa 
cells are sensitive to calicheamicin (Zhou et al., 2009). Taken together, these data 
indicate that TDP1 also participates in the repair of 3’-PG DSBs in the cellular context. 
Binding of TDP1 to DSB ends has been proposed to be achieved through binding to a 
short 3’ overhang of the DSB (Zhou et al., 2009), a conformational change of the active 
site in vivo, or a 90° rotation of the dsDNA relative to the narrow cleft of TDP1, so that 
only 3 bases at a time are in contact with the narrow cleft (Raymond et al., 2005). 
The role of TDP1 on repair of TOP2-cc linked DSBs is less clear. TDP1-/- DT40 cells 
showed sensitivity to the TOP2 poison etoposide (Murai et al., 2012), while this was 
not observed in SCAN1 cells (Miao et al., 2006) or Tdp1-/- MEFs (Hirano et al., 2007). 
In vitro biochemical assays showed no TDP1 processing of 5’ phosphotyrosyl substrate 
(Cortes Ledesma et al., 2009), while in yeast TDP1 has been shown to process a more 
physiologically relevant substrate with TOP2 peptide-linked 5’ phosphotyrosyl terminus 
(Barthelmes et al., 2004;  Nitiss et al., 2006;  Borda et al., 2015). These inconsistent 
observations could be due to cell line- or species-specific modifications of TDP1 
activity in vivo; and highlight the importance of identifying intracellular modifiers of 
TDP1 activity that may contribute to the disease phenotype of SCAN1, or when 
designing inhibitors against TDP1. 
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There are accumulating evidence supporting that the N-terminus domain of TDP1 
regulates TDP1 function in the cellular context, through post-translational modifications 
and protein-protein interactions, which are discussed in detail in chapters 3 and 4.  
1.5.3 Spinocerebellar axonal neuropathy 1 (SCAN1) 
To date, three individuals with confirmed SCAN1 diagnosis have been described 
(OMIM #607250). They were all from a large consanguineous family and were 
homozygous for the TDP1 H493R mutation (Takashima et al., 2002). The presenting 
symptom was ataxic gait of adolescent onset. Clinical evaluation showed distal muscle 
weakness, areflexia, and disturbed proprioception. Cognition was normal in all three 
individuals. MRI scan showed cerebellar atrophy in individuals 1 and 2; and nerve 
conduction studies showed demyelination of the sural nerve in individual 3. All three 
individuals had mild hypoalbuminaemia and hyperlipidaemia. Mutational screens for 
Spinocereberllar ataxia (SCA) 1, 2, 3, 6, 7 and Friedreich ataxia (FRDA) were all 
normal for individual 1, and screens for metabolic disorders were negative in individual 
2 (OMIM #607250) (Takashima et al., 2002). Taken together, the clinical phenotype 
from these three individuals resembles that of Ataxia Oculomotor Apraxia 1 (AOA1) 
(OMIM #208920), except for a later age of onset.  
The lack of signs of genomic instability and immunodeficiency, and the overlap with 
AOA1 phenotype, suggest that the pathology of TDP1 H493R mutation is likely due to 
defective SSBR in postmitotic neurons. Lymphoblastoid cell lines from the three 
SCAN1-affected individuals were defective in repair of replication-independent 
chromosomal SSBs induced by CPT and H2O2 (El-Khamisy et al., 2005); as were 
cerebellar neurons and primary astrocytes from Tdp1-/- mice (Katyal et al., 2007). 
However, Tdp1-/- mice do not develop ataxia (Katyal et al., 2007). It has therefore been 
proposed that the pathogenic lesions in SCAN1 are a combination of TOP1-cc, TDP1-
DNA intermediates (Interthal et al., 2005a;  Hirano et al., 2007;  Hawkins et al., 2009), 
and 3’-PG SSBs from endogenous ROS (Zhou et al., 2005), that together form a 
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vicious cycle to generate SSBs that eventually inhibit transcription and lead to cellular 
dysfunction (Caldecott, 2008).  
Since cerebellar ataxia is a frequent symptom of mitochondrial DNA diseases (Lax et 
al., 2012), it has also been suggested that TDP1 and APTX may play a more important 
role in protecting the mitochondrial genome than the nuclear genome (Kazak et al., 
2012;  Sykora et al., 2012). As mitochondrial TOP1 has been implicated in maintaining 
mtDNA integrity (discussed in Section 6.1.2), if TDP1 plays a significant role in repair 
of TOP1mt-cc and oxidative mtDNA damages (Das et al., 2010), these could be the 
additional pathogenic lesions in SCAN1. This hypothesis was investigated and 
described in detail in chapters 5 and 6.  
1.5.4 Tumorigenesis and targeted therapy 
TDP1 has also been an emerging player in the field of cancer research, primarily 
because of its broad-spectrum of substrates that imply the potential to modulate 
sensitivity of vertebrate cells to TOP1, TOP2 poisons (Barthelmes et al., 2004;  Nivens 
et al., 2004;  Interthal et al., 2005b;  El-Khamisy et al., 2005;  Miao et al., 2006;  Katyal 
et al., 2007;  Murai et al., 2012), as well as alkylating agents (Alagoz et al., 2013), 
radiotherapy (El-Khamisy and Caldecott, 2007), and chain-terminating nucleoside 
analogues (Huang et al., 2013;  Tada et al., 2015). However, precisely because of its 
broad-spectrum activity, finding a target that specifically inhibits TDP1 activity has 
proven challenging.  
Chemical compounds known to inhibit TDP1 in vitro include vanadate and tungstate, 
which were used to co-crystalise with TDP1 (Davies et al., 2002), however they are 
broad-spectrum inhibitors of phosphatases (Makinen, 1985;  Stankiewicz and Gresser, 
1988). Antibiotics such as aminoglycosides (neomycin B, paromomycin and 
lividomycin) and bacterial ribosome inhibitors (thiostrepton, clindamycin and 
puromycin) showed weak inhibition of TDP1 in vitro (Liao et al., 2006), and they are 
also broad-spectrum inhibitors of PLD enzymes (Huang et al., 1999). Furamidine 
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(DB75, NSC 305831), an anti-parasitic drug (Thuita et al., 2012), showed higher 
potency than the aminoglycosides and ribosome inhibitors, and likely acted through 
forming a ternary structure with ssDNA and TDP1, similar to CPT (Pommier, 2006;  
Antony et al., 2007). Interestingly, co-administration of furamidine and irinotecan 
augmented the effect of irinotecan on ameliorating nephritis in mouse model of 
systemic lupus erythematous (SLE), possibly through inhibition of DNA relaxation and 
subsequent binding by anti-dsDNA antibodies (Frese-Schaper et al., 2014;  Keil et al., 
2015), indicating potential non-oncologic application for a TDP1 inhibitor. Two 
phosphotyrosine mimetics, methyl-3,4-dephostatin and NSC88915, identified through 
high-throughput screens (Dexheimer et al., 2009;  Marchand et al., 2009), provided 
insights on the molecular basis for TDP1 active site inhibition. Lastly, using high-
throughput DT40 whole cell lysate assay to validate activity in the cellular context, two 
new compounds, NCGC00183974 and JLT048, were identified to selectively interact 
with TDP1 over TDP2 (Marchand et al., 2014). However, neither compounds induced 
cell killing by CPT in cultured cells, suggesting either inefficient uptake by cells, 
unknown cellular mechanisms that inactivate the compounds, or a cell line-specific 
compensatory upregulation in TDP1 activity level. 
It was therefore becoming clear that finding effective TDP1 inhibitors in terms of 
cytotoxicity also relies on understanding the downstream compensatory response that 
determines the ultimate cell fate. One of these responses appears to be regulation of 
TDP1 expression and function, as illustrated by several recent studies. Expression and 
enzymatic activity of TDP1 was found to be higher in over 50 % of a panel of 34 
treatment-naïve primary non-small cell lung carcinomas (NSCLC) compared to 
adjacent non-cancerous tissues from the same individuals (Liu et al., 2007); this was 
supported by another study using nanosensors to measure TDP1 activity in situ, 
whereby the activity was increased in 24 NSCLC tissues compared to adjacent non-
cancerous tissues (Jakobsen et al., 2015). These findings suggest regulation of TDP1 
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function is intrinsic to tumourigenesis in NSCLC. In addition, there appeared to be a 
reciprocal downregulation of XPF overexpression in tumours overexpressing TDP1 (Liu 
et al., 2007), suggesting crosstalk between the parallel repair pathways of TOP1-cc 
repair. Another study showed that TDP1 mRNA levels were increased in a panel of 147 
treatment-naïve primary rhabdomyosarcomas compared to normal skeletal tissues, 
and the protein levels of TDP1 as well as PARP1 were increased in 5 of the studied 
rhabdomyosarcoma cell lines compared to control cell lines (Fam et al., 2013b). 
Concomitant silencing of TDP1 and pharmacologic inhibition of PARP1 by rucaparib 
sensitised rhabdomyosarcoma cells to the DNA-damaging and cell-killing effect of CPT 
more than in control cells, suggesting an intrinsic DNA repair defect in these 
rhabdomyosarcoma cell lines that was compensated by TDP1 and PARP1 (Fam et al., 
2013b). On the other hand, downregulation of TDP1 expression was found in six out of 
nine of lung cancer tissues from the NCI-60 panel, two of which showed undetectable 
TDP1 mRNA level and enzymatic activity, as well as increased DSBs after CPT 
treatment (Gao et al., 2014).  
The studies described so far found heterogeneity in response to CPT in tissues with 
altered TDP1 expression levels. However, two small-scale studies suggest the ratio of 
TDP1:TOP1 may be a useful predictor of cellular response to CPT in colorectal 
cancers (Meisenberg et al., 2014a) and small cell lung cancers (Meisenberg et al., 
2014b).  
1.6 General aims and objectives 
At the start of this project, the catalytic mode of action of TDP1 was well-established; 
its role in repair of TOP1-associated DSBs in yeast has been demonstrated; its 
association with components of the SSBR machinery was discovered in mammals; and 
a strong association of TDP1 catalytic mutation with the SCAN1 disorder was 
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established. However, little was known about how its function is regulated in the 
cellular context.  
The interaction between XRCC1/Lig3α and TDP1 through its N-terminus domain (NTD) 
(El-Khamisy et al., 2005) was intriguing. It raised questions of the function of the NTD 
that evolved in higher eukaryotes. Perhaps in higher organisms, the larger genomic 
size and longer cellular lifespan would require a more efficient and regulated SSBR 
machinery, including TDP1. Does the addition of the NTD affect the catalytic activity in 
anyway? Does it change the tertiary structure or the stability of the protein? Does it 
promote recruitment of TDP1 to sites of chromosomal breaks? Does it mediate 
interaction of TDP1 with other enzymes that participate in repair of TOP1-cc? All these 
questions are highly relevant to the process of developing effective TDP1 inhibitors as 
discussed in Section 1.5.4. 
On the other hand, a major question of the specific vulnerability of cerebellar neuronal 
cells in SCAN1 patients remains. As the cerebellum is a metabolically active organ, 
with high ATP demand and high levels of ROS as by-products, I hypothesised that 
TDP1 may play a protective role against DNA damage in tissues with high levels of 
endogenous ROS. Specifically, I investigated whether cells with high endogenous ROS 
accumulate more chromosomal breaks in the absence of TDP1; whether TDP1 was 
involved in the repair and/or production of endogenous ROS; and whether these 
chromosomal damages impact on mitochondrial functions and cellular viability.  
In short, the original contribution of this thesis is to provide insight into the cellular 
function of human TDP1, by characterising NTD-mediated post-translational 
modifications of the protein, and its role in the mitochondria. 
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2.1 General chemicals and equipment 
General laboratory chemicals were obtained from Sigma Aldrich or Fisher Scientific 
unless otherwise specified. Restriction endonucleases were obtained from New 
England Biolabs or Roche Diagnostic. DNA and RNA oligonucleotides were 
synthesised by Eurofins MWG Operon (Ebersberg, Germany) or Integrated DNA 
Technologies (Leuven, Belgium). Cell culture media and nutritional supplements were 
obtained from Gibco® Invitrogen or Sigma Aldrich. Foetal bovine sera of South 
American origin were sourced by Sigma Aldrich (F6524) or PAN-Biotech (Aidenbach, 
Germany). Tetracycline tested FBS of South American origin was from Labtech 
(FB1001T/500). Cell culture plastic-ware was manufactured by Nunc™ or Corning.  
2.2 Molecular biology techniques 
2.2.1 DNA plasmids 
Sources of all plasmid DNA constructs used in this thesis are indicated in Tables 2.1, 
2.2, and 2.3 respectively. 
For yeast two-hybrid experiments, bait protein cDNA sequences were encoded in the 
pGBKT7 vector (Clontech, 630443), which contains the GAL4 DNA-binding domain 
(amino acids 1 – 147) and a c-Myc epitope tag upstream of the multiple cloning site 
(MCS). Constitutive expression of the fusion protein in yeast is under the control of the 
ADH1 promoter. The vector also contains a TRP1 nutritional marker and kanamycin 
resistance gene for selection in yeast and E. coli, respectively.  
The cDNA sequences of prey proteins were encoded in the pACT2 AD vector 
(Clontech, 638822), which contains the GAL4-activation domain (amino acids 768 – 
881) and a HA epitope tag upstream of the MCS. Constitutive expression of the fusion
protein in yeast is under the control of the ADH1 promoter. The vector also contains a 
Plasmid DNA construct Source/Reference
pGBKT7 Clontech
pGBKT7-TDP1 Prof. Sherif El-Khamisy
pGBKT7-TDP11-150 Prof. Sherif El-Khamisy
pGBKT7-TDP1151-608 Prof. Sherif El-Khamisy
pGBKT7-TDP1S81A This thesis
pGBKT7-TDP1S81A 1-150 This thesis
pGBKT7-TDP1S81A 151-608 This thesis
pGBKT7-TDP1S81E This thesis
pGBKT7-TDP1K111R This thesis
pACT2 Clontech
pACT2-APTX Prof. Keith Caldecott
pACT2.6-ERCC1 Dr John Rouse (Muñoz et al., 2009)
pACT2-Ku80 Prof. Keith Caldecott
pACT2-Lig3α Prof. Keith Caldecott (Caldecott et al., 1996)
pACT2-SLX1 Dr John Rouse (Muñoz et al., 2009)
pACT2-UBE2I This thesis
pACT2-XPF Dr John Rouse (Muñoz et al., 2009)
pACT2-XRCC1 Prof. Keith Caldecott
pACT2-XRCC4 Prof. Keith Caldecott
Table 2.1: Yeast two-hybrid constructs
Plasmid DNA constructs used in this thesis for yeast two-hybrid analysis and their 
sources. 
. 
Plasmid DNA construct Source/Reference
pCI-puro-Myc Prof. Keith Caldecott
pCI-puro-Myc-TDP1 This thesis
pCI-puro-Myc-TDP1S81A This thesis
pCI-puro-Myc-TDP1S81E This thesis
ΔT-Myc-DEST Dr Helfrid Hocheggar
ΔT-Myc-DEST -UBE2I This thesis
pMX-PIE-TopBP1-ER Dr Oskar Fernandez-Capetillo (Toledo et 
al., 2008)
pMX-PIE-TDP1 This thesis
pMX-PIE-TDP1S81A This thesis
pMX-PIE-TDP1K111R Dr Jessica Hudson (Hudson et al., 2012)
pMX-PIE-SOD1 This thesis
pMX-PIE-SOD1G93A This thesis
pMC-EGFPP-N-TDP1 Dr Morten Christensen
pMC-EGFPP-N-TDP1K111R Mr Chris Rookyard (Hudson et al., 2012)
pEGFP-C1-SUMO1 Prof. Alan Lehmann
pMSP-shUBE2I Open Biosystems/Dharmacon (clone V2HS_171771)
pcDNA6.2-GW-EmGFP Thermo Fisher (cat. No. K4936-00)
pcDNA6.2-GW-EmGFP-miTDP1 This thesis
pcDNA5-FRT-His Prof. Stuart Wilson
pcDNA5-FRT-miScr Prof. Stuart Wilson
pcDNA5-FRT-miTDP1 This thesis
pcDNA5-FRT-TDP1TR-miScr This thesis
pcDNA5-FRT-TDP1TR-miTDP1 This thesis
pcDNA5-FRT-SOD1-mi TDP1 This thesis
pcDNA5-FRT-SOD1G93A-miScr This thesis
pcDNA5-FRT-SOD1G93A-miTDP1 This thesis
pcDNA5-FRT-TOP1mt-miScr This thesis
pcDNA5-FRT- TOP1mt-miTDP1 This thesis
pcDNA5-FRT-TOP1mtT554A,N558H-miScr This thesis
pcDNA5-FRT-TOP1mtT554A,N558H-miTDP1 This thesis
Table 2.2: Mammalian expression constructs 
Plasmid DNA constructs used in this thesis for expression of the indicated cDNA in 
mammalian cells and their sources. 
Plasmid DNA construct Source/Reference
pET28b-SOD1 Dr Majid Hafezparasat
pET28b-SOD1G93A Dr Majid Hafezparasat
pcDNA5-FRT-TOP1mt Dr Martin Meagher
Table 2.3: Miscellaneous constructs used as cDNA templates 
Plasmid DNA constructs used in this thesis for subcloning the indicated cDNA into 
mammalian expression constructs and their sources. 
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LEU1 nutritional marker and ampicillin resistance gene for selection in yeast and E. 
coli, respectively. 
For protein expression in mammalian cells, the vectors pCI-puro-Myc (Promega, 
E1731), pMC-EGFP-P-N (Barthelmes et al., 2004), pMX-PIE and pcDNA5-FRT were 
used. The pCI-puro-Myc vector contains a c-Myc epitope tag upstream of the MCS, 
which is useful for co-immunoprecipitation (Co-IP) experiments by Myc pull-down. The 
constitutional expression of the fusion protein is driven by the CMV promoter/enhancer 
sequence. The vector also contains a puromycin resistance gene under the SV40 
promoter regulation for selection in mammalian cells; and an ampicillin resistance gene 
for propagation in E. coli cells. 
The pMC-EGFP-P-N vector, derived from the plasmid pMC-2PS-delta HindIII-P (Mielke 
et al., 2000), contains the EGFP fluorophore epitope tag downstream of the MCS, 
which allows expression of C-terminally-tagged fusion proteins, useful for fluorescence 
microscopy and FACS experiments. The constitutional expression is driven by the 
CMV promoter/MPSV (myeloproliferative sarcoma virus) enhancer sequence. The 
vector allows expression of the puromycin resistance gene with the fusion protein as a 
bicistronic transcript linked by an Internal Ribosomal Entry Site (IRES) element. The 
vector also has an ampicillin resistance gene for propagation in E. coli. 
For difficult to transfect mammalian cells, the pMX-PIE (pMX-puromycin-IRES-EGFP) 
vector was utilised for gene transfer by retroviral transduction of the virus packaging 
cells. The retrovirus vector was derived from the pMX vector (Kitamura et al., 2003), 
and contains an EGFP epitope tag downstream of the MCS linked by an IRES 
element, and puromycin and ampicillin selection markers. The transcript unit is flanked 
by the retroviral (Moloney Murine Leukaemia virus, or MMLV) long terminal repeats 
(LTRs) on the 5’ and 3’ ends. The LTRs encodes eukaryote-like promoter/enhancer 
sequences for transcription of the gene of interest after integration into the genome of 
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the virus packaging cell line, which also contains the viral env gene that encodes 
envelop protein required for assembly of complete viral particles.  
The pcDNA5-FRT vector was used to encode cDNAs of proteins that require inducible 
expression, due to cytotoxicity from constitutional overexpression. The vector contains 
a CMV/2x TetO2 promoter/enhancer sequence upstream of the MCS, and a Flp 
Recombinase Target (FRT) site upstream of a hygromycin resistance gene, which is 
activated upon Flp recombinase-mediated integration into the host genome. 
For microRNA-mediated gene silencing in mammalian cells, the expression vector 
pcDNA6.2-GW/EmGFP-miR (Life Technologies, K4939-00) was used. It allows 
polycistronic transcription of the EmGFP tag and up to three miRNA sequences under 
the control of the CMV promoter. It has blasticidin and spectinomycin resistance 
markers for selection in mammalian and bacterial cells, respectively.  
2.2.2 Propagation of plasmid DNA 
Chemically competent DH5α E. coli cells were slowly thawed on ice. 1 µg of plasmid 
DNA was incubated with 50 µL of cells on ice for 30 minutes. Cells were heat-shocked 
in 42°C water bath for 45 seconds, and cooled on ice for 2 minutes. 500 µL of LB was 
added to the cells, and the culture was incubated at 37°C for 1 hour at 225 rpm 
shaking. Transformants were selected on LB agar plates with 50 µg/mL selection 
antibiotic (ampicillin, kanamycin, or spectinomycin) at 37°C overnight. Single colonies 
were inoculated in 5 mL (for minipreps) or 100 mL (for midipreps) LB media with 
50 µg/mL of appropriate selection antibiotic, and culture was incubated at 37°C 
overnight shaking at 225 rpm. Plasmids were extracted using the Qiagen DNA 
extraction kits (QIAprep® Spin Miniprep Kit and QIAprep® Plasmid Midiprep Kit) 
following the manufacturer’s instructions.  
49 
2.2.3 Quantification of DNA/RNA concentration 
Plasmid DNA concentration was determined using the NanoDrop ND-
Spectrophotometer (software version V) at a wavelength of 230 nm. A ratio of 260/280 
absorbance between 1.8 – 2.0 indicates the preparation is free from contaminants that 
strongly absorbs at 280 nm. 
2.2.4 DNA agarose gel electrophoresis 
Electrophoresis grade agarose was dissolved in 1 x TBE buffer (89 mM Tris, 89 mM 
boric acid, 2 mM EDTA pH 8.0) to make 1 % w/v agarose gels. 2 µg/mL ethidium 
bromide was added to the gel mixture and the gel was poured and set in a gel tray. 
DNA samples were loaded to the gel in 1 x loading buffer (0.04 % w/v bromophenol 
blue, 2.5 % w/v Ficoll). 1 kb plus DNA ladder (Invitrogen, 10787018) was loaded as 
marker. The sample was subjected to electrophoresis at 100 V for 40 minutes. DNA 
was visualised by UV transillumination.  
2.2.5 DNA sequencing 
Plasmid DNA was sequenced by Sanger-sequencing (GATC Biotech) using plasmid-
specific primers. 
2.2.6 TOPO-TA Cloning 
FastStart High Fidelity PCR System (Roche Applied Science, 03553426001) was used 
to generate PCR fragment for subsequent TOPO-TA Cloning. In a 25 µL reaction, 
10 ng of template DNA, 200 µM dNTPs, 200 µM of each oligonucleotide primers, 1 U of 
Taq DNA polymerase, 1.8 mM MgCl2, and 1 µL of DMSO were added in 1 x reaction 
buffer. Thermocycling was performed on a Techne TC-3000 x thermocycler (Bibby 
Scientific) as follows: initial denaturation at 95°C for 2 minutes; 35 cycles of 95°C for 30 
seconds, (Tm of primers -5°C) annealing for 30 seconds, 72°C extension for 45 
seconds plus 1 minute per additional kb plasmid length; with final extension at 72°C for 
7 minutes. 
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Freshly amplified PCR product was analysed by agarose gel electrophoresis for 
specificity of the amplicon. Further purification was performed if necessary using the 
Qiaquick Gel Extraction Kit (Qiagen). The TOPO-TA Cloning Kit (Invitrogen) was used 
to ligate the PCR product with the pCR2.1-TOPO vector using the following reaction: 
1 µL of salt solution, 1 µL of vector, 4 µL of PCR product. The ligation reaction was 
incubated at room temperature for 15 minutes, then added to 50 µL of the chemically 
competent TOP10 cells supplied with the kit. The cells were kept on ice for 10 minutes, 
then heat-shocked in 42°C water bath for 45 seconds, and cooled on ice for 2 minutes. 
500 µL of LB was added to the cells, and the culture was incubated at 37°C shaking at 
225 rpm for 1 hour. The transformants were selected on LB agar plates containing 
50 µg/mL ampicillin and 40 mM x-gal at 37°C overnight. Single white colonies were 
picked to inoculate 5 mL LB media with 50 µg/mL ampicillin overnight at 37°C shaking 
at 225 rpm. Plasmid DNA was extracted with the QIAprep® Spin Miniprep Kit following 
manufacturer’s instructions. Purified minipreps were then digested with appropriate 
restriction endonucleases and analysed by agarose gel electrophoresis to confirm 
correct size and orientation of the inserts. Plasmid DNA with the correct size and 
orientation of inserts were then analysed by PCR sequencing to confirm no extra 
mutations were introduced to the insert during initial PCR amplification.  
2.2.7 Restriction endonuclease digestion 
DNA of the appropriate concentration (0.5 – 5 μg) was incubated with 1 – 2 U of 
appropriate restriction enzyme for 2 hours at 37°C. Complete digestion of the DNA was 
determined by comparison to an undigested control sample by agarose gel 
electrophoresis. If appropriate, DNA fragments were purified using Qiagen QIAquick® 
Gel Extraction Kit and the DNA concentration was quantified as described above. 
2.2.8 DNA ligation 
DNA ligation reactions were set up according to Sambrook and Russell protocol 
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(Sambrook and W Russell, 2001) at vector to insert molar ratio of > 1:3. Reactions 
were incubated with 1 U of T4 DNA ligase overnight at 16°C in a total volume of 10 μL. 
5 μL of the ligation reaction was transformed into chemically competent DH5α cells as 
described above in Section 2.2.6. Plasmid DNA was extracted according to 
manufacturer’s instructions for the QIAprep® Miniprep Kit (Qiagen, 27104). The 
presence of the insert and correct orientation was confirmed by digestion of the 
plasmid by restriction digest and analysis by agarose gel electrophoresis. 
2.2.9 Site-directed mutagenesis 
The KOD Hot Start DNA polymerase (Merck Millipore, 71086) was used to for PCR-
based site-directed mutagenesis. Primers used are listed in Table 2.4. In a 50 µL 
reaction, 75 ng template DNA, 15 µM forward and reverse primers, 5 µL dNTPs (2 mM 
of each nucleoside), 2 µL MgSO4 (25 mM), 1 µL PCR-grade DMSO and 1 µL KOD 
polymerase were added to 1 x reaction buffer. Thermocycling was performed using a 
Techne TC-3000X thermocycler with these conditions: initial denaturation at 95°C for 5 
minutes; 18 cycles of 95°C for 1 minute, (Tm of primers -5°C) annealing for 1 minute, 
68°C extension for 1 minute/kb template DNA; and final extension at 68°C for 10 
minutes. 5 µL of the amplified PCR reaction was analysed by agarose gel 
electrophoresis to assess specificity of the amplicon. 20 U of Dpn1 (NEB, R0176) was 
added to the rest of the PCR reaction to digest away methylated parental strand of the 
template by incubation at 37°C for 1 hour. 5 µL of the digested PCR reaction was then 
used to transform 100 µL of chemically competent DH5α cells as described in Section 
2.2.6. Single colonies were picked to inoculate 5 mL of LB with 50 µg/mL appropriate 
selection antibiotic, cultures were grown for 16 hours at 37°C shaking at 225 rpm. 
Plasmid DNA was extracted using the QIAprep® Spin Miniprep Kit following 
manufacturer’s instructions. Restriction endonucleases digestion followed by agarose 
gel electrophoresis was used to identify clones with correct insert size and orientation. 
These clones were sequenced by GATC Biotech (Konstanz, Germany), to confirm 
Primer name Sequence
TDP1S81A (F) GGCAGAAAAGCGGTGCCCAGGAGGACCTCGGC
TDP1S81A (R) GGCGAGGTCCTCCTGGGCACCGCTTTTCTGCC
TDP1S81E (F) GGCAGAAAAGCGGTGAGCAGGAGGACCTCGGC
TDP1S81E (R) GGCGAGGTCCTCCTGCTCACCGCTTTTCTG CC
TDP1K111R (F) GCTGAGAAAGTGGTGATCAGAAAGGAGAAAGACATCTCT
TDP1K111R (R) AGAGATGTCTTTCTCCTTTCTGATCACCACTTTCTCAGC
TDP1TR miRNA #1 (F) GAGGTTCACGATATCAAGCAGCGCGAAAGTGAGGAAGAAAAG
TDP1TR miRNA #1 (R) CTTTCGTCGCTGCTTGATATCGTGAACCTCCTCCCATAATC
TDP1TR miRNA #2 (F) CTTCTGCCTCTCAAGTAGCGACGATGAGCTGCAACCAG
TDP1TR miRNA #2 (R) CTCATCGTCGCTACTTGAGAGGCAGAAGCCGAGGTCCTC
TOP1mtT456A,N460H (F) GCCCTGGGCGCGTCCAAGCTCCACTACCTGG
TOP1mtT456A,N460H (R) CCTGGGGTCCAGGTAGTGGAGCTTGGACGCGCCCAGGGC
Table 2.4: Site-directed mutagenesis PCR primers 
Primers were designed according to the QuikChange XL Site-Directed Mutagenesis 
Kit from Stratagene to incorporate a single amino acid change at the protein level. 
For targeting-resistant cDNA, silent mutations were introduced using primers 
designed according to Zheng et al., 2004 Nucl. Acid Res. 32(14): e115. Nucleotide 
changes are indicated in red. 
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presence of the desired mutation.  
2.2.10 Phenol: chloroform DNA extraction  
To extract DNA from samples containing proteins, an equal volume of 
phenol:chloroform:isoamyl alcohol solution (VWR, A0944.0100) was added to the DNA 
solution. The mixture was vortexed briefly, then centrifuged at 13000 rpm for 5 minute. 
The top layer was carefully transferred to a clean tube, and mixed with equal volume of 
chloroform:IAA, vortexed briefly, then centrifuged at 13000 rpm for 2 minutes. The top 
layer is again transferred to a clean tube, then mixed with 2 x volume of 100 % ethanol 
containing 0.3 M sodium acetate and 20 µg glycogen. The DNA was precipitated by 
incubating at -80°C for 45 minutes and centrifugation at 13000 rpm for 30 minutes. The 
supernatant was carefully transferred to a clean tube, and the DNA pellet was washed 
twice with 70 % ethanol. The pellet was then air-dried until transparent, and 
resuspended in 50 µL distilled water. If after DNA quantification, the concentration was 
lower than expected, the saved supernatant was centrifuged again and the DNA pellet 
processed as described above. 
2.3 Yeast two-hybrid assay 
2.3.1 Yeast media 
YPD medium: 20 g/L peptone, 10 g/L yeast extract, 20 g/L yeast granulated agar (for 
plates), 2 % glucose 
Yeast minimum medium with Histidine (His+ YMM): 80 mg/L adenine, 40 mg/L 
histidine, 20 g/mL yeast granulated agar (for plates), 2 % glucose, 6.7 g/L yeast 
nitrogen base 
Yeast minimum medium without Histidine (His- YMM): 80 mg/L adenine, 2 % 
glucose, 6.7 g/L yeast nitrogen base with ammonium sulphate, 25 mM 3-amino-1,2,4-
triazole, 20 g/mL yeast granulated agar (for plates). 
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2.3.2 Yeast strain maintenance and storage 
Wildtype S. cerevisiae strain Y190 (Clontech) was grown at 30°C on YPD agar plate, 
and re-streaked on fresh plate every third day or when cells turned pink. Transformed 
Y190 was selected and maintained on YMM plates. For long-term storage, 
untransformed Y190 cells were stored in YPD medium with 25 % glycerol at -80°C. 
Transformed cells were stored in YMM with 25 % glycerol at -80°C. 
tdp1∆/rad1∆ S. cerevisiae strain (YW812) was generated by Thomas Wilson (Vance 
and Wilson, 2002) and provided by Keith Caldecott.  
2.3.3 Small-scale lithium acetate yeast co-transformation 
2.3.3.1 Stock solutions 
10 x TE buffer: 100 mM Tris HCl, 10 mM EDTA, pH 7.5. Autoclave to sterilise. 
10 x Lithium acetate (LiAc): 1 M lithium acetate, pH 7.5 with dilute acetic acid. 
Autoclave to sterilise 
50 % PEG: 50 % w/v PEG (MW 3350) in sterile distilled H2O. Dissolve by warming to 
50°C 
Salmon sperm DNA: 10 mg/mL salmon sperm DNA (Sigma, D1626), sonicated 2 x 30 
seconds 
2.3.3.2 Preparation of competent Y190 cells 
20 mL YPD medium was inoculated with a few colonies of healthy Y190 cells. Cells 
were grown at 30°C overnight at 200 rpm. Overnight culture was diluted in YPD 
medium to an OD600 of ~ 0.2AU and incubated at 30°C at 200 rpm until OD600 reached 
0.6 – 0.8AU (at least two divisions). Culture was centrifuged at 2500 rpm for 5 minutes, 
then the pellet washed with 1 x TE buffer, followed by washing with 1 mL 100 mM LiAc. 
Cells were resuspended with 400 µL 100 mM LiAc, 50 µL of cell suspension were 
transferred to a 1.5 mL Eppendorf tube, briefly centrifuged to remove the LiAc, and 
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kept on ice until ready to use. 
2.3.3.3 Lithium acetate transformation 
Salmon sperm DNA was denatured by boiling at 90°C for 10 minutes, then cooled on 
ice for 10 minutes. The following were added to the cell pellet in this order: 240 µL 
50 % PEG, 36 µL 1 M LiAc, 10 µL salmon sperm DNA, 1 – 5 µg plasmid DNA, and 
sterile H2O to make up to 360 uL final volume. The transformation reaction was 
vortexed vigorously for 1 minute, then incubated at 30°C for 30 minutes. The cells were 
heat-shocked in 42°C water bath for 20 minutes (strain specific), then centrifuged at 
6000 rpm for 15 seconds. The cells were gently resuspended in 1 mL sterile H2O, and 
200 µL of the suspension was plated on His+ YMM selection plate. Transformants 
were selected by growing at 30°C for 72 hours. 10 – 20 colonies were transferred to 
100 µL 1 x TE, and 50 µL each were plated on fresh His+ and His- YMM selection 
plates, then incubated for 2 – 3 days at 30°C until enough healthy cells were gown for 
β-galactosidase lift assay. 
2.3.4 β-galactosidase lift assay 
Stock solutions 
Z buffer: 62.5 mM Na2HPO4,40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4  
X-gal: 40 mg/mL in dimethylformamide  
Cells from His+ YMM selection plate were transferred to a 3 mm Whatman filter paper 
by gentle pressure applied with a roller. The filter paper was then snap frozen with 
liquid nitrogen for 10 seconds and thawed completely at room temperature. This was 
repeated three times to permeabilise the yeast cell wall. The filter paper was place with 
cells side up on top of a clean 3 mm Whatman filter paper pre-soaked in x-gal/Z-buffer 
solution (83.5 μL X-gal, 10 mL Z Buffer, 27 μL β-mercaptoethanol) at 30°C for up to 8 
hours until blue colour development. 
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2.3.5 Histidine prototrophy 
Following lithium acetate transformation, Y190 cells were grown on YMM plates lacking 
histidine for 72 hours at 30°C. Successfully transformed clones would co-express 
histidine thus allowing for growth on His- YMM plates. 
2.3.6 Quantitative β-galactosidase assay 
2.3.6.1 Preparation of yeast culture 
For each yeast strain 1 – 2 mm of cells from a single colony was picked to inoculate 
5 mL His+ YMM (for transformed strain) or YPD medium (for untransformed strain), 
and incubated at 30°C at 250 rpm shaking for 16 hours. Overnight culture was diluted 
in 50 mL YPD medium, and incubated at 30°C at 250 rpm shaking until OD600 reached 
0.5 – 0.8AU (at least two doubling cycles). 10 mL of the culture was pelleted for the 
assay. 
2.3.6.2 Liquid culture assay 
Cell pellets were washed and resuspended in 300 µL buffer 1 (100 mM Hepes, 
155 mM NaCl, 4.5 mL L-aspartate, 1 % w/v BSA, 0.05 % v/v Tween 20, pH 7.3). 10 µL 
cell suspension was diluted in 990 µL buffer 1 and OD600 was measured with a 
spectrophotometer. 100 µL of cell suspension was snap frozen in liquid nitrogen for 30 
seconds, and thawed in 37°C water bath for 30 seconds. Three freeze-thaw cycles 
were required to permeabilise the cell wall. The cells were then mixed with 700 µL of 
2.23 M CPRG in buffer 1. When reaction mixture turned from yellow to red, 500 µL of 
3 mM ZnCl2 was added to stop the reaction. Cells were spun down and the OD578 of 
the supernatant was measured. β-galactosidase units were calculated as:  
 1000 x OD578 (t x V x OD600)  
 where t = stop time – start time (in minutes), V = 0.1 x concentration factor 
1 unit of β-galactosidase is defined as the amount which hydrolyses 1 μmol of CPRG to 
chlorophenol red and D-galactose per minute per cell.  
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2.3.7 Yeast protein extraction 
Yeast culture prepared as for quantitative β-galactosidase assay was pelleted and 
washed twice with distilled H2O. Cells were then lysed in 100 µL SDS lysis buffer (8 M 
urea, 5 % w/v SDS, 40 mM Tris-HCl pH 6.8, 0.1 mM EDTA pH 8.0, 0.4 mg/mL 
bromophenol blue, 1 % v/v β-mercaptoethanol, 1 % v/v yeast protease inhibitors 
cocktail) per 7.5 OD600 units of cells, at 70°C for 10 minutes. To completely disrupt the 
cell wall, 100 µL of acid-washed glass beads was added to the lysate, followed by 
vigorous vortexing for 1 minute, centrifugation at 14000 rpm for 5 minutes, and boiling 
the supernatant at 90°C for 5 minutes. 
2.3.8 Yeast two-hybrid library screen 
2.3.8.1 Test transformation 
Maxiprep of the pACT2 human cDNA library was serially diluted to 10-4, 10-5, 10-6 and 
10-7 on ice. 20 µL of freshly thawed DH10β cells were diluted with 30 µL of sterile H2O. 
1 µL of DNA was added and gently mixed, and the cells were then transferred to a 
1 mm electroporation cuvette. The cells were electroporated at 200 Ω, 25 μF, 2.0 kV, 
and immediately transferred to 1 mL SOC medium and recovered for 1 hour at 37°C 
shaking at 225 rpm. 100 µL of the culture was plated on LB plates containing 
100 µg/mL ampicillin and grown at 37°C overnight. Transformation efficiency was 
calculated and the concentration of DNA dilution that gave at least 107 clones per µg 
DNA was used for subsequent large-scale library transformation. 
2.3.8.2 Large-scale library transformation of DH10β 
Stock solutions 
2 x LB: 100 g peptone, 50 g yeast extract, 50 g NaCl. Bring to 5 L with sterile H2O 
2 x LB agarose: 1.8 g SeaPrep agarose (Lonza, 50302), 450 mL 2 x LB. Make 10 
bottles of 500 mL. Stir to dissolve and autoclave. 
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2 x LB glycerol: 43.75 mL 2 x LB, 6.25 mL 100 % glycerol. Autoclave. 
His+ Trp- YMM: 50 mg/L adenine, 50 mg/L histidine, 150 mg/L leucine, 125 mg/L 
lysine, 50 mg/L methionine, 50 mg/L uracil, 2 % glucose, 6.7 g/L yeast nitrogen base 
with ammonium sulphate, yeast granulated agar (for plates) 
Bottles of 2 x LB agarose were warmed to 37°C and supplemented with 100 µg/mL 
ampicillin. 200 µL of DH10β cells were diluted with 300 µL of sterile H2O, and 
transformed with 10 x the optimal amount of library DNA that gave 107 transformants as 
determined by small-scale test transformation. 1/10 of the transformation was added to 
each bottle of 2 x LB agarose, and stirred for 2 minutes. Bottles were then cooled in ice 
bath for 1 hour, then incubated at 30°C for 2 days. Thereafter, transformants were 
collected by stirring the agarose for 2 minutes, then centrifuging 100 mL of the culture 
at 6000 rpm for 20 minutes at room temperature. The pellet was resuspended in 50 mL 
sterile 2 x LB glycerol, cooled on ice for 1 hour, then stored at -80°C for long-term. The 
remainder of the 900 mL culture was similarly centrifuged to recover the cell pellet, 
then washed with distilled H2O at 4500 rpm for 10 minutes. Plasmid DNA was 
extracted using the Qiagen Endotoxin-free Maxiprep kit following the manufacturer’s 
instructions. 
2.3.8.3 Optimisation of library transformation 
Y190 cells were first transformed with the bait plasmid pGBKT7-TDP1 or pGBKT7-
TDP1S81E using the small-scale lithium acetate based method as outlined in 
Section 2.3.3.3. Single clones of stable transformants were propagated on His+ Trp- 
YMM plate, or stored in 25 % glycerol at -80°C for long-term. These clones were then 
transformed with the human cDNA library in pACT2 (pACT2-cDNA library) as 
described in Section 2.3.3.3. 10-fold serial dilutions of the transformation reaction were 
plated on His+ YMM plates at 30°C for 3 days. Transformation efficiency was 
determined by: 
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Cfu/µg = (No. of clones x final cell volume) / (volume plated x dilution factor x 
µg DNA) 
2.3.8.4 Library transformation 
Once the optimal concentration of library DNA that gave 107 transformants or higher 
per µg DNA was identified, the large-scale transformation was performed. A few 
colonies of Y190 stably transformed with pGBKT7-TDP1 or pGBKT7-TDP1S81E were 
used to inoculate 20 mL of His+ Trp- YMM and grown at 30°C at 200 rpm overnight. 
After measuring the OD600 of the overnight culture, the culture was diluted 
approximately 1:6 to give an OD600 of 0.2 and a volume of ~ 120 mL. The culture was 
then incubated at 30°C shaking at 200 rpm for approximately 4 hours until the OD600 
reached 0.6. The cells were pelleted at 4500 rpm for 8 minutes, washed once with 
sterile water, then washed with 3 mL of 100 mM LiAc, and resuspended in a final 
volume of 1.2 mL of 100 mM LiAc. The library transformation was then performed as 
for the small-scale lithium acetate transformation in 21 simultaneous repeats, including 
one transformation using the empty pACT2 vector as negative control for histidine 
prototrophy. After heat-shock the cells were washed and pelleted, and the entire 
transformation reaction was plated on His- YMM plate and grown at 30°C for 5 – 7 
days. Single colonies that formed were picked and re-streaked on a His+ YMM and a 
His- YMM plate each and grown for 3 days at 30°C. A few colonies from each His- 
YMM plate were picked and used to inoculate 2 mL of His- YMM culture overnight at 
30°C shaking at 200 rpm. From the overnight culture, 0.7 mL was frozen down in 25 % 
glycerol for long-term storage, the remaining was used for plasmid extraction and 
analysis. 
2.3.8.5 Plasmid extraction and analysis 
Approximately 1.3 mL of the freshly grown cells in His- YMM culture was pelleted and 
resuspended in 250 µL of Buffer P1 of the Qiagen Miniprep kit. 250 µL of acid-washed 
glass beads were added to the cell suspension, and the mixture vortexed vigorously for 
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1 minute to disrupt the cell wall, then briefly centrifuged. The supernatant was then 
used for plasmid extraction using the Qiagen Miniprep kit following the manufacturer’s 
instructions, and the plasmid eluted with 25 µL EB buffer. The plasmid DNA was then 
used to transform the electrocompetent E. Coli strain DH10β. 5 µL of DNA was mixed 
with 50 µL of DH10β cells and transferred to a 1 mm electroporation cuvette on ice, the 
electroporation was performed at 2 kV, 200 Ω, 25 μF, and the cells were immediately 
transferred to a 1.5 mL Eppendorf tube containing 1 mL SOC medium and recovered 
at 37°C at 225 rpm for 1 hour. The entire transformation mixture was plated on LB agar 
plate containing 50 µg/mL ampicillin and incubated at 37°C overnight. One single 
colony was then picked from each plate to inoculate 5 mL LB medium containing 
50 µg/mL ampicillin and grown at 37°C overnight. The overnight culture was used to 
extract the pACT library plasmid DNA using the Qiagen Miniprep kit according to the 
manufacturer’s instructions. The purified plasmid DNA was then sequenced by GATC 
Biotech. The DNA sequence was identified using the Genome Browser Human BLAT 
database (Feb. 2009 version) hosted by the University of California Santa Cruz 
(http://genome.ucsc.edu/cgi-bin/hgBlat?command=start). 
2.4 Yeast clonogenic survival assay 
Wildtype (Y190) or tdp1Δ rad1Δ (YW812) S. cerevisiae cells were transformed with 
pGKT7 plasmids encoding myc-TDP1, myc-TDP1S81A or Myc (empty vector) as 
described in Section 2.3.3.3. The transformants were selected on His+ Trp- YMM 
plates at 30C for 72 hours. A single colony was picked from each plate and 
resuspended in 200 µL sterile water and serially diluted at 10-fold up to 10-4 dilutions. 
10 µL from each dilution was plated on His+ Trp- YMM with or without 20 µM of CPT. 
Cells were left at 30C for 72 hours to form macroscopic colonies.  
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2.5 Mammalian cell culture 
2.5.1 Maintenance of cell lines 
The human cell lines A549, HEK293, MRC5 were grown as monolayers in α-MEM 
media supplemented with 10 % FCS, 100U Penicillin, 100 µg Streptomycin, and 2 mM 
L-glutamine. Cells were maintained in humidified 5 % CO2 incubators set at 37°C for no 
more than 20 passages. 
Primary mouse embryonic fibroblasts were grown as monolayers in D-MEM media 
containing 4500 mg/L D-glucose, sodium bicarbonate, and pyruvate supplemented with 
15 % FCS, 100 U Penicillin, 100 µg Streptomycin, 2 mM L-glutamine and 1 x non-
essential amino acid solution. Cells were maintained in humidified 2 % O2, 5 % CO2 
incubators set at 37°C for no more than 7 passages. Mouse embryonic fibroblasts 
grown for more than 13 passages were considered immortalised, and were maintained 
in growth media lacking non-essential amino acids, and at normal atmospheric O2 level.  
Chicken DT40 B-lymphocytes were grown in suspension at no more than 106 cells/mL 
in RPMI medium supplemented with 10 % FCS, 1 % chicken serum (Sigma, 
16110-082), 100 U Penicillin, 100 µg Streptomycin, 2 mM L-glutamine and 25 μM β-
mercaptoethanol. Cells were maintained in humidified 5 % CO2 incubators set at 39°C 
for no more than 40 passages. 
Human lymphoblastoid cells (AG87 and JRL1) were grown in suspension at a density 
of 5 x 105 cells/mL. Cells were maintained in RPMI1640 media supplemented with 
10 % FCS Good US origin (PAN Biotech, P40-38500), 100 U Penicillin, 100 µg 
Streptomycin, and 2 mM L-glutamine. 
Flp-In T-Rex 293 cells (Thermo Fisher, R780-07) were grown in monolayer and 
maintained in DMEM supplemented with 10 % Tetracycline-free FCS (Biosera, 
FB1001T/500), Pen/Strep, L-glutamine, 100 µg/mL zeocin (InvivoGen, ant-zn-1) and 
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10 µg/mL blasticidin (InvivoGen, ant-bl-1).  
For long-term storage cells were suspended in 1 mL aliquots of 90 % FBS with 10 % 
DMSO, slowly cooled to -80°C overnight and transferred to liquid nitrogen storage. To 
revive cells, the frozen aliquot was quickly thawed in 37°C water bath and resuspended 
in warmed media. Cells were centrifuged at 1500 rpm for 5 minutes to remove residual 
DMSO, and grown in fresh media for 2 – 3 passages before experimental use.  
2.5.2 DNA-mediated gene transfer  
2.5.2.1 Calcium phosphate co-precipitation 
Plasmid DNA for transfection was prepared using Qiagen Plasmid Midiprep Kit 
following manufacturer’s instructions. HEK293 cells in logarithmic phase of growth 
were seeded at a density of 5 x 106 cells per 10 cm dish and left to adhere at 37°C 
overnight. Fresh media was added to the cells one hour prior to transfection. 0.5 mL of 
DNA/CaCl2 mix (10 µg of plasmid DNA, 245 mM CaCl2) was added drop-wise to 
0.5 mL of 2 x Hepes Buffered Saline (275 mM NaCl, 1.5 mM Na2HPO4, 55 mM Hepes) 
and mixed by continuous bubbling using a Pasteur pipette. The transfection mixture 
was then added drop-wise over cells. Cells were incubated at 37°C overnight, then 
washed twice with PBS, and left to recover in fresh media for another 24 hours before 
harvesting.  
2.5.2.2 Liposome-based transfection reagent 
Plasmid DNA for transfection was prepared using Qiagen® Plasmid Midiprep Kit. A549 
or Flp-In T-Rex 293 cells in logarithmic phase of growth were seeded at a density of 
2 x 105 cells per 3.5 cm dish and left to adhere at 37°C overnight. Fresh media was 
added to the cells one hour prior to the transfection. 3 μL Genejuice transfection 
reagent (Novagen, 70967-3) per μg plasmid DNA was added drop-wise to 100 μL 
serum free OptiMEM culture medium, mixed briefly and incubated for 5 minutes at 
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room temperature. 1 – 2 μg of each plasmid DNA was added drop-wise to the 
Genejuice®/medium, mixed by pipetting and incubated for 10 – 15 minutes at room 
temperature. 100 μL of Genejuice®/DNA mix was added drop-wise to the cells and 
incubated for 24 hours at 37°C.  
2.5.2.3 Retroviral transduction 
The retroviral packaging cell line Phoenix (gift from Dr Conchita Vens) were transfected 
with pMXPIE-TDP1, pMXPIE-TDP1K111R, pMXPIE-hSOD1, pMXPIE-hSOD1G93A or 
pMX-PIE (empty vector) using GeneJuice Transfection Reagent as described by 
manufacturer. Transfection efficiency was estimated by GFP co-expression using 
fluorescence microscopy. If the estimated transfection efficiency was above 80 %, the 
supernatant containing recombinant protein-expressing retrovirus particles was 
collected and filter-sterilised. 10 µg/mL polybrene was added to improve viral 
adherence to target cell surface. The supernatant was then added to a 6 cm dish 
containing 2 x 105 adherent immortalised Tdp1-/- MEFs and incubated at 37°C 
overnight. The supernatant was removed and replaced with fresh growth media and 
left for another 24 hours before harvesting.  
2.5.3 Gene-targeted silencing 
The sequences of RNAi-mediated gene silencing are listed in Table 2.5. 
Approximately 3 x 105 MRC5 cells in log phase growth were suspended in 5 mL normal 
growth media in 6 cm dish immediately before transfection. 80 µL of serum-free 
medium Opti-MEM was mixed with 5 µL of Metafectene Pro Transfection Reagent 
(Cambio, T040-2.0). In a separate tube, 80 µL of Opti-MEM was mixed with 80 µM of 
siRNA. The siRNA mixture was added to the Metafectene mixture, and incubated at 
room temperature for 20 minutes. The Metafectene/siRNA mixture was then added 
drop-wise on top of the cells, and incubated at 37°C for 24 hours. A second 
transfection was then repeated, and cells were harvested after further 24-hour 
Target Sequence
Scrambled siRNA UUCUUCGAACGUGUCACG
Human TOP1 siRNA*
(NM_003286.2)
#1 GAAAAUGGCUUCUCUAGUC
#2 GAUUUCCGAUUGAAUGAUU
#3 GCACAUCAAUCUACACCCA
#4 CGAAGAAGGUAGUAGAGUC
Human TDP1 siRNA*
(NM_001008744.1)
#1 GGAGUUAAGCCAAAGUAUA
#2 UCAGUUACUUGAUGGCUUA
#3 GACCAUAUCUAGUAGUGAU
#4 CUAGACAGUUUCAAAGUGA
Scrambled shRNA*
TGCTGTTGACAGTGAGCGATCTCGCTTGGGCGAGAGT
AAGTAGTGAAGCCACAGATGTACTTACTCTCGCCCAA
GCGAGAGTGCCTACTGCCTCGGA
Human UBE2I shRNA*
(NM_194260.2)
TGCTGTTGACAGTGAGCGAGCCTACACGATTTACTGC
CAATAGTGAAGCCACAGATGTATTGGCAGTAAATCGT
GTAGGCCTGCCTACTGCCTCGGA  
TDP1 miRNA
(NM_001008744.1) 
#1 TGCTGATCACTACTAGATATGGTCCAGTTTTG
GCCACTGACTGACTGGACCATCTAGTAGTGAT
#2 TGCTGATCACTGCTGGACAGACACCAGTTTT
GGCCACTGACTGACTGGTGTCTCCAGCAGTGAT
Table 2.5: RNAi sequences 
* indicate purchases from Dharmacon. TDP1 miRNA designed using Thermo Fisher 
BLOCK-iT™ RNAi Designer 
(https://rnaidesigner.lifetechnologies.com/rnaiexpress/design.do) and synthesized 
by Integrated DNA Technologies, Belgium) 
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incubation.  
MRC5 cells in log phase growth were seeded at 8 x 104 in 3 cm petri dishes, 16 – 24 
hours before transfection. Transfection of the plasmid encoding shRNA against UBE2I 
was done using Genejuice transfection reagent. After 48 hours cells were transferred 
to T75 flasks and stably integrated clones were selected with 0.5 µg/mL puromycin for 
7 days. 
2.5.4 Selection and maintenance of stable cell lines  
MEFs transduced with hTDP1, hTDP1K111R, hSOD1 and hSOD1G93A were selected with 
1 µg/mL puromycin for 3 days. Pooled populations of stable clones were analysed for 
GFP expression by fluorescence microscopy, and TDP1 or SOD1 expressions by 
Western blotting using antibodies against TDP1 or SOD1 antibody, respectively 
(Tables 2.6A, 2.7A). 
Stable Flp-In T-Rex 293 cell lines expressing miRNA sequences were selected with 
100 µg/mL hygromycin B (Invivogen, ant-hg-1) for 3 weeks until formation of 
macroscopic colonies. Single colonies were picked and expanded for 2 more weeks. 
The cells were then harvested and the whole cell lysates analysed for protein 
expression by Western blotting using antibodies listed in Tables 2.6A and 2.7A. 
2.6 Analyses of cellular protein extracts 
2.6.1 Preparation of whole cell protein extracts 
Approximately 5 x 105 cells were harvested, washed with PBS twice, resuspended in 
50 μL of lysis buffer (20 mM Tris-HCl pH 7.5, 10 mM EDTA pH 8.0, 100 mM NaCl, 1 % 
Triton X-100, 1 x protease inhibitor cocktail (Roche, 4693159001), 1 x phosphatase 
inhibitor cocktail (Roche, 4906837001), 25 U.ml−1 benzonase (Merck, 71205) and 
incubated on ice for 30 minutes. Cell lysates were cleared by centrifugation at 
13000 rpm at 4°C for 15 minutes. The concentration of soluble proteins was quantified 
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by the Bradford assay (Bio-Rad, 500-0001). For long-term storage the cell lysates were 
kept at -80°C. 
2.6.2 Protein co-immunoprecipitation 
Human HEK293 cells were seeded at 2 x 106 cells per 10 cm petri dish 24 hours before 
transfection. Cells were transfected with plasmids coding for Myc-tagged proteins of 
interest using calcium phosphate-based method and harvested after 48 hours. For 
cross-linking experiments, cells were fixed with 1 % paraformaldehyde for 10 minutes, 
washed once with PBS, washed with 100 mM glycine, then washed again with PBS. 
200 μL lysis buffer (20 mM Hepes pH 7.4, 40 mM NaCl, 2 mM MgCl2, 0.5 % NP40, 1 x 
protease inhibitor cocktail, 1 x phosphatase inhibitor, 20 mM N-ethyl maleimide, and 
25 U.ml−1 benzonase) was used to lyse 10 cm dish of cells on ice for 30 minutes. The 
lysate was centrifuged at 13000 rpm for 10 minutes at 4°C to isolate the soluble 
fraction, 30 μL of which was removed and resuspended in 30 μL of 2 x SDS lysis buffer 
and boiled at 90°C for 15 minutes, the sample was used as input control on a SDS-
PAGE gel later. For the rest of the lysate, the NaCl concentration was adjusted to 
140 mM, and 2 μL of anti-Myc antibody was added. The lysate was incubated with the 
antibody for 1 hour at 4°C, then in 30 μL proteinase G beads for 1 hour at 4°C. The 
beads were centrifuged at 1500 rpm, and washed at least three times with wash buffer 
(20 mM Hepes pH 7.4, 140 mM NaCl). The beads were resuspended in 50 μL 2 x 
SDS-PAGE lysis buffer (Section 2.6.3), boiled at 90°C for 15 minutes, then briefly 
centrifuged. 10 μL of the supernatant was loaded on SDS-PAGE gel along with the 
3 μL of the input sample.  
2.6.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
For protein fractionation by SDS-PAGE, polyacrylamide gels were made using the 
Sambrook and Russell method (Sambrook and W Russell, 2001) and cast in a 1 mm 
XCell SureLock Mini-Cell cassette (Fisher Scientific, VXNC2010). 50 – 100 µg of 
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soluble proteins from each cell lysate sample were mixed with SDS-PAGE lysis buffer 
(final concentration 50 mM Tris pH 8.0, 2 % w/v SDS, 10 % v/v glycerol, 0.1 % w/v 
bromophenol blue, 200 mM DTT). Samples were denatured at 90°C for 5 minutes, 
briefly centrifuged, then loaded onto a polyacrylamide gel. The Precision Plus Protein 
Dual Colour Standards (Bio-Rad, 1610374) was used as protein marker for proteins 
between 10 – 250 kDa. Electrophoresis was performed in the XCell SureLock Mini-Cell 
system using 1 x SDS running buffer (25 mM Tris, pH 8.3, 192 mM glycine, 0.1 % 
SDS) at 150 V for 1.5 – 2 hours. 
The fractionated protein samples were either visualised by Coomassie brilliant blue 
staining (Bio-Rad, 161-0435) for 30 minutes, followed by de-staining in 30 % methanol, 
10 % acetic acid; or processed for Western blotting by transferring to a 0.45 μm 
nitrocellulose membrane (Bio-Rad, 170-4271) at 25 V for 1.5 hour in transfer buffer 
(25 mM Tris, pH 8.3, 192 mM glycine, 20 % methanol) using the XCell SureLock Mini-
Cell system. 
2.6.4 Western blotting 
Nitrocellulose membrane with transferred proteins was blocked with blocking buffer 
(5 % milk, 0.1 % Tween-20 diluted in PBS) for 1 hour at room temperature. The primary 
antibody was diluted in blocking buffer according to Table 2.6A. The membrane was 
incubated in the primary antibody overnight at 4°C, then washed three times for 5 
minutes with PBS containing 0.1 % Tween-20. The HRP-conjugated secondary 
antibodies (Table 2.7A) were diluted 1:4000 in blocking buffer. The membrane was 
incubated in the secondary antibody for 1 hour at room temperature, then washed 
three times for 5 minutes with PBS containing 0.1 % Tween-20. The membrane was 
then incubated in the Clarity Western ECL blotting substrate (Bio-Rad, 1705060) for 5 
minutes at room temperature and visualised using the ChemiDoc MP gel docking 
system (Bio-Rad, 1708280). 
A 
Antibody Host species Source (cat. no.) Concentration
β-actin Mouse Sigma (A5316) 1:2000
Gal4-AD Rabbit Millipore (ABE476) 1:2000
GFP Rabbit Abcam (ab290) 1:2000
Ligase 3 Mouse Abcam (ab587) 1:2000
Myc Mouse Cell Signalling (2276) 1:2000
Human 
OXPHOS 
cocktail
Mouse Abcam (ab110411) 1:500
SOD1 Rabbit Santa Cruz (sc-11407) 1:1000
TDP1 Rabbit Abcam (ab4166) 1:2000
TOP1 Mouse Santa Cruz (sc-32736) 1:1000
TOP1mt Rabbit Abcam (ab135423) 1:250
β-Tubulin Mouse Abcam (ab7792) 1:2000
UBE2I Rabbit Abcam (ab21193) 1:2000
VDAC1 Rabbit Abcam (ab15895) 1 μg/ml
p-XRCC1
(S485, T488) Rabbit
Bethyl Laboratories 
(A300-231A) 1:2000
B 
Antibody Host species Source (cat. no.) Concentration
53BP1 Rabbit Bethyl Laboratories (A300-271A) 1:1000
p-H2AX
(Ser139) Mouse Millipore (05-636) 1:800
Table 2.6: Primary antibodies 
Source, type and working concentration for primary antibodies used for  
(A) immunoblotting and (B) immunofluorescence.
A 
Antibody Host species Source (cat. no.) Concentration
Mouse IgG (H + L)-
HRP Conjugate Goat Bio-Rad (170-6516) 1:4000
Rabbit IgG (H + L)-
HRP Conjugate Goat Bio-Rad (170-6522) 1:4000
B 
Antibody Host species Source (cat. no.) Concentration
Goat Anti-Mouse IgG 
(H+L)-Alexa Fluor 488 Goat
Molecular Probes 
(A28175) 1:800
Rabbit IgG-Alexa 
Fluor 555
Goat Molecular Probes 
(A27039)
1:800
Table 2.7: Secondary antibodies
Source, type and working concentration for secondary antibodies used for  
(A) immunoblotting and (B) immunofluorescence.  
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2.6.5 TDP1 activity assay using the Gyrasol system 
WCE proteins prepared as described in Section 2.6.1 was diluted to 1 μg/μL in 1 x 
assay buffer (50 mM Tris pH 8.0, 5 mM MgCl2, 80 mM KCl, 0.05 % TritonX-100) 
supplemented with 1 mM DTT. 13-mer DNA oligonucleotide substrate with 5’-FITC 
label and 3’-phosphotyrosine (5’-FITC-GATCTAAAAGACT(pY)-3’) (Midland Certified 
Reagent, TX, USA) was diluted to 30 nM in 1 x assay buffer. 2 μg of WCE proteins was 
incubated with 10 nM substrate in 1 x assay buffer in a 15 μL reaction volume in a 384-
well black flat-bottomed immunoassay plate for 10 minutes at 25°C. 30 μL of enhancer 
buffer (Gyrasol Technologies, KS, USA) and 2 μL sensor buffer (Gyrasol Technologies, 
KS, USA) were mixed together and added to each well to quench the reaction. FITC 
fluorescence was immediately measured using a BMG Labtech Pherastar plate reader 
at excitation and emission wavelengths of 490 nm and 520 nm, respectively (Walker et 
al.,2014). 
2.6.6 TDP1 activity assay using C5.5-conjugated oligonucleotide substrate 
Reactions were performed in 10 μL reaction volumes containing assay buffer (25 mM 
HEPES, pH 8.0, 130 mM KCl, 1 mM DTT), WCE (50 – 100 ng) and 50 nM Cy5.5 
labelled substrate oligomer containing a 3 ′ -phosphotyrosyl group, (5 ′ -(Cy5.5)-
GATCTAAAAGACT(pY)-3 ′ ) (Midland Certified Reagent Company Texas, 
USA).Reactions were carried out at 37°C for 1 hr and stopped by addition of 10 μL 
loading buffer (44 % deionized formamide, 2.25 mM Tris-borate, 0.05 mM EDTA, 0.01
% xylene cyanol, 1 % bromophenol blue). Samples were then heated at 90°C for 10 
minutes prior to separation on a 20 % Urea SequaGel (Fisher, EC-833-1) by gel 
electrophoresis at 150 V for 1 hr. Reaction products were visualised by gel imaging 
using the Bio-Rad ChemiDoc MP imaging system at 635 nm and bands quantified 
using Image Studio Lite v5.2 (LI-COR). 
  
Primer name Sequence 
Human ND1 (F) CCCTAAAACCCGCCACATCT  
Human ND1 (R) GAGCGATGGTGAGAGCTAAGGT  
Human B2M (F) CCAGCAGAGAATGGAAAGTCAA  
Human B2M (R) TCTCTCTCCATTCTTCAGTAAGTCAACT 
Human TOP1mt* 15873 (F)  TACTCAAATGGGCCTGTCCT 
Human TOP1mt* 15873 (R) AAAGACTTTTTCTCTGATTTGTCC 
Mouse CO1 (F) TGCTAGCCGCAGGCATTAC 
Mouse CO1 (R)                GGGTGCCCAAAGAATCAGAAC 
Mouse NDUFV1 F1             CTTCCCCACTGGCCTCAAG 
Mouse NDUFV1 R1             CCAAAACCCAGTGATCCAGC 
 
Table 2.8: qPCR primers 
qPCR primers used for amplifying gDNA of the target genes and their sequences from 
5’ to 3’. 
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2.6.7 Protein stability assay 
Human TDP1, TDP1S81A and TDP1S81E were cloned into mammalian expression vector 
pCI-puro-Myc, and transfected into human A549 cell line using Genejuice transfection 
reagent. Expression levels were confirmed at two days by Western blotting. 
Transfected cells were treated with 30 μM CPT for 2 hours at 37°C, washed and left to 
recover in normal growth media for up to 24 hours in the presence or absence of 
cycloheximide, an inhibitor of protein synthesis. Samples were taken at 6- and 24-hour 
intervals to assess TDP1 expression levels by Western blotting.  
2.7 DNA damage repair assays 
2.7.1 Clonogenic survival assay 
Sod1+/+ and SOD1G93A+/- primary MEFs were seeded at 2000 – 10000 cells per 9 cm 
petri dish and incubated overnight in normal growth media. Similarly, immortalised 
Tdp1-/- MEFs complemented with wildtype hSOD1, hSOD1G93A or empty vector were 
seeded at 1000 – 5000 cells; MRC5 cells were seeded at 500 – 3000. Cells were then 
treated with CPT (1 hour at 37°C), x-ray (250 kV at 12 mA), or H2O2 (10 minutes on 
ice), at the indicated doses. Cells treated with CPT or H2O2 were washed twice in PBS, 
and grown in normal growth media for 7 days. Cells were then fixed with 80 % ethanol 
for 15 minutes and stained with 1 % methylene blue. Percentage of colony survival was 
normalised to mock-treated sample. The average +1 standard errors of the mean 
(S.E.M.) were calculated from 3 independent experiments. 
2.7.2 Cell viability assay using CellTiter-Blue reagent 
Flp-In T-Rex 293 cells were induced with 1 μg/mL doxycycline for 24 hours, then 
seeded at densities of 2000 – 20000 cells/100 μL, and treated with the indicated 
concentrations of CPT or TBH in the absence of doxycline for 48 hours. Cell viability 
was measured using the CellTiter-Blue Viability Assay kit (Promega, G8080). 20 μL of 
the CellTiter-Blue reagent was mixed with the cells and incubated at 37°C for 1 hour. 
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Fluorescence intensity was measured at Ex584/Em590-10 nm using a FLUOstar 
Omega microplate reader (BMG Labtech). Viability of untreated cells was set to 1 and 
error bars represent standard error from 3 independent biological repeats. 
2.7.3 Alkaline single cell gel electrophoresis (comet assay) 
Immortalised Tdp1+/+ and Tdp1-/- MEFs (~ 3 x 105 cells/sample) were suspended in 
normal growth media (for IR treatment) or cold PBS (for H2O2 treatment) and subjected 
20 Gy (caseum 137, Cammael 1000) or 10 µM H2O2 on ice, then incubated in normal 
growth media at 37°C for the indicated repair time. Repair was stopped by placing cells 
on ice and replacing media with cold PBS. ~ 5,000 cells were mixed with equal 
volumes of PBS and 1.2 % type VII agarose (Sigma, A0701) at 42°C, and plated on 
frosted microscope slides pre-coated with 0.6 % agarose and chilled until set. Cells 
were then incubated in lysis buffer (2.5 M NaCl, 10 mM Tris-HCl, 100 mM EDTA pH 8, 
1 % Triton X-100, 1 % DMSO, pH 10) at 4°C for 1 hour, and washed twice with cold 
distilled water. Slides were equilibrated in alkaline electrophoresis buffer (50 mM 
NaOH, 1 mM EDTA, 1 % DMSO) for 45 minutes, then subjected to electrophoresis at 
12 V (100 mA) for 25 minutes. Quantification of DNA breaks were performed using 
Comet Assay IV software, counting 100 cells per sample. 
2.7.4 Modified alkaline single gel electrophoresis for TOP1-cc detection 
For modified alkaline comet assay that detects protein-linked DNA breaks, 0.8 mg/mL 
proteinase K was added to the cells straight after CPT or H2O2 treatment, cells were 
then mixed with equal volumes of PBS and 1.2 % type VII agarose and plated on 
frosted microscope slides pre-coated with 0.6 % agarose. Lysis was performed in the 
presence of 0.4 mg/mL proteinase K at 37°C for 3 hours. Slides were then processed 
as described in the previous section.  
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2.7.5 γH2AX and 53BP1 immunofluorescence assay 
Tdp1-/- MEFs complemented with hTDP1, hTDP1K111R, or empty vector were plated on 
13 mm round coverslips in 30mm dish format and incubated overnight. Cells were then 
treated with 2 Gy γ-irradiation or 1 μM CPT (1 hour at 37°C), and repaired for the 
indicated periods. Cells were washed three times with PBS and fixed with 3 % 
paraformaldehyde for 10 minutes. Cold 0.2 % Triton was added for 2 minutes to 
permeate cell membrane, cells were then washed 3 time with PBS, and incubated in 
2 % BSA for 30 minutes. Cells were probed with primary antibodies listed in Table 
2.6B for 30 minutes at room temperature, washed 3 times with PBS, then stained with 
fluorophore-conjugated secondary antibodies listed in Table 2.7B for 30 minutes and 
washed 3 times with PBS. The coverslips were transferred to 26 x 76 mm microscope 
slides and fixed with VectorShield mounting medium H-1000 (Vector). Cells were 
visualised on a Nikon E400 microscope and γ-H2AX foci (red channel) were counted in 
50 GFP-positive cells (complemented with pMXPIE-TDP1, pMXPIE-TDP1K111R or 
pMX-PIE alone). 
2.7.6 UV laser tracking using confocal microscopy 
MRC5 cells (control and UBE2I knockdown) growing in log phase were plated at 
1 x 105 cells per 3 cm dish and transfected with either pMC-EGFPP-TDP1 or 
pMC-EGFPP-TDP1K111R using GeneJuice transfection reagent (Novagen). After 24 
hours, transfection efficiency was assessed by FACS analysis of GFP-positive cells. At 
least 3 x 105 cells were fixed with cold 70 % ethanol at 4°C for at least 4 hours, washed 
once with PBS, then resuspended in 0.5 mL PBS and transferred to a BD Falcon 
35 μm cell strainer in 12 x 75 mm polystyrene tube and analysed on a FACS Canto 
machine (BD Biosciences). Mean EGFP intensities of 104 cells were recorded for each 
cell line.  
A parallel transfection was performed on cells similarly plated on 3 cm glass-bottomed 
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dishes (MatTek) for confocal microscopy. At 24 hours post-transfection, cells were 
stained with 10 µg/mL Hoechst 33285 (Sigma) for 30 minutes at 37°C. Cells were then 
visualised under a Zeiss Axiovert confocal microscope with 40x/1.2-W objective. GFP-
positive cells were irradiated with 351 nm UVA (4.36 J/m2) on an area of 0.1 μm width 
“track” and images were taken at 5-second intervals for 95 seconds. Quantification of 
track fluorescence intensity was performed using LSM 520 Meta software. 
2.8 Mitochondrial morphological and functional assays 
2.8.1 Qualitative analysis of mitochondrial network morphology by high 
resolution fluorescence microscopy 
2 x 105 MEFs were seeded on glass coverslips (0.08 – 0.13 mm) in 6-well dishes and 
treated with or without 10 µM tert-Butyl hydroperoxide (TBH) for 24 hours at 37°C. 
Cells were stained with 250 nM of Mitotracker Deep Red FM (Life Technologies, 
M22426) for 30 minutes, then fixed with 3 % paraformaldehyde for 10 minutes. Cell 
membranes were permeabilised with cold 0.2 % Triton-X100 for 2 minutes, washed 
three times with PBS, then stained with 1:10000 DAPI. Coverslips were then mounted 
on microscope slides with VectorShield Mounting medium (Vector Laboratories, H-
1000). Single-cell images were taken with Core DeltaVision at 60 x magnification, 
640 x 640 resolution, with excitation filters for DAPI or Cy5, with Z-stacking. 3D images 
were deconvoluted using the OMERO software. 
2.8.2 Quantitative analysis of mitochondrial membrane potential by FACS 
3 x 105 MEFs were seeded in 6-well dishes for 24 hours at 37°C. Cells were stained 
with 250 nM Mitotracker Red CMXRos (Life Technologies, M22425) and Mitotracker 
Green FM (Life Technologies, M7514) for 30 minutes, then harvested and washed 
twice with PBS and analysed on a BD FACSCanto machine (BD Bioscience) using the 
PE and FITC channels. Mean fluorescence intensity from 104 events were recorded.  
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2.8.3 Quantitative analysis of mitochondrial superoxide production by FACS 
3 x 105 MEFs were seeded in 6-well dishes for 24 hours at 37°C. Cells were treated 
with 1 μM rotenone or DMSO (mock) for 10 minutes at 37˚C, then stained with 250nM 
MitoSOX Red (Life Technologies, M36008) for 30 minutes at 37˚C, then harvested and 
washed twice with PBS and analysed on a BD FACSCanto machine (BD Bioscience) 
using the PE channels. Mean fluorescence intensity from 104 events were recorded.  
2.8.4 Mitochondrial bioenergetics profiling by Seahorse Bioanalyzer 
106 Flp-In T-Rex 293 cells were induced by 1 μg/mL doxycycline for 24 hours, then 
seeded at 6 x 104 cells per well in a XF24 cell microplate (Seahorse Bioscience, 
100777-004) pre-coated with Cell-Tak cell adhesive (Corning, 354240) in 575 μL XF 
assay media (Seahorse Bioscience, 101022-100) supplemented with 4.5 mg/mL 
glucose, 2 mM L-glutamine and 1 x sodium pyruvate. Cells were incubated at 37°C 
with atmospheric CO2 for 1 hour. A XF24 flux plate pre-hydrated in calibrant (Seahorse 
Bioscience, 100840-000) was loaded with 75 μL of 10 μM oligomycin, 82.5 μL of 3 μM 
FCCP, and 91.6 μL of 5 μM rotenone (final concentrations of 1 μM, 0.3 μM and 1 μM, 
respectively) diluted in the supplemented XF assay medium. Three basal readings 
were taken over 3 minutes each after 3 minutes of mixing and 2 minutes waiting. The 
same protocol was repeated after addition of each drug. Cells were then washed with 
PBS once, and incubated in normal growth medium containing 25 μg/mL Hoechst 
33342 at 37°C for 30 minutes. The images were captured with an IN Cell Analyzer 
6000 cell imaging system (GE Healthcare), and the nuclei number in each well was 
quantified using the IN Cell Developer software (GE Healthcare).  
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2.9 Mitochondrial DNA metabolism 
2.9.1 Mitochondrial DNA copy number quantification by qPCR 
3 x 105 MEFs were treated with or without 240 μM H2O2 for 1 hour on ice, washed 
twice with PBS, then left to recover in normal medium for 24 hours. Cells were then 
harvested and the genomic and mitochondrial DNA extracted using the Qiagen 
DNAeasy Blood and Tissue Kit (Qiagen, 69504). The DNA concentrations were 
measured using the QuantiFluor dsDNA system (Promega, E2670) and a FLUOstar 
Omega microplate reader (BMG Labtech) at EX485/EM520. The DNA templates were 
diluted to 10 ng, then serial dilutions of 10-1 – 10-5 were used to establish the standard 
curve for the mtDNA amplification reaction; and serial dilutions of 10-1 – 10-3 were used 
to establish the standard curve for the nDNA amplification reaction. For the qPCR 
reaction, 1 μL of DNA and 15 μM of each primer (Table 2.8) were diluted in 2 x 
LightCycler 480 SYBR-Green I mastermix (Roche, 04707516001) and TE buffer in a 
20 μL reaction volume, and amplified using the following cycling conditions: initial 95°C 
for 2 minutes, then 40 cycles of 95°C for 10 second and 60°C for 20 seconds, with 
signal acquisition at end of each cycle using a Roche LightCycler 480 qPCR machine. 
Mitochondrial copy number was calculated by 2 x 2(ΔCT) whereby ΔCT = NDUFV1 
average CT – CO1 average CT. 
2.9.2 Mitochondrial transcript abundance by RT-qPCR 
Total RNA from 5 x 106 Flp-In cells was extracted using Qiagen RNAeasy Plus kit 
(Qiagen, 74134) as per manufacturer’s instructions, which included removal of 
genomic DNA from the samples, followed by reverse transcription of 5 µg total RNA 
using the Tetro cDNA synthesis kit (Bioline, BIO-65042). PCR primers used are listed 
in Table 2.9. Removal of genomic mtDNA contamination was confirmed by standard 
PCR amplification of non-reverse transcribed sample and analysis by DNA gel 
electrophoresis. Quantitative PCR was set up using 1:10 dilution of cDNA samples and 
6 μM of primers in a 1 x SensiMix SYBR Hi-ROX master mix (Bioline, QT605-05) in a 
Primer name Sequence
Human CO1 (F) GGAGCAGGAACAGGTTGAACAG
Human CO1 (R) GTTGTGATGAAATTGATGGC
Human CO2 (F) CCCTTACCATCAAATCAATTGGCC
Human CO2 (R) ATTGTCAACGTCAAGGAGTCGC
Human ND1 (F) CTACTACAACCCTTCGCTGAC
Human ND1 (R) GGATTGAGTAAACGGCTAGGC
Human CYTB (F) CTGATCCTCCAAATCACCACAG
Human CYTB (R) GCGCCATTGGCGTGAAGGTA
Human RNR1 (F) TAGAGGAGCCTGTTCTGTAATCGAT
Human RNR1 (R) CGACCCTTAAGTTTCATAAGGGCTA
Human GAPDH (F) ACATCGCTCAGACACCATG 
Human GAPDH (R) TGTAGTTGAGGTCAATGAAGGG 
Table 2.9: RT-qPCR primers
qPCR primers used for amplifying reverse-transcribed mRNA of the target genes 
and their sequences from 5’ to 3’.
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Rotor-Gene 6000 qPCR machine (Corbett Research). The thermocycling conditions 
are: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 50°C for 15 
seconds, and 72°C for 30 seconds. 
2.9.3 Quantification of TOP1mt-cc by caesium chloride fractionation 
2 x 107 Flp-In cells were induced with 1 μg/mL doxycycline for 48 hours and harvested. 
Mitochondria were isolated using the mitochondria isolation kit for cultured cells 
(Thermo Scientific, 89874) following manufacturer’s instructions. The mitochondria 
pellet was lysed in 1.1 mL lysis buffer (8 M guanidine hydrochloride, 30 mM Tris-HCl 
pH 7.5, 10 mM EDTA, 1 % sarkosyl, pH adjusted to 7.5) for 15 minutes at 65°C. 1 mL 
of mitochondrial lysate was gently layered on top of a 4-step caesium chloride gradient 
(densities of 1.45 g/ml, 1.5 g/ml, 1.72 g/ml, 1.82 g/mL of 1 mL each) in a 5 mL 
polyallomer centrifuge tube (Beckman, 326819), and centrifuged at 30000 rpm in a 
swinging rotor in a Beckman Ultima LE-80K ultracentrifuge for 24 hours at 25°C without 
brake. From the remaining 100 μL of mitochondrial lysate, 10 μL was mixed with 90 μL 
of 1 x TE buffer containing 0.5 μg/mL RNAse A and incubated at 37°C overnight. The 
lysate was briefly centrifuged at maximum speed, then 50 μL of the supernatant was 
mixed with 50 μL of 1 x TE buffer containing 1:200 dilution of PicoGreen (Invitrogen, 
P7581). In parallel, 50 μL of 1 x TE (as blank control) and 50 μL of λ DNA diluted to 25 
– 500 ng in 1 x TE buffer (as standards) were prepared. DNA concentration was 
quantified using a FLUOstar Omega microplate reader (BMG) at EX485-12/EM520 
spectra. To collect the CsCl fractionated lysates, the centrifuge tube was pierced near 
the bottom with a 19G syringe needle at 45° (bevel facing upwards), the needle was 
connected to a peristaltic pump via silicone tubing. Ten fractions of 0.5 mL were 
collected per cell line. To visualise TOP1mt-cc, the fractions were slot-blotted onto a 
0.45 μm nitrocellulose membrane (GE Healthcare, 106000002) pre-wetted in PBS, 
using equal amounts of DNA across cell lines (equivalent to the amount in 200 μL of 
the cell line with the lowest DNA concentration). The membrane was air-dried, then 
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blocked in 5 % milk/TBS for 30 minutes on a shaker. The GFP antibodies (Abcam, 
ab290) were diluted 1:2000, then added to the membrane, which was left shaking at 
4°C overnight. The membrane was then further processed as described in 
Section 2.6.4. Quantification was performed using Image Studio Lite (LI-COR). 
2.9.4 Chromatin immunoprecipitation and quantification of TOP1mt-cc 
1.5 x 107 Flp-In T-Rex 293 cells were induced by 1 μg/mL doxycycline for 48 hours 
then scraped and lysed in 0.6 mL ChIP lysis buffer (50 mM HEPES-KOH pH 7.5, 
140 mM NaCl, 1 mM EDTA pH 8, 1 % Triton X-100, 0.1 % sodium deoxycholate, 0.1 % 
SDS, 1 x protease inhibitors cocktail) on ice for 30 minutes. The chromatin was 
sonicated for 30 cycles at 30 seconds on 30 seconds off at high speed setting, then the 
supernatant collected. A 50 μL aliquot was taken and the remaining chromatin snap-
frozen and stored at -80°C. The 50 μL aliquot was treated with 1 μg RNAse A at 37°C 
for 30 minutes, then 25 μg of Proteinase K at 45°C for 30 minutes. The DNA was 
extracted using phenol-chloroform and precipitated by ethanol (Section 2.2.10), and 
run on a 1.5 % TBE-agarose gel to confirm that the size of the sheared chromatin 
ranged from 200 – 500 bp. The frozen chromatin was then thawed and 45 μL (10 % of 
total chromatin) was set aside as input. The remainder was diluted 4-fold with RIPA 
buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 2 mM EDTA pH 8, 1 % NP-40, 0.5 % 
sodium deoxycholate, 0.1 % SDS, 1 x protease inhibitors cocktail). 20 μL/sample of 
GFP-conjugated magnetic agarose beads (Chromotek, gtma-10) were washed with 
2 x bead volume of RIPA buffer twice, then blocked in 5 mg/mL BSA/RIPA buffer at 
4°C for 1 hour. The GFP beads were then mixed with the diluted chromatin overnight at 
4°C. The beads were then washed in a thermomixer at 25°C for 5 minutes in low salt 
wash buffer (0.1 % SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8, 150 mM 
NaCl) twice, then for 5 minutes in high salt wash buffer (0.1 % SDS, 1 % Triton X-100, 
2 mM EDTA, 20 mM Tris-HCl pH 8, 500 mM NaCl) twice, for 5 minutes in lithium 
chloride buffer (0.25 M LiCl, 1 % NP-40, 1 % sodium deoxycholate, 1 mM EDTA, 
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10 mM Tris-HCl pH 8) once, and finally for 5 minutes in 1 x TE buffer (10 mM Tris pH 9, 
1 mM EDTA) twice. The immunoprecipitated complex was then eluted from the beads 
in 150 μL of elution buffer (1 % SDS, 100 mM NaHCO3). The eluent, together with the 
input samples, were treated with RNAse A at 37°C for 30 minutes then Proteinase K at 
45°C for 30 minutes. The DNA was then purified using phenol chloroform extraction 
and ethanol precipitation. The pellet was resuspended in 30 μL distilled water. 
For qPCR, the input and ChIP samples were diluted 1:10, then 5 μL was mixed with 
2.8 μL of 5 μM forward and reverse primers (Table 2.8) and 10 μL of 2 x SensiMix 
SYBR Hi-ROX mastermix (Bioline, QT605-05). The mastermix was aliquoted into 20 μL 
reaction volumes in duplicates using a robotics workstation (Corbett Robotics, 
CAS 1200). The PCR reactions were carried out in a Rotor-Gene 6000 qPCR machine 
(Corbett Research) with thermocycling conditions as follows: 95°C for 10 minutes, then 
40 cycles of 90°C for 15 seconds, 50°C for 15 seconds, and 72°C for 30 seconds, with 
signal acquisition at end of each cycle. Mitochondrial copy number was calculated by 
2 x 2(ΔCT) whereby ΔCT = B2M average CT – ND1 average CT. Enrichment of the 
TOP1mt-bound region was expressed as percentage to the input sample, and was 
calculated as: 10 x 2(adjusted Input CT – IP CT), whereby adjusted Input CT = Input CT – 3.32. 
The percentage input was then normalised against the mtDNA copy number. 
 2.10 Mitochondrial protein analysis 
Mitochondrial pellets from Flp-In T-Rex 293 cells were isolated as described in 
Section 2.9.4. and resuspended in 50 µl homogenisation buffer (0.6 M mannitol, 
10 mM Tris-HCl pH 7.4, 1 mM EGTA, 1 mM PMSF, 0.1 % BSA), then quantified using 
Bradford assay (Bio-Rad, 500-0001). To remove nuclear and cytoplasmic 
contaminants, 20 ng RNAse-free proteinase K was added per 5 µg of mitochondria for 
30 minutes on ice. The reaction was stopped by adding 100 µM PMSF before 
centrifugation at 12000 g for 10 minutes. The mitochondrial pellets were washed with 
Primer name Sequence
Human ND1 (F) CCCTAAAACCCGCCACATCT 
Human ND1 (R) GAGCGATGGTGAGAGCTAAGGT 
Human B2M (F) CCAGCAGAGAATGGAAAGTCAA 
Human B2M (R) TCTCTCTCCATTCTTCAGTAAGTCAACT
Human TOP1mt* 15873 (F) TACTCAAATGGGCCTGTCCT
Human TOP1mt* 15873 (R) AAAGACTTTTTCTCTGATTTGTCC
Mouse CO1 (F) TGCTAGCCGCAGGCATTAC
Mouse CO1 (R) GGGTGCCCAAAGAATCAGAAC
Mouse NDUFV1 F1 CTTCCCCACTGGCCTCAAG
Mouse NDUFV1 R1 CCAAAACCCAGTGATCCAGC
Table 2.8: qPCR primers 
qPCR primers used for amplifying gDNA of the target genes and their sequences 
from 5’ to 3’.
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500 µL homogenisation buffer with 100 mM PMSF and centrifuged as previous. The 
pellets were then lysed as described in Section 2.6.1 and quantified with Bradford 
assay. 5 µg of mitochondrial lysate was fractionated using SDS-PAGE (Section 2.6.3) 
and immunoblotted (Section 2.6.4) to assess levels of protein expression.  
2.11 Transgenic mice genotyping 
Tdp1−/− mice were generated as described previously (Katyal et al., 2007). Tdp1+/− 
mice were mated with SOD1G93A mice (Gurney et al., 1994) to generate Tdp1+/− 
SOD1G93A males, which were backcrossed with Tdp1+/+, Tdp1+/− or Tdp1-/- females. 
Genotyping of adult mice was confirmed using tail biopsies, which were lysed in 100 μL 
of 25 mM NaOH at 95°C for 2 hours, then neutralised in 400 μL of 10 mM Tris-HCl pH 
8. 5 μL of lysates were used as templates in PCR reactions as described previously 
(Katyal et al., 2007). Genotyping for SOD1G93A was performed using primers Fwd: 
CATCAGCCCTAATCCATCTGA and Rev: CGCGACTAACAATCAAAGTGA. All 
animals were housed and maintained in accordance with the institutional animal care 
and ethical committee at the University of Sussex. 
2.12 Statistical analysis 
For the survival assays, the mean and standard errors were calculated from at least 
three biological repeat experiments consisting of three technical replicates at each 
treatment condition. The p values of samples from each time point or concentration 
were analysed by two-tailed Student t-test. For the alkaline comet assays, the mean 
and standard errors were calculated from at least three biological repeat experiments 
consisting of tail moment scores from 50 cells. For H2O2 comet assay, the mean comet 
tail moments of all samples were normalized to the mock-treated wildtype sample. The 
p values of samples from each time point or concentration analysed by two-tailed 
Student t-test unless otherwise specified. For RT-qPCR experiments, relative 
quantification of the CT values of all samples were extrapolated from the standard 
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curve, and normalized against GAPDH values. The normalized values were then 
expressed as fold change relative to the control miScr cell line. The mean values and 
standard errors were calculated from three biological repeat experiments. The p values 
were calculated using two-tailed Student t-tests. For Seahorse analysis, the OCRs 
under basal and stressed conditions were normalized against cell numbers derived 
from Hoechst 33342 staining. The mean OCRs and standard errors were calculated 
from three biological repeat experiments consisting of three technical replicates. The p 
values were calculated using two-tailed Student t-tests.  
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    CHAPTER 3 
TDP1 serine 81 mediated interaction with DNA 
Lig3α promotes TDP1 protein stability and DNA 
repair
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3.1 Introduction 
Although catalytic mutation of TDP1 is clearly associated with defective SSBR at a 
cellular level and cerebellar degeneration at an organism level (Takashima et al., 2002;  
Katyal et al., 2007), little was known about the mechanisms that regulate TDP1 
function at a molecular level. As with many DNA repair proteins that form stable 
complexes during the multi-step process, TDP1 has been shown to associate with 
XRCC1 to increase the efficiency of SSBR (Plo et al., 2003). Previous work from our 
lab has shown that TDP1 directly interacts with another component of the SSBR 
machinery, DNA ligase 3α (Lig3α), using the yeast two-hybrid system. Specifically, 
Lig3α binds to the N-terminus domain of TDP1 (El-Khamisy et al., 2005).  This domain 
is only present in higher eukaryotes, with very low sequence homology amongst them 
(Chiang et al., 2010). This late addition and rapid evolution of the N-terminus domain 
suggest a non-essential but advantageous role in the function of the protein. For this 
reason, the N-terminus domain is highly relevant to the hypothesis of my thesis, i.e. in 
higher organisms, suboptimal control of the function of TDP1 in vivo may contribute to 
the neurodegeneration phenotype of SCAN1 patients.  
Post-translational modifications by small molecule modifiers fine-tune enzymatic 
activities, protein-protein interactions, subcellular localisation, solubility and 
degradation. Phosphorylation, the addition of a phosphate group to an amino acid by 
covalent bonding, is mediated by protein kinases. The kinases ATM, ATR and DNA-PK 
play a crucial role in orchestrating the complex DNA damage response 
(Section 1.3.1.1), and the lists for their biological substrates are constantly expanding. 
A proteomic screen of potential substrates of ATM and ATR identified TDP1, and 
mapped the putative phosphorylation sites to S81, S365, and S563 (Zhou et al., 2005;  
Mu et al., 2007). S81 is of particular interest since it is the only site in the N-terminus 
domain identified in this study. S81 is conserved amongst several higher organisms 
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(Chiang et al., 2010). I was therefore intrigued by the possibility that the interaction 
between TDP1 and Lig3α may be regulated by phosphorylation of S81 by ATM or ATR 
in response to DNA damage. If so, this would be the first indication of the regulatory 
role of the N-terminus domain, which would support the hypothesis that regulation of 
TDP1 activity is important for TDP1 function in higher organisms. 
This may have practical implications, as TDP1 inhibitors are currently being developed 
as novel anti-cancer drugs (Huang et al., 2011).  Understanding TDP1 activity in the 
broader context of DNA repair could help identify potential factors that can contribute to 
understanding how resistance to TDP1 inhibitors can develop in cancer cells, as well 
as how neuronal cells repair DNA damage. 
In this chapter, I will present evidence for the requirement of S81 phosphorylation in 
the interaction between TDP1 and Lig3α. I will also assess its functional importance in 
the cellular context. I will look at how S81 phosphorylation and interaction with Lig3α 
impacts on TDP1 protein metabolism, catalytic activity, and DNA repair efficiency.  
3.2 Methods 
3.2.1 Identifying novel protein-protein interactions using yeast two-hybrid assay 
First described in 1989 (Fields and Song, 1989), the yeast two-hybrid assay is a well-
established method for studying protein-protein interactions in a cellular system. It 
utilises the fact that many transcription factors in higher eukaryotes are modular, i.e. 
the different domains can be expressed separately and transcription can be activated 
when the different domains are brought near each other at the promoter site. In 
Saccharomyces cerevisiae, the transcription factor Gal4 contains a DNA binding 
domain (BD), and an activation domain (AD). When Gal4-BD is fused to a bait protein 
and Gal4-AD is fused to a prey protein, if the two proteins of interest interact, the 
proximity of the two Gal4 domains at its target promoter site would activate 
transcription of two reporter genes, his3 and lacZ in the Y190 host strain. Activation of 
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his3 confers histidine prototrophy, which allows growth in histidine depleted medium; 
while activation of lacZ produces β-galactosidase, which metabolises a synthetic 
galactose substrate (x-gal) and produces a blue by-product.  
The procedure of a standard two-hybrid assay involves transforming the host strain 
with two plasmids, one of which encodes the bait protein fused to Gal4-BD; the other 
plasmid encodes the prey protein fused to Gal4-AD. The vectors also contain 
nutritional selection markers to allow selection of clones that stably express the fusion 
proteins, and a nuclear localisation signal to ensure transcription of the reporter gene. 
The readouts were performed 72 hours after transformation using histidine prototrophy 
or β-galactosidase assay.  
The advantages of using the yeast two-hybrid system over standard biochemical 
assays include: 
• It utilises an easily manipulated model cellular system with many conserved cellular 
processes in higher eukaryotes; 
• The post-translational processing of proteins is more sophisticated than in 
prokaryotes; 
• It requires only small amount of plasmid DNA, which is easier to prepare than 
purified proteins; 
• The readouts are fast and can be quantitative; 
• It allows mapping of the interaction site by testing interaction with truncated or 
point-mutated forms of the protein of interest. 
However, the main caveat in the yeast two-hybrid assay is false positive results. These 
can be due to technical or biological reasons: 
• When proteins are overexpressed, the interaction can be forced (non-specific and 
not physiological);  
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• Targeting of proteins tagged with the transcription factor domains to the nucleus 
can potentially induce non-specific transcription of the reporter genes without 
physical interaction of the bait and prey proteins (“auto-activation”);  
• Overexpression or targeting the proteins of interest to the nucleus may be cytotoxic 
and inhibits transcription or cell growth;  
• Truncated proteins may interact differently than full-length proteins due to 
conformational changes; 
• The interaction between two proteins may be indirect via a third protein or DNA; 
• Yeast lacks certain post-translational modifications such as glycosylation, 
disulphide bonds and certain phosphorylations, which may inhibit interactions in the 
host species; 
• In library screens using a cDNA library, interactions may be biased towards high 
expressing genes specific to the cell type from which the library is prepared; and 
each subsequent round of propagation of the cDNA library in bacteria may increase 
bias towards high expressers in bacteria. 
(Van Criekinge and Beyaert, 1999;  Brückner et al., 2009). 
Measures that I have taken in this thesis to address the possibility of false negative 
results include: 
• For “auto-activation”, include a negative control where Gal4-BD-tagged bait protein 
and untagged Gal4-AD are overexpressed; use two reporter genes his3 and lacZ; 
• Use immunoblotting to confirm levels of over-expressed proteins; 
• Use phosphomimetic and phosphomutant versions of the target phosphorylation 
site; 
• Use protein co-immunoprecipitation to validate the interaction in the mammalian 
system.  
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3.2.2 Single Cell Gel Electrophoresis (SCGE)/Comet Assay  
The comet assay is widely-used for measuring DNA damage in single cells. Originally 
developed by Östling & Johansson (Ostling and Johanson, 1984) and modified by 
Singh et al. (Singh et al., 1988), it was based on the concept of combining DNA 
electrophoresis with fluorescence microscopy. The procedure entails first 
“encapsulating” single cells in agarose, then disrupting cellular protein and RNA 
contents by a detergent and high salt solution. The remaining DNA is then dissociated 
from the chromatin and nuclear membrane and fills up the entire encapsulated space 
of the cell, forming a “nucleoid”. When the nucleoid is subjected to electrophoresis, 
damaged DNA ends migrate out of the nucleoid due to loss of supercoiling, forming the 
appearance of a comet under the microscope when stained with a fluorescent dye that 
binds dsDNA (Olive and Banáth, 2006). The intensity and length of the comet tail 
(containing loops of relaxed DNA) relative to the comet head (supercoiled undamaged 
DNA) can be expressed as the tail moment (Olive et al., 1990), which can be 
calculated for each individual cell.   
The main advantages of the comet assay are: 
• Simple and inexpensive to set up; 
• Can be used on a wide range of nucleated cells; 
• Can measure SSBs, DSBs, abasic sites, and protein-linked breaks, and interstrand 
cross-linked breaks, and the repair kinetics thereof; 
• Can detect apoptotic cells (distinct appearance from viable cell with large number 
of DNA breaks); 
• Can detect heterogeneity in response to genotoxins, especially useful in screening 
of potential drug-resistant clones of cancer cell lines; 
• Has high sensitivity especially for SSBs (as low as 50 breaks per cell); 
• Does not require a large cell number (as low as a few thousands); 
• Does not require radiolabelling as in alkaline elution assay  
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Disadvantages of the method include: 
• Only suitable for fresh live cells 
• Requires single cell suspension, therefore not suitable for tissues not easily 
dissociated without inadvertent damage to the DNA content (can be circumvented 
in certain tissue types by culturing overnight to allow recovery); 
• When working with genetically-modified cell lines, a homogenous expressing 
population is required expressing and non-expressing cells are weighted equally in 
the scoring process; 
• Does not quantify sizes of DNA fragments; 
• The unmodified protocol does not allow distinction between different types of DNA 
lesions, e.g. H2O2 which generates many different types of lesions; 
• For drugs requiring long period of treatment (e.g. cisplatin), or breaks rapidly 
repaired during treatment (e.g. H2O2 and CPT), the readout is a mixture of damage 
induction and repair at steady-state; 
• The amount of DNA damage does not necessarily correlate with the cell fate or 
viability 
(Olive and Banáth, 2006) 
To conclude, the comet assay is a useful technique in our lab to monitor DNA repair 
kinetics in cell lines and to screen for DNA damage repair defect of a new cell line 
(usually from patients, transgenic mice, or genetically-modified human or mouse cell 
lines). Examples of genotoxins used in this thesis and the predominant lesion they 
produce are listed in Table 3.1. 
To assess the cell fate after DNA damage, I used clonogenic survival assay to 
measure the ability of cells to recover from geneotoxic stress and proliferate to form 
colonies. 
 Genotoxins Types of DNA breaks 
Hydrogen peroxide (H2O2) SSBs, AP-sites, complex DSBs at high dose, 
protein-DNA breaks (PDBs) 
tert-butyl hydroperoxide 
(TBH) 
SSBs, AP-sites, complex DSBs at high dose 
Gamma-ray SSBs, DSBs (~ 40:1 SSBs:DSBs) 
Camptothecin (CPT) TOP1-cc 
 
Table 3.1 Genotoxins and the types of associated DNA damage.   
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3.2.3 Clonogenic Survival Assay (Colony Formation Assay)  
In the presence of genotoxic stress, immortalised/cancer cell lines can respond by 
complete recovery, partial recovery, or death. Complete recovery is indicated by 
retention of reproductive integrity, i.e. the ability to divide indefinitely and form 
macroscopic colonies. Partial recovery is indicated by retention of viability (to produce 
proteins and synthesise DNA) for a few cell divisions but not indefinitely (Franken et al., 
2006). Cell death can occur by apoptosis, autophagy, or necrosis (Section 1.3.3). It is 
noteworthy that loss of specific pathway (e.g. apoptosis) does not usually result in 
reversion to reproductive integrity, instead an alternative pathway of cell death is often 
activated (e.g. necrosis). 
The clonogenic survival assay was developed as early as 1956 by Puck and Marcus 
(Puck and Marcus, 1956) to measure the radiosensitivity of HeLa cells. Since then, it 
has been used to generate most of the radiotherapy and chemotherapy response data 
on known mammalian cell lines.   
The clonogenic survival assay entails plating a known number of single cells in a 
number of petri dishes corresponding to each treatment condition (usually increasing 
drug concentrations), then incubating the cells in optimal growth medium until they are 
fully adhered (but not undergone cell divisions yet), then treating with the genotoxin for 
a defined period. Cells are left to recover in optimal growth medium to form 
macroscopic colonies. The plating efficiency of each dish is calculated in percentage 
as the number of colonies counted divided by the number of cells plated. The surviving 
fraction is calculated in percentage as the plating efficiency of treated samples to 
untreated sample. The surviving fraction of each drug concentration can be plotted as 
a dose-response to obtain a “survival curve”, whereby the IC50 of the drug can be 
deduced.  
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The clonogenic survival assay is highly sensitive in detecting cellular response to 
genotoxic drugs. However, it is labour-intensive and time-consuming, making it 
unsuitable for high-throughput screening. 
3.3 Results 
3.3.1 The N-terminus domain of TDP1 interacts with Lig3α 
To determine the mechanism of interaction between TDP1 and Lig3α using the yeast 
two-hybrid system, it was important to first confirm the interaction between the N-
terminus of TDP1 and Lig3α as previously published (El-Khamisy et al., 2005). Fig. 3.1 
shows that the N-terminus domain (TDP11-150) but not the C-terminus domain 
(TDP1151-608) interacted with Lig3α, as detected by both histidine prototrophy and β-
galactosidase assays. The interaction was specific, as confirmed by the lack of auto-
activation of either Gal4BD-TDP11-150 or the Gal4AD-Lig3α (Fig. 3.1A). Immunoblotting 
of whole cell lysates confirmed all proteins of interest were expressed (Fig. 3.1B).  
3.3.2 TDP1 S81 mediates interaction with Lig3α 
I then generated constructs encoding TDP1S81A (phosphomutant), or TDP1S81E 
(phosphomimetic with a negatively charged –COOH group). In Fig. 3.2A, again using 
the yeast two-hybrid assay, interaction between TDP1 and Lig3α was shown to be 
abrogated in the S81A mutant but not in the S81E mutant, indicating that it was likely 
the phosphorylation status, rather than structural modification, that mediated the loss of 
interaction. To ascertain whether the apparent mild activation of the his3 gene in 
TDP1S81A was significant, quantitative β-gal assay using CPRG as substrate was 
performed. Fig. 3.2B,C show that TDP1S81A interaction with Lig3α was close to 
background level, i.e. when no TDP1 was expressed.    
I then looked at this interaction event in the mammalian cell system using the human 
alveolar adenocarcinoma cell line A549, suitable for transient over-expression of 
proteins. Cells were transfected with either Myc-TDP1 or Myc-TDP1S81A, and the 
Figure 3.1 The N-terminus domain of TDP1 interacts with Lig3α. (A) Y190 cells co-
transformed with the indicated pGBKT7 and pACT constructs were plated onto selective
media containing either histidine (“Control”) or lacking histidine and containing 3-aminotriazole
(“His”) to test for the activation of the his3 reporter gene. The activation of the β-gal reporter
gene was detected using the filter lifts from control plates (“β-Gal”). (B) WCEs (10 μL of
0.075 OD600/μL) from (A) were fractionated with SDS-PAGE and immunoblotted using
antibodies against Myc and Gal4AD. WCE from untransformed cells was included as negative
control (far left lane). A duplicate gel was stained with Coomassie blue as loading control.
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Figure 3.2 TDP1 S81 is required for interaction with Lig3α in yeast two-hybrid system.
(A) Yeast Y190 co-transformed with pACT-Lig3α and pGBKT7-TDP1, pGBKT7-TDP1S81A or
pGBKT7-TDP1S81E were plated onto selective media containing either histidine (“Control”) or
lacking histidine and containing 3-aminotriazole (“His”) to test for the activation of the his3
reporter gene. The activation of the β-gal reporter gene was detected using the filter lifts from
control plates (“β-Gal”). (B) WCEs (10 μL of 0.075 OD600/μL) were fractionated with SDS-
PAGE and immunoblotted using antibodies against Myc and Gal4AD. WCE from
untransformed cells was included as negative control (far right lane). A duplicate gel was
stained with Coomassie blue as loading control.
Control His β-Gal
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interacting proteins purified using Myc immunoprecipitation. The interaction of 
TDP1S81A with endogenous Lig3α was greatly diminished but not completely abolished 
(Fig. 3.3). This interaction is again TDP1-specific as no Lig3α pull-down was 
detectable in cells transfected with Myc alone. 
3.3.3 Interaction between TDP1 and Lig3α is independent of exogenous 
genotoxic stress 
That the interaction between TDP1 and Lig3α depends on conservation of a putative 
ATM/ATR consensus site suggests that this interaction may be regulated by DNA 
damage. To test this, I co-expressed TDP1 and Lig3α in the yeast two-hybrid system, 
and quantified the interaction after treatment with CPT or IR using CPRG-based 
quantitative β-gal assay. However, there was no change in the amount of β-gal 
metabolised at the doses known to induce detectable levels of DNA damage (Redon et 
al., 2003), suggesting the interaction was constitutive (Fig. 3.4). This result should be 
interpreted in the context of the yeast two-hybrid system, whereby the other regulatory 
mechanisms of the interaction in humans such as XRCC1 and PNK are not conserved 
in yeast (Kelley et al., 2003).    
3.3.4 TDP1 S81-mediated interaction with Lig3α promotes TDP1 stability 
Incidentally, while I observed that the TDP11-150 truncated protein interacted with Lig3α 
in the yeast two-hybrid system, I was unable to express the S81A version of TDP11-150
(data not shown), despite correct cDNA sequence and reading frame in the plasmid. 
To test the possibility that the S81-mediated interaction of TDP1 with Lig3α stabilises 
TDP1 and prolongs its half-life, I overexpressed Myc-TDP1 or Myc-TDP1S81A in A549 
cells, challenged the cells with CPT, then inhibited protein synthesis with 
cyclohexamide (CHX) for up to 24 hours. Immunoblotting of Myc-TDP1 showed 
minimal degradation of the wildtype Myc-TDP1 during this period, while the level of 
Myc-TDP1S81A was visibly lower reduced within 24 hours (Fig. 3.5A). Alternatively, 
inhibiting TDP1 phosphorylation by caffeine, an inhibitor of ATM, ATR and DNA-PK 
Figure 3.3 TDP1 S81 promotes interaction with Lig3α in human A549 cells. A549 cells
were transiently transfected with pCI plasmids encoding Myc-TDP1, Myc-TDP1S81A, or
untagged Myc. 100 μg WCEs were immunoprecipitated with antibodies against Myc. Levels
of Lig3α, Myc-TDP1 and Myc-TDP1S81A present in WCEs (“Load”) and in immunoprecipitated
samples (“E”) were determined by immunoblotting with antibodies against Lig3α or Myc.
Lig3α
Myc-TDP1
IgG 
(H-chain)
75
50
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Figure 3.4 Interaction of TDP1 with Lig3α is constitutive in the yeast two-hybrid
system. Y190 cells were transformed with the indicated plasmids and selected on yeast
minimal medium lacking histidine and containing 3-aminotriazole for 72 hours. Transformants
were then grown in complete culture medium for two doubling cycles, followed by treatment
with 30 μM CPT for 6 hours or 200 Gy ionising radiation, then harvested. The WCEs were
incubated in CPRG until the medium turned from yellow to red colour and the reaction was
stopped with 3 mM ZnCl2. The OD578 of the supernatant was measured. β-galacosidase units
was calculated as 1000 x OD578 (t x V xOD600), where t = stop time – start time (in minutes),
V = 0.1 x concentration factor. 1 unit of β-galacosidase is defined as the amount which
hydrolyses 1 µmol of CPRG to chlorophenol red and D-galactose per minute per cell. 1 unit of
β-galactosidase equals the amount of enzyme required to hydrolyse CPRG per minute.
Figure 3.5 TDP1 S81 promotes protein stability (A) A549 cells transfected with the
indicated pCI-Myc constructs were treated with DMSO (”Mock”) or 35 μM CPT for 2 hours at
37˚C (left), then incubated in CPT-free medium with 10 μg/ml cycloheximide (“CHX”) for the
indicated time periods (right). (B) A549 cells transfected with pCI-Myc-TDP1 were treated
with or without 2 mM caffeine for 30 minutes, followed by 35 μM CPT treatment for 2 hours
at 37˚C, then incubated in CPT-free medium containing 10 μg/ml cycloheximide (“CHX”) and
caffeine for 12 hours at 37˚C. Cells were harvested for immunoblotting using antibodies
against Myc or β-actin as loading control. (C) A549 cells transfected with pCI-Myc-TDP1,
pCI-Myc-TDP1S81A, or pCI-Myc-TDP1S81E were similarly treated as described in (A) and
WCEs were immunoblotted using antibodies against Myc and β-actin. as loading control.
Data collected with help from Prof. Sherif El-Khamisy.
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activities (Blasina et al., 1999;  Hall-Jackson et al., 1999;  Sarkaria et al., 1999;  Zhou 
et al., 2000), reduced the stability of wildtype Myc-TDP1 after 12 hours of CHX 
incubation (Fig. 3.5B). To exclude the effect of caffeine as being non-specific, the half-
life of the phosphomimetic mutant Myc-TDP1S81E was assessed by CHX and appeared 
even longer than that of Myc-TDP1 (Fig. 3.5C).  
Phosphorylation of S81 could promote TDP1 protein stability by inducing a 
conformational change that inhibits proteasomal targeting, or due to complex formation 
with Lig3α. This was tested in HeLa cells stably depleted of Lig3α, which were 
transfected with pCI-Myc-TDP1, treated with CPT, and left to incubate in CHX as 
described before. In cells depleted of Lig3α, Myc-TDP1 degraded faster than Lig3α-
expressing cells (a decrease of 47 % compared to ~ 26 % after 6 hours), which was 
further exacerbated by treatment with CPT (a decrease of ~ 91 % compared to ~ 67 % 
after 6 hours) (Fig. 3.6). Taken together, these data suggest that TDP1 S81 promotes 
formation of a stable complex with Lig3α via its N-terminus domain both constitutively 
as well as in response to CPT treatment, thereby protecting it from degradation.  
3.3.5 The catalytic activity of TDP1 is independent of S81 
Next we examined whether maintaining protein stability in response to CPT damage 
was required for enzymatic activity of TDP1. My lab colleague Jean Carroll performed 
an in vitro enzymatic assay using 10 x His-TDP1 and 10 x His-TDP1S81A purified from 
E. coli, and a substrate of 43-mer duplex oligonucleotide containing a nick with a 3’-
phosphotyrosyl group (3’-PY) (Fig. 3.7A). In the absence Lig3α, the efficiency of 
10 x His-TDP1 and 10 x His-TDP1S81A to process the 3’-PY to 3’-hydroxyl group (3’-
OH) was similar (Fig. 3.7B). To confirm this in cells, I complemented a CPT-
hypersensitive strain of S. cerevisiae (tdp1Δ/rad10Δ) (Vance and Wilson, 2002) with 
human TDP1 or TDP1S81A, and observed similar levels of protection against CPT 
conferred by TDP1S81A as wildtype TDP1 (Fig. 3.8). Since S. cerevisiae lacks known 
Figure 3.6 Lig3α promotes stability of Myc-TDP1. HeLa cells depleted of Lig3α by shRNA
were treated with DMSO (“Mock”) or 35 μM CPT for 2 hours at 37˚C, then incubated in CPT-
free medium with 1 μg/ml cycloheximide (“CHX”) for the indicated time periods. Cells were
harvested and the WCEs were immunoblotted with antibodies against Lig3α, Myc or β-actin
as loading control. The level of Myc-TDP1 in each sample was quantified and normalised
against the β-actin level using ImageJ. The numbers at the bottom row indicate the fraction of
Myc-TDP1 of the treated samples relative to the untreated sample (far left lane). Where not
shown, quantification was not accurate due to low levels of Myc-TDP1 or β-actin.
Lig3α
Myc-TDP1
β-actin
shLig3α - +        - +     - +             - +        - +     - +               
CHX (hrs) - - 6     6    20   20               - - 6       6      20     20                
1 0.91   0.74  0.48  0.46     - 1.03  0. 68   0.34 0.06   0.01  0.003       
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Figure 3.7 TDP1 S81 is not required for enzymatic activity in vitro. (A) Histidine-tagged
TDP1 and TDP1S81A were purified from BL21 E. coli and 300 ng of each was analysed by
SDS-PAGE and stained with Coomassie blue. (C) 32P-radiolabelled 43-mer duplex (50 nM)
containing a nick with a tyrosine (Y) linked to the 3'-terminus of the labelled 18-mer was
incubated in the absence or presence of the 30 nM of the indicated purified recombinant
proteins for 1 hr at 37°C. Repair products were analysed by denaturing PAGE and
phosphorimaging. Positions of the 32P-radiolabelled substrate (18-Y) and product (18-P) are
indicated in red. Data collected by Dr Jean Carroll.
(A)
(B)
Figure 3.8 Interaction with Lig3α is not required for TDP1 activity in vivo. Serial dilutions
of wild-type (top) and tdp1Δ/rad1Δ (bottom) yeast cells transformed with empty pGBKT7,
pGBKT7-TDP1 or pGBKT7-TDP1S81A and plated in 10-fold dilutions onto leucine-lacking
media with or without 20 μM CPT, and left to form macroscopic colonies at 30°C for 72 hours.
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homologues of Lig3α, XRCC1 and PNK, the rescue was most likely due to the catalytic 
activity of TDP1S81A and not dependent on interaction with Lig3α.   
3.3.6 The rapid phase repair of TOP1-cc by TDP1 is independent of S81  
As both the in vitro and yeast data relied on expression of the human TDP1 protein in 
non-native hosts, they may not reflect the situation in human cells. To address this, 
repair of TOP1-cc was assessed in the SCAN1 patient lymphoblastoid cells 
complemented with recombinant His-TDP1 or His-TDP1S81A and treated with CPT for 1 
hour. Immunoblotting of whole cell lysates at start of CPT treatment showed equal 
levels of the recombinant proteins (Fig. 3.9A). Cells complemented with recombinant 
TDP1S81A were able to repair TOP1-cc as efficiently as cells complemented with 
recombinant TDP1, although not to the same extent as wildtype cells (Fig. 3.9B). This 
could be due the dominant negative effect of the TDP1H493R mutation in SCAN1 cells, 
which gets trapped on the DNA break itself, forming persistent covalent DNA 
complexes (Interthal et al., 2005a). In Tdp1-/- MEFs complemented with recombinant 
hTDP1 or hTDP1S81A (Fig. 3.10A), the efficiency of SSBR was comparable between 
the two groups (Fig. 3.10B). Therefore, TDP1 S81 does not seem to be required for 
rapid phase of repair of repair of SSBs induced by CPT. 
3.3.7 TDP1 S81 promotes cellular survival following genotoxic stress 
The alkaline comet assay assessed the repair kinetics of primarily SSBs within an hour 
after damage. However, since TDP1 has also been implicated in the repair of 
replication-associated TOP DSBs (Section 1.5.1), the effect of TDP1S81A on replicating 
cells was assessed indirectly by measuring clonogenic survival after CPT treatment. 
Tdp1-/- MEFs complemented with recombinant TDP1 or TDP1S81A were challenged with 
bolus doses of CPT for one hour to induce TOP1-cc, then left to recover in drug-free 
medium up to 7 – 10 days. Only cells which retained replicative potential were able to 
form macroscopic colonies. Fig. 3.11 shows that complementation with recombinant 
TDP1 rescued the survival of CPT-treated Tdp1-/- MEFs while mock (BSA) 
Figure 3.9 TDP1 81 is not required for rapid-phase single-strand break repair in human
lymphoblastoid cells. (A) SCAN1 lymphoblastoid cells (“LCLs”) were electroporated with
200 μg BSA, 10xHis-TDP1, or 10xHis-TDP1S81A and left to recover at 37˚C for 2 hrs. Cells
were harvested and WCEs were immunoblotted with antibodies against TDP1 and β-actin as
loading control. Arrow points at 10xHis-TDP1. (B) LCLs were incubated with 14 μM CPT for 1
hr and DNA strand breakage was quantified immediately by alkaline comet assay. Data are
the mean of 3 independent experiements (100 cells per experiment) and error bars indicate
+1 S.E.M. Data collected with help of Prof. Sherif El-Khamisy.
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Figure 3.10 TDP1 S81 is not required for rapid-phase single-strand break repair in
MEFs. (A) Tdp1-/- MEFs were electroporated with 200 μg BSA, recombinant TDP1, or
recombinant TDP1S81A and left to recover at 37˚C for 2 hrs. Cells were harvested and WCEs
were immunoblotted with antibodies against TDP1 and β-actin as loading control. (B)
Electroporated cells were treated with 14 μM CPT or DMSO (“Mock”) for 1 hr at 37°C. DNA
strand breakage was quantified by alkaline comet assay. Data are the mean of 3 independent
experiments (100 cells per experiment) and error bars indicate +1 S.E.M. Data collected with
help of Prof. Sherif El-Khamisy.
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Figure 3.11 TDP1 S81 promotes survival after genotoxic stress in MEFs. Tdp1-/- MEFs
were electroporated with 200 μg BSA, recombinant TDP1, or recombinant TDP1S81A and left
to recover at 37˚C for 2 hrs, Cells were plated in 10 cm dishes and treated with the indicated
doses of CPT for 1 hr at 37°C (A), or irradiated with the indicated doses of ionizing radiation
(IR) (B). Cells were then left to recover in normal growth medium for 7 – 10 days to allow
formation of macroscopic colonies. Surviving fraction was calculated by dividing the number
of colonies on treated plates by the number on untreated plates. Data are the mean of 3
independent experiments for each drug and error bars represent ±1 S.E.M. Where not visible,
error bars are smaller than the symbols. Data collected with help of Prof. Sherif El-Khamisy.
(A)
(B)
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complemented cells did not. TDP1S81A complementation conferred an intermediate level 
of resistance, suggesting a defect in repair of TOP-associated DSBs by TDP1S81A.  
3.4 Discussion 
In this chapter, I have present data confirming that, in the yeast two-hybrid system, 
human TDP1 directly interacts with Lig3α (Fig. 3.1, 3.2), but not XRCC1 or APTX, nor 
the other candidate proteins of the NER and DSBR pathways tested. I also confirmed 
the previous finding that TDP1 N-terminus is the binding site for Lig3α (Fig. 3.1).  
I have then shown that this interaction requires the serine 81 residue both in the yeast 
two-hybrid system (Fig. 3.2) and the mammalian cell system (Fig. 3.3) in the absence 
of exogenous DNA damage. Adding exogenous damage by CPT or IR did not alter the 
speed or intensity of the interaction in the yeast two-hybrid system (Fig. 3.4). 
The apparent constitutive nature of interaction between TDP1 and Lig3α needs to be 
interpreted with caution. As mentioned, protein-protein interactions in a non-native host 
species may lack physiological regulatory elements. Furthermore, as the quantitative β-
gal assay readout can take up to 12 hours, after induction of exogenous DNA damages 
transcription may be stalled globally, and dampen any effect of increased interaction 
due to lower protein expression level. A protein co-immunoprecipitation experiment 
using mammalian cells was performed to address these issues, and will be presented 
in chapter 4 (Fig. 4.5). The result indicates that CPT damage did not alter the quantity 
of complex formation between TDP1 and Lig3α, suggesting that this interaction is 
mainly regulated by endogenous sources of damage, the most likely being TOP1-cc in 
the proximity of abasic sites, oxidised bases, or the transcription or replication 
machinery (Pommier et al., 2003).    
Concurrent with my project, a study by Yves Pommier’s group also showed that in 
mammalian cells, TDP1 S81 is phosphorylated in response to CPT and IR (Das et al., 
2009). This phosphorylation event is dependent on ATM and DNA-PK, and that 
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phospho-TDP1 co-localises with phospho-ATM, γH2AX and XRCC1 at sites of CPT-
induced DSBs. Phosphorylated TDP1 is also retained at sites of DNA damage for up to 
hours, suggesting a stable complex formation with XRCC1 (Das et al., 2009). These 
findings are consistent with my result, as XRCC1 and Lig3α form a stable heterodimer 
in the nucleus (Caldecott et al., 1994;  Caldecott et al., 1995).  
More recently, the Pommier group also showed a physical interaction between TDP1 
and PARP1, a crucial factor in BER/SSBR. PARP1 binds TDP1151-168 (Das et al., 2014). 
PARylation of TDP1 by PARP1 promotes its protein stability, interaction with XRCC1, 
and recruitment to sites of DNA damage induced by UVA, CPT, (Das et al., 2014) and 
monofunctional alkylating agents (Murai et al., 2012;  Alagoz et al., 2013;  Lebedeva et 
al., 2015). Interestingly, inhibition of PARP1 activity seemed to promote accumulation 
of phospho-S81 TDP1, suggesting a negative feedback mechanism of TDP1 
PARylation on S81 phosphorylation.  
The fortuitous finding that human TDP11-150 S81A did not express in yeast pointed me to 
the possibility that S81 may play a role in stabilising the protein. While it is common for 
truncated proteins to be unstable, the large size of the Gal4BD tag could have 
stabilised the truncated TDP11-150. In addition, as Lig3α was absent in yeast (Kelley et 
al., 2003), the stabilising effect was not due to Lig3α. It was therefore important to 
examined this in human cells. I used cycloheximide to determine the half-lives of Myc-
TDP1 and Myc-TDP1S81A in A549 cells (Fig. 3.5), as well as HeLa cells depleted of 
Lig3α (Fig. 3.6). The results indicate that in human cells, S81 promotes TDP1 stability 
by forming a complex with Lig3α. Although it is possible that the N-terminal Myc-tag 
could alter the protein structure at the N-terminus domain, this was unlikely to be the 
case, as the finding was reproduced by another group, whereby Flag-TDP1 and Flag-
TDP1S81A were used (Das et al., 2009). To conclusively test this, tertiary structural 
analysis would need to be performed, but that would fall outside the time frame of this 
thesis. However, characterising the binding sites of TDP1 and Lig3α could be of 
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therapeutic potential, as more effective small molecule inhibitors of TDP1 are being 
developed to improve the clinical outcome of TOP-based therapies commonly used in 
breast, lung and colorectal cancers (Huang et al., 2011). 
Although the molecular mechanism by which TDP1:Lig3α interaction regulates TDP1 
protein turnover in cells has been established, in vitro the enzymatic activity seemed 
independent of this interaction (Fig. 3.7). This was not too surprising as the N-terminus 
domain has been shown to be dispensable for catalytic activity in vitro (Interthal et al., 
2001).  
Next the effect of TDP1:Lig3α interaction on DNA repair in the chromosomal context 
was explored. Again, TDP1 S81 phosphorylation appeared not to play a role in the 
repair of TOP1-cc, which are expected to be predominantly SSBs in the time frame of 
the treatment (Fig. 3.9, 3.10). It must be noted that recombinant proteins from E. coli 
were used instead of cDNA transfection, as the efficiency of DNA transfection is low in 
MEFs, therefore unsuitable for comet assay. The possibility of the recombinant 
proteins lacking important post-translational modifications could explain the 
discrepancy between my data and that published by Das et al, who found a reduction 
in SSBR capacity after CPT treatment in MEFs complemented with hTDP1S81A. The 
MEFs used by this group were transduced with lentiviral particles containing the cDNA 
of the relevant proteins, and repair in cells complemented with wildtype TDP1 was as 
efficient as Tdp1 MEFs (Das et al., 2009).  
With the clonogenic survival assay, although a partial defect was seen in cells 
expressing recombinant TDP1S81A compared to wildtype TDP1, this again could be due 
to the shorter half-life of the recombinant TDP1S81A without compensation by increased 
protein synthesis. As shown by Das et al, phosphorylated TDP1 is retained at sites of 
CPT-induced breaks for hours, even long after the removal TOP1-cc. The shorter half-
life of TDP1S81A could account for more unrepaired lesions persisting into S-phase and 
the subsequent cell killing.  
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To conclude, TDP1 S81 prolongs the protein half-life, likely by forming a stable 
complex with Lig3α. This interaction does not promote enzymatic activity in vitro, but 
promotes DNA repair efficiency as measured by clonogenic survival assays. 
In the next chapter, I will describe the discovery and characterisation of another 
element of post-translational modification in the N-terminus domain of TDP1 that 
regulates its DNA repair efficiency – the Small Ubiquitin-like Modifier (SUMO) pathway.  
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            CHAPTER 4 
SUMOylation of TDP1 at K111 accelerates 
recruitment to DNA damage sites and promotes 
cellular survival after genotoxic stress 
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4.1 Introduction 
Although I have confirmed that TDP1 S81 is required for its interaction with Lig3α, its 
significance in SSBR and SCAN1 pathology is still not clear. Lig3α knockout mice are 
embryonically lethal (Puebla-Osorio et al., 2006), but Lig3α is dispensable for nuclear 
SSBR (Gao et al., 2011;  Simsek et al., 2011), as there is a functional overlap with 
Lig1. As Lig3α is the only form of DNA ligase in the mitochondria, it is possible that 
TDP1 S81 is more important for mitochondrial DNA repair than nuclear DNA repair. It is 
also possible that TDP1 interacts with other DNA ligases in the nucleus such as Lig1 or 
Lig4. To explore the possibility that S81 may mediate specific interactions with other 
DNA repair proteins, I used the yeast two-hybrid system again to screen for proteins 
interacting with the TDP1S81E mutant, which acts as a phosphomimetic and should 
increase the likelihood of detecting S81 phosphorylation-dependent protein-protein 
interactions. To this end, a novel interacting partner was discovered, which has a clear 
role in the SUMOylation pathway. This suggests that TDP1 is post-translationally 
modified by a second mechanism. This chapter describes the characterisation of N-
terminus domain – SUMOylation of lysine 111 (K111) by SUMO1, and the mechanism 
by which it regulates TDP1 function at a cellular level.  
4.1.1 The SUMOylation pathway and TOP1 
SUMOylation can regulate the activity of target proteins in terms of transcription, 
stability, protein-protein interaction, and sub-cellular localisation. Increasing evidence 
confirms its role in DNA damage response and repair (Dou et al., 2011). The 
SUMOylation pathway, similar to the ubiquitination pathway, is a multi-step process 
involving: 1) processing of SUMO precursor to mature form; 2) activation of SUMO by 
SUMO-activating enzyme (E1), consisting of the heterodimer Uba2(Sae2)/Aos1(Sae1); 
3) conjugation of SUMO to target protein by SUMO-conjugating enzyme (E2), UBC9, 
with or without the help of a SUMO ligase (E3) (Dohmen, 2004) (Fig. 4.1). SUMO 
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Figure 4.1 The SUMOylation pathway. (A) The SUMO precursor is activated by cleavage of
its C-terminal tail by sentrin-specific proteases (“SENPs”), exposing a di-glycine site. The di-
glycine site forms a covalent bond with Uba2 of the E1 activating heterodimeric enzyme
Uba2/AOS1 in an ATP-dependent reaction. (B) Activated SUMO is transferred from
Uba2/AOS1 to UBC9 via a transesterification reaction. (C) In vitro, UBC9 can directly
conjugate to the lysine residue in the Ψ-K-x-[D/E] consensus site of the target protein.
However in vivo it is facilitated by a target-specific E3 ligase, resulting in transfer of SUMO to
the target protein. (D) SUMO2/3 can form poly-SUMO chains on target proteins while SUMO1
cannot. However SUMO1 can terminate a SUMO2/3 chain. (E) De-SUMOylation of target
protein occurs through cleavage of SUMO by SENPs. Free activated SUMO can re-enter the
pathway and bind another target protein. (F) SUMOylation/de-SUMOylation can affect
protein-protein interaction by modifying their binding sites. (G) Poly-SUMO-chains can be
recognised by SUMO-targeted ubiquitin ligases (STUbl’s) and be ubiquitinated through the
ubiquitination pathway, targeting the protein for proteasomal degradation. Adapted from
Dohmen, 2004; Geiss-Friedlander and Melchior, 2007.
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conjugation is usually transient, as de-SUMOylation by SUMO/Sentrin-specific 
proteases (SENPs) is very rapid (Mukhopadhyay and Dasso, 2007;  Yeh, 2009). In 
humans, there are four SUMO paralogues: SUMO-1 to SUMO-4 (Dou et al., 2011). 
SUMO-1 has been shown to interact with TOP1 after CPT damage (Mao et al., 2000;  
Yang et al., 2006); and dominant-negative UBC9 mutant is associated with cellular 
hypersensitivity to CPT (Mo et al., 2004;  Jacquiau et al., 2005). However, TOP1 
SUMOylation has also been shown to increase cellular sensitivity to CPT (Horie et al., 
2002). In addition, although it has been suggested that TOP1 activity is regulated after 
CPT-induced damage, by translocating TOP1 from the nucleolus to the nucleus (Mo et 
al., 2002), it may not be SUMO-dependent (Christensen et al., 2004). The conflicting 
data possibly reflect the underlying complexity of the mechanisms through which 
SUMOylation regulates TOP1 activity and DNA damage response. It has been shown 
that in yeast, SUMO-targeted ubiquitin ligase (STUbl), SUMO-mimetic Rad60, and E3 
ligase Nse2 function as TDP1 independent pathway in repairing TOP1 linked breaks 
(Heideker et al., 2011). The identification of a novel interaction between TDP1 and a 
component of the SUMOylation pathway suggest SUMOylation may have a role in 
TDP1-mediated DNA repair. Understanding how and why TDP1 is SUMOylated would 
provide important information on this regulatory system.   
4.2 Results 
4.2.1 Yeast two-hybrid library screen of TDP1S81E interacting proteins  
For the library screen for TDP1 S81 phosphorylation dependent interacting proteins, I 
used sequential transformation of first the bait plasmid, pGBKT7-TDP1S81E, then the 
prey, human cDNA library-encoding pACT constructs, in order to improve 
transformation efficiency of the cDNA library. Y190 cells were transformed with 
pGBKT7-TDP1S81E and selected in yeast minimal media without leucine. Four 
individual clones were picked, and the expression of Gal4-BD-TDP1S81E was confirmed 
by Western blotting (data not shown). A large-scale transformation of the TDP1S81E-
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expressing clone with 14 μg of cDNA library was performed, with transformation 
efficiency of ~ 4 x 104 colonies per μg DNA. 56 clones were confirmed by for histidine 
prototrophy, of which 35 encoded known genes. Fourteen of the 35 clones encoded 
full-length UBE2I, the human homologue of the SUMO E2 conjugating enzyme UBC9. 
Two clones encoded SETDB1, which has been recently been identified as a chromatin 
compacter at sites of DSBs required for efficient homologous recombination (Alagoz et 
al., 2015). Other hits of some interest were KPNA2, MYCBP2, PIAS4, NPM1, and 
MCART1, which could mediate TDP1 sub-cellular translocation or ubiquitination. 
However, these clones were either in the wrong orientation or lacked the start codon 
therefore could not be expressed. To rule out any technical errors during Sanger 
sequencing, these clones were re-streaked and interaction with TDP1S81E were re-
tested by yeast two-hybrid. However, none of the interactions could be reproduced 
(data not shown).  
4.2.2 S81 phosphomimetic mediates TDP1 interaction with UBE2I  
The interaction of TDP1S81E with two clones of UBE2I (clone 5 and clone 6) was 
confirmed by yeast two-hybrid assays (Fig. 4.2). This interaction was mediated by 
phosphorylation of S81, as wildtype TDP1 was able to interact with UBE2I, while 
TDP1S81A largely abrogated the interaction, as confirmed by CPRG-based quantitative 
yeast two-hybrid assay (Fig. 4.3). These interactions were specific, as expression of 
neither pGBKT7-TDP1S81E nor pACT-UBE2I alone auto-transactivated the β-gal or His 
prototrophic reactions (Fig. 4.2A, Right panel) and the expression levels of TDP1, 
TDP1S81E and TDP1S81A were comparable (Fig. 4.2B).  
To validate this interaction in mammalian cells, I transfected HEK293 cells with pCI-
Myc-TDP1 and immunoprecipitated the whole cell lysates using Myc antibodies. As the 
step of UBE2I binding to TDP1 to transfer SUMO is likely to be  transient, cellular 
proteins were crosslinked with 1% paraformaldehyde before cell lysis, to increase the 
chance of detecting this interaction. Fig. 4.4A shows that endogenous UBE2I co-
Control β-gal His
pGBKT7-TDP1S81E + pACT-UBE2I-5
pGBKT7-TDP1S81E + pACT-UBE2I-6
pGBKT7-TDP1 + pACT-UBE2I-6
pGBKT7-TDP1S81A + pACT-UBE2I-6
pGBKT7 + pACT-UBE2I-5
pGBKT7 + pACT-UBE2I-6
pGBKT7-TDP1S81E + pACT
pGBKT7-TDP1 + pACT-Lig3α
Control β-gal His
(A)
pGBKT7-TDP1         S81E  S81E S81E - - WT   S81A  
pACT-UBE2I                6        5        - 5      6       6        6      
Gal4BD-myc-TDP1
Gal4AD-UBE2I
(B)
Figure 4.2 Validation of TDP1S81E interaction with UBE2I in yeast two-hybrid. (A) Y190
cells were co-transformed with the indicated pGBKT7 and pACT constructs. Transformants
were selected on selective medium containing histidine (“Control”) or lacking histidine and
containing 3-aminotriazole (“His”) to test for the activation of the his3 reporter gene. The
activation of the β-gal reporter gene was detected using the filter lifts from control plates (“β-
Gal”). (B) WCEs (10 µL of 0.075 OD600/μL) were fractionated with SDS-PAGE and
immunoblotted using antibodies against Myc and Gal4AD. A duplicate gel was stained with
Coomassie blue as loading control.
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pGBKT7-TDP1          WT              S81A               S81E                 -
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Figure 4.3 Quantification of TDP1 interaction with UBE2I in yeast two-hybrid. Y190 cells
were transformed with pACT-UBE2I or pACT and the indicated pGBKT7 constructs and
selected on yeast minimal medium lacking histidine and containing 3-aminotriazole.
Transformants were then grown in complete culture medium for two doubling cycles and
harvested. The WCEs were incubated in CPRG until the medium turned from yellow to red
colour and the reaction was stopped with 3 mM ZnCl2. The OD578 of the supernatant was
measured. β-galactosidase units was calculated as 1000 x OD578 (t x V xOD600), where
t = stop time – start time (in minutes), V = 0.1 x concentration factor. 1 unit of β-galactosidase
is defined as the amount which hydrolyses 1 µmol of CPRG to chlorophenol red and D-
galactose per minute per cell. 1 unit of β-galactosidase equals the amount of enzyme required
to hydrolyse CPRG per minute. Data are the mean of 3 independent experiments and error
bars represent ±1 S.E.M.
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Figure 4.4 TDP1 interacts with UBE2I in HEK293 cells. (A) HEK293 cells were transfected
with pCI-Myc-TDP1 (+) or empty pCI-Myc vector (-). 48 hours post-transfection, cells were
fixed with 1 % paraformaldehyde for 10 minutes to crosslink proteins, washed with 100 mM
glycine, then lysed. WCEs were immunoprecipitated using Myc antibodies. Levels of Myc-
TDP1, UBE2I and Lig3α in the WCEs ("Input") and in the immunoprecipitates (“IP”) were
determined by immunoblotting with antibodies against Myc, UBE2I and Lig3α. Lig3α served
as positive IP control. Levels of IgG heavy chain served as loading control. (B) HEK293 cells
were transfected with ΔT-Myc-DEST-UBE2I or empty ΔT-Myc-DEST vector, and WCEs were
immunoprecipitated with Myc antibodies. Levels of Myc-UBE2I and TDP1 in the input and IP
samples were determined by immunoblotting with antibodies against Myc and TDP1.
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immunoprecipitated with Myc-TDP1 but not untagged Myc. Lig3α blotting was used as 
positive control and detected no non-specific binding, possibly due to 
paraformaldehyde fixing. Reciprocal IP showed that endogenous TDP1 co-
immunoprecipitated with Myc-UBE2I (Fig. 4.4B).  
4.2.3 TDP1 is covalently modified by SUMO1  
My colleague Dr Jessica Hudson tested SUMO-modification of TDP1 by SUMO1, 
SUMO2 and SUMO3 in the mammalian system, and confirmed that TDP1 is 
SUMOylated by all three paralogues, but predominantly by SUMO1 (Hudson et al., 
2012). 
To detect covalent binding of SUMO1 with TDP1 in mammalian cells, I overexpressed 
Myc-TDP1 and GFP-SUMO1 in HEK293 cells. GFP-SUMO1 appeared to co-
immunoprecipitate with Myc-TDP1 (Fig. 4.5). Although there were non-specific pull-
down of GFP-SUMO1 in cells overexpressing untagged Myc, the interaction was 
stronger in cells co-transfected with Myc-TDP1 and GFP-SUMO1. In this experiment, 
the effect of  CPT treatment on TDP1/SUMO1 interaction was unclear, as SUMO1 pull-
down was increased in the absence of TDP1. Interestingly, Lig3α pull-down appeared 
to be increased in the presence of GFP-SUMO1, although this was not CPT-
dependent.  
Taken together, my results indicate that TDP1 is SUMOylated by SUMO1, and this 
modification may promote TDP1 interaction with Lig3α.   
4.2.4 SUMOylation of TDP1 at K111 is not required for interaction with Lig3α 
In silico prediction indicated that there are five putative SUMO modification sites on 
TDP1, two in the N-terminus domain and three in the C-terminus domain (Fig. 4.6). 
Sequence alignment shows that K111 is conserved amongst vertebrates. My lab 
colleague Dr Jessica Hudson confirmed that K111 is the main SUMOylation site in 
mammalian cells (Hudson et al., 2012). Since K111 is in the N-terminus domain of 
TDP1, we postulated that it may regulate the function of TDP1.  
Figure 4.5 TDP1 interacts with SUMO1 in HEK293 cells. HEK293 cells were co-
transfected with pCI-Myc-TDP1 (“+”) or empty pCI-Myc vector (“-”) and pEGFP-C3-
SUMO1 (“+”) or empty pEGFP-C3 vector (“-”). 48 hours post-transfection the cells were
treated with 30 µM CPT (“+”) or DMSO (“-”) for 30 minutes at 37˚C, washed with PBS,
then lysed. WCEs were immunoprecipitated with Myc antibodies. Levels of Myc-TDP1,
GFP-SUMO1 and Lig3α present in total cell extracts (“Input”) and the immunoprecipitates
(“IP”) were determined by immunoblotting with antibodies against Myc, GFP and Lig3α.
Lig3α served as positive control for Myc-TDP1 IP. Levels of IgG heavy chain served as
loading control in the IP samples.
IP
Lig3α
IgG H-chain
Myc-TDP1
GFP-SUMO1
Myc-TDP1             - - - - +      +      +      +  
GFP-SUMO1       - +      - +   - +      - +
CPT                       - - +   +    - - +  +
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Input
Lig3α
Myc-TDP1             - - - - +      +      +      +  
GFP-SUMO1        - +      - +           - +      - +
CPT                       - - +    +            - - +      +
GFP-SUMO1
Myc-TDP1
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37
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Figure 4.6 TDP1 K111 is conserved in higher eukaryotes. The SUMOsp 2.0 online
database was used to predict potential sites for SUMO modification. K111 and K139
were predicted based on the consensus sequence Ψ-K-X-E, while prediction of K231,
K417 and K527 was based on non-consensus sites. Multiple sequence alignment of
TDP1 using ClustalW indicates that K111 is conserved in humans (Homo sapiens;
NP_001008744), cattle (Bos taurus; NP_001180084; XP_874680), monkey (Pongo
abelii; XP_002825063), chicken (Gallus gallus; XP_421313), frog (Xenopus tropicalis;
NP_001039242), and zebrafish (Danio rerio; XP_700174).
K111 K139
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It has been shown that SUMOylation can modulate protein-protein interactions and 
subcellular localisation of target proteins (Bergink and Jentsch, 2009). This could 
indirectly regulate TDP1 activity, for example, by promoting its interaction with 
components of the SSBR or DSBR machinery, and recruiting it to sites of DNA 
damage.  
I first tested whether K111 SUMOylation influenced TDP1 interaction with Lig3α by 
yeast two-hybrid. Mutation of K111 to arginine (K111R) did not affect TDP1 interaction 
with Lig3α (Fig. 4.7). My lab colleague also confirmed in HEK293 cells that K111R 
mutation did not abrogate co-immunoprecipitation of Lig3α with TDP1 (Hudson et al., 
2012).  
Another lab member also showed that TDP1K111R mutation did not cause structure 
conformational changes, nor impact on enzymatic activity in vitro (Hudson et al., 2012).  
4.2.5 TDP1 K111 SUMOylation promotes cell survival after CPT damage 
I then tested the importance of TDP1 SUMOylation on DNA repair in mammalian cells. 
Tdp1-/- MEFs complemented with wildtype hTDP1, TDP1K111R or empty vector were 
treated with CPT or γ-radiation, and the cellular repair response was assessed by 
clonogenic survival assay. TDP1K111R-complemented cells showed a mild CPT survival 
defect compared to wildtype TDP1-complemented cells (Fig. 4.8A, p < 0.05; 
Student’s t-test), but no defect was observed for IR damage repair. The difference in 
CPT survival was not due to differences in protein expression levels (Fig. 4.8B) or cell 
cycle arrest after CPT, as assessed by FACS (Fig. 4.9). These results suggest that 
TDP1 SUMOylation promotes repair of CPT-induced damage throughout the cell cycle. 
4.2.6 TDP1 K111 SUMOylation promotes repair of chromosomal strand breaks 
induced by CPT and IR 
To confirm a direct effect of TDP1 SUMOylation on DNA damage repair, we measured 
CPT-induced chromosomal strand breaks by the alkaline comet assay. Tdp1-/- MEFs 
complemented with human TDP1K111R accumulated ~ 3 fold more breaks compared to 
Figure 4.7 TDP1 K111 SUMOylation is not required for interaction with Lig3α. (A) Y190
cells co-transformed with the indicated pGBKT7 and pACT constructs were plated onto
selective media either containing histidine (”Control”) or lacking histidine and containining 3-
aminotriazole (“His”) to test for the activation of the his3 reporter gene. Activation of the β-Gal
reporter gene was determined using filter lifts from control plates (“β-Gal”). (B) WCEs (10 µL
of 0.075 OD600/μL) from (A) were fractionated with SDS-PAGE and immunoblotted using
antibodies against Myc and Gal4AD. A duplicate gel was stained with Coomassie blue as
loading control.
(A)
Control           β-gal                 His
pGBKT-TDP1 + 
pACT-Ligα
pGBKT-TDP1K111R + 
pACT-Ligα
pGBKT + 
pACT-Ligα
pGBKT-TDP1K111R + 
pACT
(B)
Coomasssie blue
pGBKT7-TDP1        WT    K111R      - K111R      
pACT             Lig3α Lig3α Lig3α -
Gal4BD-myc-TDP1
Gal4AD-Lig3α
(kDa)
150
100
Figure 4.8 TDP K111 SUMOylation promotes cellular survival after CPT damage. (A)
Tdp1-/- MEFs complemented with hTDP or hTDP1K111R by retroviral transduction were plated
on 10 cm dishes and incubated at 37˚C overnight. Cells were then treated with the indicated
doses of CPT for 1 hour at 37˚C (left), or x-ray at 12 mA / 250V on ice (right), then left to
recover in drug-free medium for 7 – 10 days until macroscopic colonies formed. Surviving
fraction was calculated by dividing the number of colonies on treated plates by the number on
mock treated plates. Data are the mean of 4 independent experiments and error bars
represent ±1 S.E.M. p values were derived using two-tailed Student’s t-test. (B) Expression
levels of hTDP1 and hTDP1K111R in Tdp1-/- MEF WCEs from experiments in (A) were
assessed by immunoblotting with antibodies against TDP1 and β-actin.
(A)
(B)
TDP1
β-actin
(kDa)
75
37
50
Figure 4.9 TDP1 K111 SUMOylation does not affect cell proliferation. Tdp1-/- MEFs
complemented with hTDP1, hTDP1K111R, or empty vector were treated with (A) DMSO
(“Mock”), or (B) 20 µM CPT for 1 hour at 37˚C, then recovered in drug-free medium for 6 to
(C) 24 hours. Cells were fixed with 70 % ethanol and stained with 50 µg/ml propidium iodide.
DNA content was analysed by FACS using the 585/42 spectrum filter.
TDP1 TDP1K111R Vector
Tdp1-/- MEFs
Mock
6hr post-CPT
24hr post-CPT
(A)
(B)
(C)
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cells complemented with wildtype TDP1 (Fig. 4.10A, p < 0.05; Student’s t-test). The 
difference was due to K111 SUMOylation, as overexpression of SUMO1 in wildtype 
TDP1-complemented HEK293 cells reduced the number of CPT-induced breaks 
(Fig. 4.10B, p < 0.01; Student’s t-test), which was not seen with the hTDP1K111R-
complemented cells. With IR damage, Tdp1-/- MEFs complemented with TDP1K111R 
accumulated ~ 25 % more breaks than wildtype TDP1-complemented cells 
(Fig. 4.10C, p < 0.05; Student’s t-test), and showed a delay in the repair kinetics 
comparable to that of Tdp1-/- cells. These results indicate that SUMOylation at K111 
promotes DNA repair efficiency of TDP1. 
4.2.7 TDP1 SUMOylation does not affect repair of DSBs induced by IR and CPT 
Unrepaired CPT and IR induced single-stranded DNA breaks can be converted into 
cytotoxic double-stranded breaks during DNA replication, which are then repaired by 
homologous combination (HR). I used immunofluorescence quantification of the DSB 
marker γ-H2AX to assess DSBR after CPT or IR treatments. After one hour of recovery 
following CPT treatment, Tdp1-/- cells showed a clear delay in the repair of DSBs, while 
cells complemented with wildtype TDP1 or hTDP1K111R exhibited similar rates of repair 
(Fig. 4.11A). This is in agreement with the cell cycle analysis in Fig. 4.9B&C showing 
no difference in the S- and G2/M arrested populations between cells complemented 
with hTDP1K111R or wildtype hTDP1. After 2 Gy IR damage, there was no difference in 
the number of γ-H2AX foci in all three cell lines, indicating that at this IR dosage, TDP1 
was dispensable for DSBR (Fig. 4.11B). These results suggest the survival defect in 
TDP1K111R-complemented MEFs treated with CPT was not due to attenuated DSBR or 
cell cycle checkpoint response.  
4.2.8 TDP1 SUMOylation accelerates its recruitment to DNA damage sites 
A lab member then showed that TDP1K111R mutation did not affect the nuclear and 
nucleolar localization of TDP1 after CPT damage (Hudson et al., 2012). I then 
examined the kinetics of EGFP-TDP1 or EGFP-TDP1K111R accumulation at sites of 
Figure 4.10 TDP1 K111 SUMOylation promotes early-phase repair of SSBs induced by
CPT and ionising radiation. Tdp1-/- MEFs complemented with hTDP1, hTDP1K111R, or empty
vector were treated with (A) 20 µM CPT for 1 hour at 37˚C, then incubated in drug-free
medium at 37˚C for the indicated periods. DNA strand breakage was quantified by alkaline
comet assay. (B) HEK293 cells transfected with pCI-Myc-TDP1 or pCI-Myc-TDP1K111R and an
empty GFP “−SUMO1” or GFP1-SUMO1 “+SUMO1” vector were treated as described in (A)
and analysed by alkaline comet assay. (C) MEFs from (A) were treated with 20 Gy γ-ray then
left to recover at 37˚C for the indicated periods. DNA strand breakage was quantified by
alkaline comet assay. The average of DNA strand breaks was from 3 independent
experiments (100 cells per experiment) and error bars represent ±1 S.E.M. p values were
derived using two-tailed Student’s t-test.
p = 0.1492
p = 0.032
p = 0.067
p = 0.085
(A)
(C)
(B)
p = 0.042
p = 0.188 p = 0.292
Figure 4.11 TDP1 K111 is not required for repair of double-stranded DNA breaks
induced by IR and CPT. (A) Tdp1-/- MEFs complemented with hTDP1, hTDP1K111R, or empty
vector were treated with 1 µM CPT for 1 hour at 37˚C, then incubated in drug-free medium for
the indicated periods. Cells were then fixed and immunostained with γH2AX antibodies and
DAPI (left). Percentage of cells with more than 80 foci per cell or pan-nuclear staining,
indicating S- and G2-phase cells (right). (C) Tdp1-/- MEFs as in (A) were subjected to 2 Gy γ-
ray and left to repair for the indicated periods. Cells were then fixed and immunostained with
γH2AX antibodies and DAPI. Data are the mean of 3 independent experiments (50 cells per
experiment) and error bars represent ±1 S.E.M. p values were derived using two-tailed
Student’s t-test.
(A)
(B)
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nuclear DNA damage induced by UVA irradiation in live cells. UVA produces a 
spectrum of DNA lesions that can trap TOP1, as well as 3’-phosphoglycolate and 3’-
dRP ends that can be repaired by TDP1 (discussed in Section 1.5.1).  I used laser 
microirradiation to induce UVA damage in MRC5 cells overexpressing EGFP-TDP1 or 
EGFP-TDP1K111R (Fig. 4.12A, top panel), and measured the EGFP fluorescence 
intensity within the laser track before and after damage (Fig. 4.12B) as an indicator of 
recruitment of EGFP-TDP1 or EGFP-TDP1K111R to the sites of DNA damage.  The 
background florescence immediately before irradiation was comparable between 
EGFP-TDP1- and EGFP-TDP1K111R-complemented cells (Fig. 4.12A, bottom panel). 
After irradiation, EGFP-TDP1K111R accumulated significantly slower than EGFP-TDP1 
at the laser tracks during the 90 seconds. Whereas EGFP-TDP1 level peaked within 15 
seconds after irradiation, EGFP-TDP1K111R level failed to reach saturation even at 90 
seconds (Fig. 4.12C). Notably, depletion of the obligate SUMO E2 conjugating 
enzyme, UBE2I, (Fig. 4.13A) in MRC5 cells expressing GFP-TDP1 (Fig. 4.13B) 
attenuated the recruitment of EGFP-TDP1 to the laser track, while having no further 
impact on recruitment of EGFP-TDP1K111R (Fig. 4.13C), suggesting the slower 
recruitment of GFP-TDP1K111R to DNA damage sites  was due to loss of SUMOylation.  
4.3 Discussion 
TDP1 plays a role in repairing endogenous TOP1-associated DNA breaks (TOP1-cc), 
and its deficiency leads to neurodegeneration and cerebellar ataxia in humans. 
Although it is generally accepted that TDP1 functions within the context of the SSBR 
machinery, how TDP1 is recruited to and activated at the sites TOP1-cc was unclear. 
This is a physiologically relevant question, as repair of TOP1 breaks have been shown 
to require high concentrations of TDP1 in vitro (Raymond et al., 2005). The findings 
presented in this chapter answer this question by showing a second molecular 
mechanism through which the N-terminus domain of TDP1 regulates its function, 
specifically, by increasing its concentration at sites of nuclear DNA damage.  
Figure 4.12 TDP1 K111 SUMOylation promotes its accumulation at sites of DNA
damage. (A) Human MRC5 cells were transfected with pMC-EGFP-TDP1 or pMCEGFP–
TDP1K111R and the expression levels of EGFP-TDP1 and EGFP-TDP1K111R were compared
by immunoblotting WCEs with antibodies against TDP1 and β-actin (top) and FACS using
the EX493/EM525 spectrum (bottom). (B) MRC5 cells from (A) were plated onto glass-
bottomed dishes and transfected with pMC-EGFP-TDP1 or pMC-EGFP–TDP1K111R. Cells
expressing similar levels of GFP signal were locally irradiated with UV-A laser (351 nm), and
images were taken with a Zeiss ConfoCor 2/LSM510 confocal microscope every 5 seconds
up to 90 seconds. (B) EGFP–TDP1 accumulation at the sites of damage was quantified by
LSM 520 Meta software for the indicated time periods, where “C” represents undamaged
control. Data are the average of ~ 60 cells measured from 6 independent experiments, and
error bars indicate ±1 S.E.M. p values were derived using two-tailed Student’s t-test. Figures
taken from Hudson et al., 2012.
(A) (B)
(C)
TDP1       TDP1K111R
Figure 4.13 UBC9 promotes TDP1 accumulation at sites of DNA damage. (A) MRC5
cells were stably depleted of UBC9 by shRNA transfection and selected with 1 µg/ml
puromycin for 2 weeks. Expression levels of UBC9 in knocked-down (“UBC9 KD”) and control
(“CT”) cells were compared by immunoblotting WCEs with antibodies against UBC9 and β-
actin. (B) MRC5 cells with or without UBC9 knock-down as described in (A) were transfected
with pMC-EGFP-TDP1 or pMC-EGFP-TDP1 and the mean EGFP intensity was measured by
FACS using the EX493/EM525 spectrum. (C) EGFP–TDP1 accumulation at the sites of
damage was quantified by LSM 520 Meta software for the indicated time periods, where “C”
represents undamaged control. Data are the average of ~ 60 cells measured from 6
independent experiments, and error bars indicate ±1 S.E.M. Figures taken from Hudson et
al., 2012.
(A) (B)
(C)
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The interaction of TDP1 with UBE2I, the human homologue of the obligate SUMO E2 
conjugating enzyme Ubc9, implies modification of TDP1 by SUMOylation. 
SUMOylation is an important post-translational modification that regulates protein 
activity in terms of transcription, stability, protein-protein interaction, and sub-cellular 
localisation. Increasing evidence confirms its role in DNA damage response and repair 
(Dou et al., 2011).  
My results showed that TDP1 interacts with UBE2I/UBC9 in yeast two-hybrid assay 
and co-immunoprecipitation in HEK293 cells (Fig. 4.2 – 4.4). In the yeast two-hybrid 
assays, interaction of TDP1 with UBE2I was dependent on S81. In human cells, my lab 
colleague has showed that overexpression of TDP1S81A in HEK293 reduced the in vitro 
SUMOylation of TDP1, while overexpression of TDP1S81E also reduced it, but to a 
lesser extent than the phosphomutant (Wells, 2014). This could suggest that a dynamic 
phosphorylation/de-phosphorylation switch is required for maintaining SUMOylation of 
TDP1. Interestingly, he also identified a casein kinase 2 phosphorylation site at 
S91/S92 that may negatively regulate SUMOylation. The crosstalk between post-
translational modification mechanisms implies a high level of regulation of TDP1 
activity in higher organisms. 
In HEK293 cells overexpressing Myc-TDP1 and GFP-SUMO1, interaction between 
TDP1 and SUMO1 appeared to be increased after treatment with CPT (Fig. 4.5). 
However, it appeared to be somewhat non-specific, as SUMO1 pull-down was also 
increased after CPT treatment in cells not overexpressing Myc-TDP1. Dr Jessica 
Hudson then showed that there was no detectable increase in SUMO1-conjugated 
TDP1 after CPT treatment (Hudson et al., 2012), suggesting that the interaction is 
constitutive and likely has a housekeeping function against DNA damage arising from 
endogenous sources. This is in contrast to the SUMO2/3 modification triggered by 
damage as seen in COS-7 cells (Saitoh and Hinchey, 2000). However, the preference 
between SUMO1 or SUMO2/3 modification in response to exogenous damage appears 
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to be cell line-specific, as SUMO1 modification seems to be the predominant response 
to exogenous stress in HeLa cells (Vertegaal et al., 2006;  Impens et al., 2014). In 
HEK293 cells, modifications of protein extracts from PML bodies by both SUMO1 and 
SUMO3 have been shown to be increased by after arsenic trioxide damage (Galisson 
et al., 2011).  
Interestingly, overexpression of SUMO1 increases TDP1 interaction with Lig3α 
(Fig. 4.5). However, SUMOylation of TDP1 at K111 is not required for this interaction in 
the yeast two-hybrid assay (Fig. 4.7), and in HEK293 co-immunoprecipitation 
experiments (Hudson et al., 2012). It is possible that in this case SUMOylation occurs 
on Lig3α, or another protein such as XRCC1 that can stabilise TDP1/Lig3α interaction 
(Gocke et al., 2005;  Bruderer et al., 2011;  Weber et al., 2014).  
TDP1 K111 SUMOylation promotes cellular survival following CPT (Fig. 4.8), and 
repair of CPT and IR induced DNA strand breaks (Fig. 4.10). The molecular basis of 
these effects does not appear to be mediated by altered catalytic activity, protein 
structure and stability, subcellular translocation, interaction with DNA ligase 3α 
(Hudson et al., 2012), involvement in DSBR (Fig. 4. 11) (El-Khamisy and Caldecott, 
2007;  Katyal et al., 2007) or cell cycle checkpoint signalling (Fig. 4.9). 
I did observe a significant reduction in the rate of recruitment of TDP1K111R to UVA-
induced DNA damage sites (Fig. 4.12). This effect was SUMOylation-specific, as 
depletion of the obligate E2 conjugating enzyme UBE2I/UBC9 decreased the rate of 
recruitment of TDP1 but not TDP1K111R (Fig. 4.13). Although I could only use cells 
transiently overexpressing EGFP-TDP1 and EGFP-TDP1K111R (due to constitutive 
TDP1 overexpression being poorly tolerated by mammalian cells), I tried to account for 
the intrinsic inter-clonal variations by examining only cells expressing similar levels of 
GFP-TDP1 or GFP-TDP1K111R before UVA irradiation (Fig. 4.12A, 4.13B).  
Using the transcription inhibitor 5,6-dichlorobenzimidazole 1-b-d-ribofuranoside (DRB), 
my colleague Mr Chris Rookyard also showed that recruitment of both TDP1 and 
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TDP1K111R was partially inhibited (Hudson et al., 2012). This suggests that: 1) a portion 
of the UVA-induced DNA damage sites were transcription-mediated SSBs, or 2) a 
subgroup of TDP1 (independent of the SUMOylation status) is recruited to the damage 
sites that are being actively transcribed. Given the short duration of the irradiation and 
recruitment time-course of the laser microirradiation experiment, the latter explanation 
seems more plausible, although this does not automatically exclude the former 
explanation. Either way, the implication that TDP1 accumulates at transcriptionally 
active sites points to its functional significance in postmitotic, highly-transcribing 
neurons, in which endogenous SSBs are the most abundant chromosomal lesions. 
Indeed, Tdp1-/- mouse neuronal cells complementation with hTDP1K111R could not fully 
protect against cell killing following CPT treatment compared to cells complemented 
with wildtype hTDP1 (Hudson et al., 2012). 
How does SUMOylation promote recruitment of TDP1 at transcription-associated break 
ends? SUMOylation is widely used to regulate transcription, chromatin remodeling, and 
DNA damage repair (Garcia-Dominguez, 2013;  House et al., 2014). One specific 
mechanism may be through interaction with stalled TOP1, which is SUMOylated after 
CPT treatment and undergoes proteasomal degradation (Mao et al., 2000;  Yang et al., 
2006). This could act as a signal to recruit TDP1 to further process the lesion. Our lab 
has preliminary data demonstrating interaction between TDP1 and chromatin-bound 
TOP1 (data not shown).  
Further pressing questions include: what is this subgroup of TDP1 that interacts with 
the transcription machinery? What is its role in repair of transcription-associated SSBs? 
Does TDP1 associate with products of stalled transcription such as R-loops? Does 
TDP1 play a role in transcription of the mitochondrial genome? 
Clearly, the regulation of TDP1 activity at the cellular level is more complex than we 
initially anticipated. It also points to new areas of biological processes in which TDP1 is 
involved.  In the next two chapters, I will explore the role of TDP1 in repair of DNA 
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lesions from endogenous oxidative stress, and the impact it has on mitochondrial 
functions and cellular viability.  
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            CHAPTER 5 
Tdp1 protects against endogenous oxidative 
stress in mouse embryonic fibroblasts 
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5.1 Introduction 
The second part of my PhD project was to test the hypothesis that TDP1 repairs a 
broader spectrum of ROS-induced DNA lesions other than TOP1-DNA adducts, which 
may contribute to cerebellar neurodegeneration.  
In postmitotic neurons, oxidative stress induces lesions that can trap TOP1 (Pourquier 
and Pommier, 2001;  Daroui et al., 2004;  Pommier et al., 2003;  Katyal et al., 2007;  
Katyal et al., 2014), which in turn can impede transcription (Sordet et al., 2009;  Alagoz 
et al., 2013;  Katyal et al., 2014), generate DSBs, and activate apoptosis or lead to 
cellular senescence (Sordet et al., 2003;  Sordet et al., 2009). However, Tdp1-/- mice 
demonstrated only late-onset cerebellar degeneration and no ataxia (Hirano et al., 
2007;  Katyal et al., 2007), suggesting that the effect of the unrepaired DNA lesions in 
the absence of Tdp1 is gradual. This makes the mouse model less useful for studying 
the role of ROS in SCAN1 in vivo, due to the short life-span of the organism.  
In vitro studies suggest that TDP1 can repair a broader spectrum of ROS-induced 
breaks other than TOP1-DNA adducts, such as 3’-phosphoglycolates, 3’-phosphates 
and abasic sites in vitro (Inamdar et al., 2002;  Interthal et al., 2005a;  Zhou et al., 
2005). Tdp1-/- astrocytes, MEFs and chicken B-lymphocytes (DT40) showed 
hypersensitivity to hydrogen peroxide, ionising radiation, and bleomycin which induce 
broad-spectrum oxidative DNA damage (Hirano et al., 2007;  Katyal et al., 2007;  Murai 
et al., 2012). Incidentally, using Tdp1-/- MEFs complemented with hTDP1 as a control, I 
also observed the hypersensitivity to H2O2 and IR in Tdp1-/- MEFs (Fig. 5.1).  
However, acute treatment with ROS-inducing agents in cultured cells may not 
recapitulate the situation induced by endogenous ROS in vivo. Our lab has previously 
generated a mouse model which uncovered the role of another SSBR factor, aprataxin 
(APTX), against endogenous oxidative stress (Carroll et al., 2015). By crossing Aptx-/- 
Figure 5.1 Tdp1-/- MEFs are sensitive to exogenous ROS. (A) Tdp1-/- MEFs were
complemented with hTDP1 or empty vector by retroviral transduction and selection in 1 μg/ml
puromycin for 2 weeks. WCEs were analysed by immunoblotting using antibodies against
human TDP1 and β-actin. Arrow indicate the hTDP1 product. Between 2000 – 6000 MEFs
from (A) were plated in 10 cm petri dishes and incubated at 37˚C overnight. Cells were then
treated with the indicated doses of H2O2 for 10 minutes on ice (B), or x-ray at 12 mA / 250V on
ice (C), then left to recover in normal growth medium for 7 – 10 days until macroscopic
colonies formed. Surviving fraction was calculated by dividing the number of colonies on
treated plates by the number on untreated plates. Data are the mean of 3 independent
experiments and error bars represent ±1 S.E.M.
(A)
(B)
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Tdp1-/-
 
108 
mice, which exhibited no DNA repair and survival defect against oxidative stress, with 
mice overexpressing mutated human SOD1 (SOD1G93A), which have documented 
mitochondrial defect and elevated levels of endogenous ROS and ROS-induced DNA 
lesions (Gurney et al., 1994;  Robberecht, 2000), it was shown that Aptx indeed repairs 
endogenous ROS-induced DNA lesions and promotes neuronal viability.   
Thus, I used the same approach to generate a mouse model, whereby Tdp1-/- mice 
were crossed with those overexpressing hSOD1G93A, to study the role of Tdp1 against 
endogenous oxidative stress, 
5.1.1 Endogenous ROS generation by SOD1G93A 
SOD1 is a Cu/Zn superoxide dismutase, ubiquitously expressed in the cytosol, 
mitochondrial intermembrane space (IMS) (Weisiger and Fridovich, 1973;  Okado-
Matsumoto and Fridovich, 2001;  Sturtz et al., 2001), nucleus, and peroxisosomes 
(Chang et al., 1988;  Del Maestro and McDonald, 1989;  Keller et al., 1991;  Crapo et 
al., 1992). It acts as a first-line ROS scavenger by converting superoxide to hydrogen 
peroxide, which is in turn catalysed into water and oxygen by catalase and glutathione 
peroxidase (Fridovich, 1986).   
Mutations of SOD1 account for ~ 5 % of the motor neuron disease amyotrophic lateral 
sclerosis (ALS) (Andersen et al., 2003;  Valentine et al., 2005). The pathogenesis of 
SOD1G93A mutation, although rare in ALS patients, has been extensively studied in the 
transgenic mouse model overexpressing human SOD1G93A (Gurney et al., 1994). 
hSOD1G93A-overexpressing mice exhibit higher oxidative stress (Ferrante et al., 1997;  
Andrus et al., 1998;  Liu et al., 1998;  Poon et al., 2005;  Casoni et al., 2005) and 
mitochondrial dysfunctions with reduced ATP production (Jung et al., 2002;  Browne et 
al., 2006), defective ETC function (Mattiazzi et al., 2002;  Kirkinezos et al., 2005), 
dysregulation of calcium homeostasis and loss of membrane potential (Damiano et al., 
2006;  Jaiswal and Keller, 2009;  Jaiswal et al., 2009), and mitochondrial axonal 
transport (Magrane and Manfredi, 2009;  Sotelo-Silveira et al., 2009). 
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The SOD1G93A protein is catalytically active (Cleveland, 1999) but possesses reduced 
zinc-binding capacity, which destabilizes the structure and promotes aggregate 
formation (Chattopadhyay et al., 2008;  Furukawa et al., 2008). SOD1G93A aggregates 
targeted to inclusion bodies are particularly toxic as they can sequester Hsp70 and 
inhibit proteolysis and overall protein quality control (Matsumoto et al., 2005;  
Matsumoto et al., 2006;  Wang et al., 2009;  Weisberg et al., 2012). SOD1G93A 
aggregates in the mitochondria (Vijayvergiya et al., 2005;  Kawamata and Manfredi, 
2008) can sequester the anti-apoptotic protein Bcl-2 and promote motor neuron death 
(Pasinelli et al., 2004;  Pedrini et al., 2010;  Tan et al., 2013). SOD1G93A has also been 
shown to promote apoptosis through the endoplasmic reticulum stress response 
(Kieran et al., 2007;  Nishitoh et al., 2008). It has also been proposed that the 
conformational change of SOD1G93A promotes its binding with hydrogen peroxide, 
converting it to more reactive hydroxyl radicals in the presence of ferric ions through 
Fenton reaction (Wiedau-Pazos et al., 1996). This aberrant peroxidase activity of 
SOD1G93A has been linked to increased oxidative DNA damage in the mitochondria and 
nucleus of the spinal cord of SOD1G93A mice (Warita et al., 1999;  Martin et al., 2007) 
and human SH-SY5Y neuroblastoma cells (Barbosa et al., 2010). More recently, it has 
been shown that SOD1 translocates to the nucleus in response to hydrogen peroxide 
(but not superoxide) in an ATM-dependent manner, and promotes transcription of anti-
oxidant and DNA repair genes (Tsang et al., 2014). Whether SOD1G93A translocates to 
the nucleus as efficiently as wildtype SOD1 is controversial and may depend on the 
level of overexpression (Sau et al., 2011;  Barbosa et al., 2010;  Gertz et al., 2012). 
Taken altogether, there is overwhelming evidence for the increased endogenous ROS 
production by SOD1G93A overexpression, through multiple mechanisms in the 
mitochondria and nucleus. 
5.2 Results 
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5.2.1 Generation of hSOD1G93A;Tdp1-/- double mutant MEFs 
Transgenic SOD1G93A male mice (Gurney et al., 1994) were crossed with female mice 
with different Tdp1 backgrounds (Katyal et al., 2007), as female SOD1G93A mice are 
infertile. The genotypes of live offspring are listed in Table 5.1.  
The first observation was that only 2 live births out of the predicted ~ 61 were 
SOD1G93A;Tdp1-/- double mutants. Secondly, the genotypes of the offspring differed 
significantly from the predicted Mendelian ratio when the male SOD1G93A parents were 
heterozygous for Tdp1 deletion (Table 5.1A) but not in the case when both copies of 
Tdp1 were present (Table 5.1B). Specifically, the numbers of Sod1+/+;Tdp1+/- offspring 
were significantly decreased (6 as opposed to the predicted 54.5). This is unexpected 
as Tdp1+/- mice do not have known developmental defects. Conversely, the numbers of 
Sod1+/+;Tdp1-/- and hSOD1G93A;Tdp1+/- offspring were significantly increased (115 and 
96, respectively, compared to the expected 54.5). These anomalies were present at 
early embryonic state (Table 5.1C). Taken together, these findings suggest non-
random segregation of the hSOD1G93A alleles and Tdp1 alleles.  
The hSOD1G93A transgenic mice were generated with multiple copies (~ 10) randomly 
integrated into the mouse genome (Gurney et al., 1994). It may be possible that one 
copy was inserted close to the Tdp1 locus. On closer inspection, SOD1G93A seemed to 
co-segregate with the Tdp1 wildtype allele, making the statistical probability of 
generating the SOD1G93A;Tdp1-/- offspring very low. 
To circumvent this problem, we decided to use a cellular model instead to further 
investigate the role of Tdp1 in cells with high endogenous ROS levels. To do this, I 
established Tdp1-/- MEFs which overexpress either wildtype Sod1 or hSOD1G93A. 
5.2.2 Tdp1 modulates levels of SOD1G93A-induced DNA free radicals 
To measure the levels of endogenous ROS generated by hSOD1G93A, our collaborator 
Dr Nick Kassouf used 5,5-Dimethyl-1-Pyrroline-N-Oxide (DMPO) to capture 
intracellular free radicals induced by UVA photolysis, and analysed the profile by 
A 
Male parent hSOD1G93A; Tdp1+/-
Female 
parent Sod1
+/+; Tdp1-/- Sod1+/+; Tdp1+/- Sod1+/+; Tdp1+/+
Offspring 
(No. live 
births)
Expected Obtained Expected Obtained Expected Obtained
Sod1+/+; 
Tdp1+/+ 6.25 3 2.25 0
Sod1+/+; 
Tdp1+/- 54.5 6 12.5 5 2.25 4
Sod1+/+; 
Tdp1-/- 54.5 115 6.25 14
hSOD1G93A; 
Tdp1+/+ 6.25 14 2.25 5
hSOD1G93A; 
Tdp1+/- 54.5 96 12.5 12 2.25 0
hSOD1G93A; 
Tdp1-/- 54.5 1 6.25 2
Total 218 218 50 50 9 9
B 
Male parent hSOD1G93A; Tdp1+/+
Female 
parent Sod1
+/+; Tdp1-/- Sod1+/+; Tdp1+/- Sod1+/+; Tdp1+/+
Offspring 
(No. live 
births)
Expected Obtained Expected Obtained Expected Obtained
Sod1+/+; 
Tdp1+/+ 15.25 9 7 6
Sod1+/+; 
Tdp1+/- 24.5 21 15.25 15
Sod1+/+; 
Tdp1-/-
hSOD1G93A; 
Tdp1+/+ 15.25 23 7 8
hSOD1G93A; 
Tdp1+/- 24.5 28 15.25 14
hSOD1G93A; 
Tdp1-/-
Total 49 49 61 61 14 14
C 
Male parent hSOD1G93A; Tdp1+/-
Female parent Sod1+/+; Tdp1-/-
Offspring (No. of E12 
embryos) Expected Obtained
Sod1+/+; Tdp1+/- 6.5 0
Sod1+/+; Tdp1-/- 6.5 14
hSOD1G93A; Tdp1+/- 6.5 12
hSOD1G93A; Tdp1-/- 6.5 0 (1 underdeveloped embryo)
Table 5.1: Genotypes of offspring of crossing hSOD1G93A mice with different Tdp1 
backgrounds
Sod1+/+ = wild-type Sod1; hSOD1G93A+/- = heterozygous for multiple copies of 
hSOD1G93A transgene; Tdp1+/+ = wild-type Tdp1; Tdp1+/- = heterozygous for Tdp1 
deletion; Tdp1-/- = homozygous for Tdp1 deletion. 
(A, B): number of offspring surviving past one month postnatal 
(C):  number of E12 embryos 
Highlighted in red where the numbers of offspring obtained differed from predicted.  
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electron spin resonance (ESR) spectroscopy. He confirmed that the pattern of free 
radicals captured corresponded to that of purified salmon sperm DNA (Haywood et al., 
2008;  Haywood et al., 2011) (Fig. 5.2A), suggesting they were of DNA origin. He then 
showed that Tdp1-/- MEFs accumulated ~ 6 fold more carbon adducts than wildtype 
MEFs (Fig. 5.2B, p < 0.001; Student’s t-test). Importantly, the level of carbon adducts 
correlated with SOD1 expression, as overexpression of hSOD1 largely reversed this 
phenotype (Fig. 5.2B, p < 0.01; Student’s t-test), while overexpression of SOD1G93A 
increased the carbon adducts by ~ 12 fold (Fig. 5.2B, p < 0.01; Student’s t-test). This 
effect correlated with the level of SOD1G93A expression, as reduction in the ratio of 
ectopic hSOD1G93A to endogenous SOD1 expression from 1.1 to 0.8 (Fig. 5.3A) 
attenuated the increase in carbon adducts from ~ 12-fold to 8-fold (Fig. 5.3B). A further 
reduction in the ratio of hSOD1G93A to endogenous SOD1 to 0.37 (Fig. 5.3C) failed to 
impact on the level of carbon adducts compared to levels detected in Tdp1-/- cells 
(Fig. 5.3D). These data validate the use of ESR in detecting SOD1G93A-induced DNA 
free radicals in MEFs.  
I then examined the correlation between the carbon adducts with TDP1 expression 
level. For this, we took advantage of a previously established Tdp1-/- chicken DT40 cell 
line, whereby clones of various levels of hTDP1 were stably expressed (Alagoz et al., 
2014). After confirming the levels of hTDP1 protein (Fig. 5.4A) and catalytic activity 
(Fig. 5.4B), we repeated the ESR experiment on these cells. Again the carbon adduct 
profile was consistent with nucleic acids (Fig. 5.4C), and Tdp1-/- cells showed ~ 8-fold 
accumulation of these adducts (Fig. 5.4D, p < 0.01; Student’s t-test). 
Complementation with low-expressing level of hTDP1 reduced the carbon adducts by 
~ 60 %, and surprisingly, to a lesser extent, by ~ 35 % in the high-expressing TDP1 
clone (Fig. 5.4D). These data strongly indicate that Tdp1 plays a role in counteracting 
accumulation of SOD1G93A-induced DNA free radicals in vertebrate cells.     
C C C CC C
(A)
Tdp1-/-
Tdp1-/- + hSOD1
WT
Tdp1-/- + hSOD1G93A
***
**
**
Figure 5.2 Tdp1 prevents accumulation of carbon adducts in DNA molecules induced
by ROS in MEFs. (A) Electron spin resonance (ESR) spectra obtained during 30 min UVA-
irradiation of WT MEFs or Tdp1-/- MEFs complemented with either empty vector, hSOD1 or
hSOD1G93A. “C” indicates deflection caused by carbon adducts. (B) Bar charts showing the
mean integration of all 6 carbon adducts in above spectra noted as a percentage of integrated
manganese reference lines. Data are the means of 3 independent experiments and error bars
represent +1 S.E.M. p values were derived from two-tailed Student’s t-test , whereby
** = p < 0.01, *** = p < 0.001. (C) WCEs (50 μg) for Tdp1-/- MEFs complemented with either
hSOD1 or hSOD1G93A were fractionated by SDS-PAGE and immunoblotted using antibodies
against human and mouse SOD1. Expression levels of hSOD1 and hSODG93A relative to
endogenous mouse Sod1 (“mSod1”) were quantified by ImageJ and expressed as fractions in
bottom panel. Data collected in collaboration with Dr Nick Kassouf.
mSod1 
Tdp1-/- MEFs
hSOD1
(B) (C)
0.18  1.13     hSOD1:mSod1    
Tdp1-/- MEFs
Figure 5.3 Levels of carbon adducts detected by ESR correlate with expression levels
of hSOD1 or hSOD1G93A. (A, C) Immunoblotting of Tdp1-/- MEF lysates overexpressing
hSOD1 or hSOD1G93A. Expression levels of hSOD1 and hSODG93A relative to endogenous
mouse Sod1 (“mSod1”) were quantified by ImageJ and expressed as fractions in bottom
panel. (B, D) Bar chart showing the mean integration of all 6 carbon adducts noted as a
percentage of integrated manganese reference lines from ESR data obtained from MEFs in
(A). Data collected in collaboration with Dr Nick Kassouf.
(A)
hSOD1:mSod1      0.83  0.81
hSOD1:mSod1     0.43  0.37
hSOD1
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Tdp1-/- MEFs
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Figure 5.4 TDP1 prevents accumulation of carbon adducts in DNA molecules induced
by ROS in chicken DT40 B-lymphocytes. (A) Immunoblotting of two clones of Tdp1-/- DT40
cells complemented with human TDP1 (clone 8 and clone 14) using antibodies against human
TDP1 and β-actin as loading control. (B) Enzymatic activities of DT40 cells from (A) measured
in vitro using a 13-mer oligonucleotide substrate containing a 3’-phosphotyrosine residue
conjugated to a 5’-FITC molecule. WCEs (2 μg) of cells from (A), wildtype DT40 cells (“WT”)
and 6.25 pM of recombinant human TDP1 (“rTDP1”) were incubated with 10 nM of TDP1
substrate for 15 minutes at room temperature. The reaction was stopped and fluorescence
intensities from triplicate samples were measured using a BMG Labtech PHERAstar plate
reader and analysed by the PHERAstar software. (C) Electron spin resonance spectra
obtained during 30 min high intensity (80 mW/cm2) UVA-irradiation of DT40 cells: wildtype
(“WT”); Tdp1 knockout (“Tdp1-/-”); clone 8 with low levels of hTDP1 (“Tdp1-/- + hTDP1(8)”);
and clone 14 with high levels of hTDP1 (“Tdp1-/- + hTDP1(14)”). (D) Bar charts showing the
mean integration of all 6 carbon adducts shown in (C) noted as a percentage of integrated
manganese reference lines. Data are the mean of 3 independent experiments and error bars
represent ±1 S.E.M. p values were derived from two-tailed Student’s t-test , whereby
* = p < 0.05, ** = p < 0.01 and ns = non-significant. Data collected in collaboration with Dr Nick
Kassouf.
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5.2.3 Tdp1 prevents accumulation of SOD1G93A-induced chromosomal DNA 
breaks 
To determine the consequence of the SOD1G93A-induced DNA free radicals in the 
chromatin context, I measured chromosomal DNA strand breaks in wildtype and 
hSOD1G93A-overexpressing MEFs (Fig. 5.5A) using the alkaline comet assay after UVA 
irradiation under the same condition as for the ESR experiment. Immediately after 
irradiation, there was an increase in DNA strand breaks, with cells overexpressing 
hSOD1G93A accumulating ~ 50 % more breaks than wildtype cells (Fig. 5.5B). This 
suggests that SOD1G93A overexpression is directly responsible for the generation of 
chromosomal strand breaks after UVA. 
To test whether Tdp1 can repair these breaks, I repeated the experiment using low 
dose H2O2 to induce production of endogenous ROS. H2O2 in this case acts as a 
substrate for SOD1G93A, which converts it to the more reactive hydroxyl and superoxide 
radicals in vivo through the Fenton reaction (Shibata, 2001). After 10 minutes of H2O2 
treatment, Tdp1-/- cells displayed ~ 2-fold more strand breaks than wildtype cells 
(Fig. 5.5C, p < 0.001; Student’s t-test), while overexpression of hSOD1G93A in Tdp1-/- 
cells increased the breaks further by ~ 50 % (Fig. 5.5C, p < 0.05; Student’s t-test). 
Conversely, overexpression of hSOD1 in Tdp1-/- cells suppressed the observed 
increase in DNA strand breaks to background levels detected in wildtype cells 
(Fig. 5.5C). However, subsequent incubation in H2O2-free media led to rapid clearance 
of SSBs with no detectable difference in repair kinetics (Fig 5.5D), suggesting Tdp1 is 
not essential for repair of SOD1G93A-induced DNA strand breaks. This result is perhaps 
unsurprising, as Tdp1 is not essential for repair of ROS-induced SSBs, with factors 
such as glycosylases and APE1 known to play a more prominent role (Demple and 
Sung, 2005).  
However, as recent data from our lab and the McKinnon lab suggest that endogenous 
ROS (induced by Atm deletion in mice) can trap TOP1 near oxidised DNA lesions 
Figure 5.5 Tdp1-/- MEFs overexpressing hSOD1G93A accumulate more SSBs induced by
H2O2. (A) Immunoblotting of WCEs of Tdp1-/- MEFs complemented with hTDP1, empty vector,
hSOD1G93A and wildtype MEFs overexpressing hSOD1G93A using antibodies against human
and mouse SOD1. (B) MEFs from (A) were damaged with 1 mW/cm2 UVA irradiation for 30
minutes on ice, and immediately harvested for quantification of SSBs by alkaline comet assay.
Average tail moments from 50 cells were quantified using the Comet Assay IV software. (C)
Tdp1-/- MEFs complemented with hTDP1, hSOD1, hSOD1G93A or empty vector were treated
with 10 μM of H2O2 or PBS (“Mock”) for 10 minutes on ice, then left to repair in drug-free
medium at 37˚C for the indicated time periods. SSBs induced were measured using the
alkaline comet assay. Average tail moments from 50 cells were quantified using the Comet
Assay IV software. (D) Data from (C) expressed as percentage of remaining breaks. Data are
the mean of 3 independent experiments and error bars represent ±1 S.E.M. p values were
derived from paired two-tailed Student’s t-test , whereby * = p < 0.05, *** = p < 0.001.
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(Alagoz et al., 2013;  Katyal et al., 2014), forming TOP1 cleavage complexes (TOP1-
cc) that are physiological substrates for TDP1, it was important to assess the levels of 
ROS-induced TOP1-cc in TDP1-proficient and -deficient cells.  
5.2.4 TDP1 promotes repair of TOP1-mediated chromosomal DNA breaks 
induced by ROS  
Due to the bulk of TOP1 peptide, TOP1-cc cannot normally be detected by alkaline 
comet assay. However, pre-digestion with proteinase K prior to gel electrophoresis can 
unmask all protein-bound DNA strand breaks. To detect TOP1-specific DNA adducts, I 
used a stable MRC5 cell lines whereby TDP1 was depleted alone or in combination 
with TOP1 (Fig. 5.6A). I then repeated the alkaline comet assay with proteinase K 
treatment. As a control experiment, TOP1-cc were induced with CPT treatment. As 
expected, wildtype and TDP1-depleted cells accumulated comparable levels of TOP1-
cc, since TDP1 is known to be involved only in the repair of CPT-induced TOP1-cc. 
Depletion of TOP1 markedly reduced formation of TOP1-cc both in the presence or 
absence of TDP1, although the reduction was less in the absence of TDP1 (Fig. 5.6B). 
This difference was unlikely to be due to increased formation of TOP1-cc in TDP1 
deficient cells, but rather a higher residual TOP1 level as confirmed by immunoblotting 
(Fig. 5.6A). Similarly, after H2O2 treatment, TDP1 deficient cells accumulated similar 
levels of protein DNA adducts as in wildtype cells, of which ~ 50 % were TOP1-
dependent, as shown by their reduction in TOP1 depleted cells (Fig. 5.6B). When 
TDP1 was co-depleted, only ~ 25 % of TOP1-cc were abolished, suggesting more 
TOP1-cc were formed in the absence of TDP1. However, the TDP1-dependent 
proportion could be slightly lower, as more TOP1-cc could have been formed because 
of the higher residual TOP1 levels (Fig. 5.6A).  
Although the exact proportion of ROS-induced TOP1-cc accumulated in the absence of 
TDP1 was unclear, the consequences of accumulation of these lesions on cell 
replicative potential were significant in the absence of TDP1, as revealed by clonogenic 
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Figure 5.6 H2O2 induces TOP1-linked breaks in MRC5 cells. (A) MRC5 cells were stably
depleted for TOP1, TDP1, or both, using shRNA’s and maintained in 1 μg/ml puromycin
selection. Cells transduced with scrambled shRNA (“CT shRNA”) acted as control for off-target
effects of the shRNA’s. WCEs were immunoblotted with antibodies against TOP1, TDP1, and
β-actin as loading control. (B) Cells from (A) were treated with 50 μM of CPT for 1 hour at
37°C or 10 μM H2O2 for 10 minutes on ice, and immediately analysed for DNA breaks using
modified alkaline comet assay, which measures both protein-linked breaks and frank breaks.
(C) Cells from (A) were treated with the indicated doses of H2O2 for 10 minutes on ice, and left
to recover in drug-free medium for 7 – 10 days to form macroscopic colonies. Data are the
mean of 3 independent experiments and error bars represent ±1 S.E.M. p values were derived
from paired two-tailed Student’s t-test , whereby * = p < 0.05, ** = p < 0.01 and ns = non-
significant.
 
114 
survival assays (Fig. 5.6C). Depletion of TOP1 rescued survival after H2O2 in TDP1-
depleted cells by ~ 3 fold (from ~ 20 % – 60 % at 400 μM H2O2), whereas in TDP1-
proficient cells there was only a 1.2 fold rescue (from ~ 60 – 70 % at 400 μM H2O2). 
In summary, these results indicate that in mammalian cells TDP1 prevents initial stage 
accumulation of chromosomal breaks induced by endogenous ROS. A significant 
proportion of these breaks is TOP1-mediated and counteracted by TDP1. It is also 
likely that TDP1 can repair non-TOP1-mediated breaks induced by oxidative stress. 
The unexpected role in inhibiting formation of oxidative DNA lesions alerted us to the 
possibility that TDP1 may function at the level of oxidant production, located in the 
mitochondria. 
5.2.5 Tdp1 maintains mtDNA copy number  
Although TDP1 has been identified in mammalian mitochondria (Das et al., 2010;  Fam 
et al., 2013a), its molecular role was not clearly characterised. The mitochondrial DNA 
also relies on topoisomerases for DNA transactions such as replication and 
transcription, and vertebrate cells have a mitochondrial specific isoform of TOP1, 
TOP1mt. One probable function of mitochondrial TDP1 would be to repair 
mitochondrial TOP1 (TOP1mt)-cleavage complexes, which have been shown to be 
induced by TOP1 poisons (Zhang and Pommier, 2008;  Dalla Rosa et al., 2014) and 
ROS (Medikayala et al., 2011). If this were true, TDP1-deficient cells should 
accumulate more mtDNA breaks than wildtype cells.  
To assess mitochondrial genome instability, I quantified mtDNA copy numbers with or 
without H2O2 induction and 24-hour recovery using qPCR (Chan and Chen, 2009). In 
the unstressed condition, Tdp1-/- cells had 50 % fewer mtDNA copies (250 as opposed 
to 500) compared to wildtype cells; SOD1G93A overexpression was not associated with 
mtDNA loss; while the overexpression of SOD1G93A in Tdp1-/- cells resulted in a further 
reduction of mtDNA copy number (~ 100) (Fig. 5.7). After oxidative stress, mtDNA 
copy numbers were increased by ~ 2 fold in all cell lines examined. Increase in 
Figure 5.7 Tdp1-/- MEFs show attenuated mitochondrial DNA synthesis after oxidative
stress. MEFs were treated with 240 μM of H2O2 or PBS (“Mock”) for 1 hour on ice then left to
recover in drug-free medium for 24 hours. Total gDNA was extracted using the Qiagen
DNAeasy Blood and Tissue Kit. 1 ng of gDNA was used as mitochondrial DNA template and
10 ng of gDNA was used as nuclear DNA template. The template was mixed with 2x SYBR-
Green I PCR mastermix and the PCR reaction was carried out in triplicates. Concentrations of
starting templates were derived from CT values of standard curves for the mtDNA and nDNA
reactions. Mitochondrial copy number was calculated by 2 x 2(ΔCT) whereby ΔCT = B2M
average CT – ND1 average CT. Data represent the averages of 2 independent experiments
and error bars denotes upper and lower ranges.
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mitochondrial DNA synthesis is a known compensatory mechanism during 
mitochondrial stress (Lee et al., 2000;  Hori et al., 2009). The proportional increase in 
all the cell lines suggests neither Tdp1 nor SOD1G93A are required for mtDNA synthesis 
after acute oxidative stress. The loss of mtDNA in unstressed Tdp1-/- cells that is 
associated with endogenous (SOD1G93A-mediated), but not exogenous ROS, suggest 
that there may be a more sustained and global change in mitochondrial function and 
mass when Tdp1 is inactivated.  To test this, I first visualised the gross mitochondrial 
network morphology with fluorescence microscopy. 
5.2.6 Tdp1 inactivation is associated with mitochondrial stress 
Using the membrane potential specific probe TMRM, which is specific for depolarised 
(functional) mitochondria, our collaborator Dr Martin Meagher did not see obvious 
morphological differences in the mitochondrial network in Tdp1-/- MEFs compared to 
the wildtype. However, treatment with TBH, a stable analogue of H2O2, showed a 
discernible increase in mitochondrial lengths (“mitochondrial fusion”) in Tdp1-/- cells 
(Fig. 5.8). This suggests that Tdp1-/- cells have a lower threshold for oxidative stress, 
as mitochondrial hyper-fusion is a known compensatory response to counteract 
mitochondrial stress (Friedman and Nunnari, 2014). Strikingly, the hyper-fusion 
phenotype changed to that of hyper-fission in Tdp1-/- cells when SOD1G93A was 
overexpressed, whereby the mitochondria were highly fragmented and circularised, 
indicating a decompensated state of severe mitochondrial stress (Fig. 5.8).  
To assess the degree of mitochondrial stress quantitatively, I used flow cytometry to 
measure the fluorescence intensities of membrane potential-specific probe, Mitotracker 
Red CMXRos, and non-membrane potential-specific probe, Mitotracker Green. The 
total mitochondrial mass is indicated by the fluorescence intensity of Mitotracker 
Green, while the membrane potential is expressed as the fluorescence intensity of 
Mitotracker Red CMXRos normalised to Mitotracker Green. Fig. 5.9A shows that in 
cells overexpressing hSOD1G93A, which are known to have dysfunctional mitochondria 
Figure 5.8 Overexpressing hSOD1G93A in Tdp1-/- MEFs increases mitochondrial
fragmentation. Cells were seeded at 5 x 105 in WillCo-dish® Glass Bottom dishes and treated
with 10 μM tert-butyl-hydroperoxide (“TBH”) at 37°C for 24 hours. Cells were then stained with
3 μl PicoGreen (for dsDNA) for 45 minutes at 37oC and 5 nM tetramethylrhodamine, tethyl
ester, perchlorate (TMRM) at 37°C for 10 minutes. Blow-up images in white boxes.
Experiment performed by Dr Martin Meagher.
TBHMock
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Tdp1-/-
+ hSOD1G93A
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Figure 5.9 Tdp1-/- MEFs show increase mitochondrial mass in absence of exogenous
stress. (A) Wildtype (“WT”), Tdp1 knockout (“Tdp1-/-”), wildtype overexpressing hSOD1G93A,
(hSOD1G93A) and Tdp1-/- overexpressing hSOD1G93A (“Tdp1-/- + hSOD1G93A”) MEFs were
incubated in 250 nM Mitotracker Green (“MTG”) to stain mitochondria irrespective of
membrane potential, for 30 minutes at 37˚C, washed with PBS, then analysed by
fluorescence-activated cell sorting using using the EX493/EM525 spectra. (B) Mock treated
MEFs from (A) were incubated in 250 nM MTG and 250 nM Mitotracker Red (MTR) (to stain
for metabolically active mitochondria with negative membrane potential) for 30 minutes at
37˚C, washed with PBS, then analysed by FACS using the EX493/EM525 and EX565/EM670
spectra. Relative MTR:MTG fluorescence intensity denotes the membrane potential
normalised to total mitochondrial mass. Data are the means of 3 independent experiments and
error bars indicate +1 S.E.M. p values were derived from two-tailed Student’s t-test , whereby
ns = non-significant, ** = p < 0.01, *** = p < 0.001, and ns = non-significant.
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(discussed in Section 5.1.1), the membrane potential decreased by ~ 50 % compared 
to wildtype cells, even though there was a ~ 3-fold compensatory increase in total 
mitochondrial mass. This is consistent with an accumulation of dysfunctional 
mitochondria. Interestingly, while Tdp1-/- MEFs had a normal membrane potential 
comparable to wildtype cells (Fig. 5.9A), the mitochondrial mass was also increased 
by ~ 3 fold (Fig. 5.9B). This data, together with the heightened response in 
mitochondrial morphology dynamics to oxidative stress (Fig. 5.8), suggests that the 
need for Tdp1-/- cells to markedly increase mitochondrial biogenesis may be a 
compensatory response to some underlying mitochondrial dysfunction (Lee et al., 
2000). To further support this notion, intra-mitochondrial ROS production, specifically, 
of superoxide, was measured using FACS analysis of MitoSOX Red fluorescence. 
Tdp1-/- MEFs showed ~ 2-fold higher superoxide level relative to wildtype cells, while 
hSOD1G93A-overexpressing cells showed ~ 4 fold more (Fig. 5.10A). The fluorescence 
signal was specific to mitochondrial superoxide, as treatment with the ETC complex I 
inhibitor rotenone increased the signal in all three cell lines by ~ 4 fold (Fig. 5.10B). 
The extent of increase was comparable in all the cell lines, suggesting that the 
mitochondrial defect in Tdp1-/- and hSOD1G93A-overexpressing MEFs was not specific 
to complex I dysfunction. 
5.2.7 Tdp1-/- MEFs are more sensitive to endogenous ROS induced by SOD1G93A 
To assess whether the mitochondrial dysfunction in Tdp1-/- negatively impacts cellular 
resistance against endogenous ROS, I quantified clonogenic survival after H2O2 
induction, using SOD1 and SOD1G93A overexpression to modulate the levels of 
endogenous ROS. Overexpression of SOD1G93A sensitized Tdp1-/- cells to H2O2 while 
SOD1 overexpression offered some protection (Fig. 5.11A, p < 0.05; Student’s t-
test). In contrast, overexpression of SOD1G93A had no impact on cell survival of 
wildtype cells (Fig. 5.11B), suggesting the protective effect against endogenous ROS 
was Tdp1-specific.  
Figure 5.10 Tdp1-/- MEFs show increased mitochondrial superoxide not specific to
complex I dysfunction. (A) MEFs were incubated in 250 nM MitoSOX Red, for 15 minutes
at 37˚C in the dark, washed with PBS, then analysed by FACS using the EX488/EM575
spectra. Data represent the average of 2 independent experiments and error bars indicate
the upper and lower ranges. (B) MEFs were treated with 1 μM rotenone or DMSO (“Mock”)
for 10 minutes at 37°C, then stained with 250 nM MitoSOX Red in the dark, for 15 minutes
at 37˚C, washed with PBS, and analysed by FACS using the EX488/EM575 spectra.
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Figure 5.11 Overexpression of hSOD1G93A hypersensitisizes Tdp1-/- MEFs to H2O2. (A),
(B) MEFs were plated in 10 cm petri dishes overnight, then treated with the indicated doses of
H2O2 for 10 minutes on ice. Cells were left to recover in drug-free medium for 7 – 10 days until
macroscopic colonies formed. Data are the mean of 3 independent experiments and error bars
represent ±1 S.E.M. p values were derived from paired two-tailed t-test , whereby * = p < 0.05,
** = p < 0.01.
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** Tdp1-/- + vector vs
Tdp1-/- + hSOD1G93A
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5.3 Discussion 
Oxidative stress is a major contributing factor in aging and neurodegeneration, and 
oxidative DNA damage with defective repair is implicated in an increasing number of 
diseases such as cancer, metabolic disorders, and neuromuscular diseases.  
In this chapter, I have shown that the SOD1/SOD1G93A-overexpression system 
modulates the levels of endogenous ROS in vertebrate cells, and that Tdp1 is 
protective against oxidative stress in several ways: Tdp1-/- MEFs accumulate more 
endogenous ROS, nuclear oxidative DNA breaks, and reduced cellular replicative 
potential which are all exacerbated in a high endogenous ROS background. 
In the nucleus, there was strong evidence of TDP1 being a broad-spectrum end-
processing factor involved in the repair of oxidised DNA ends (discussed in 
Section 1.5.1). However, in the cellular context, my comet data demonstrate that Tdp1 
is dispensable for repair of oxidative DNA breaks, but instead is required to prevent 
formation of these lesions, which include TOP1-cc. This prompted us to think outside 
the nucleus and look at the source of ROS production itself. 
The mitochondria are the major source of ROS production, and they are also intimately 
involved in cellular proliferation and the apoptotic pathway. Mitochondrial respiratory 
function is closely regulated by cellular energy demands via its own gene expression 
regulatory mechanisms. The mitochondrial genome relies on nuclear-encoded repair 
factors for maintenance, one of which may be TDP1. Although its precise molecular 
mechanism of action in the mitochondria has not been elucidated, its importance can 
be inferred from the hallmark ataxic phenotype, a common manifestation of 
mitochondrial disorders, in TDP1-mutated patients.  
I first tested whether Tdp1 plays a role in repair of mtDNA breaks induced by 
endogenous ROS using long-range qPCR, which would detect polymerase-blocking 
lesions along the whole length of the mitochondrial genome. Although highly sensitive, 
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this assay does not distinguish the number of lesions per copy of mtDNA. But rather, it 
quantifies the number of mtDNA molecules that contain at least one lesion.  Although 
the result from Das et al. suggests that Tdp1-/- MEFs have a higher proportion of 
mtDNA molecules containing unrepaired lesions after H2O2 damage, the concentration 
of H2O2 used was 10 – 100 fold higher than what I used to induce endogenous ROS. 
Indeed, using the published condition of H2O2 treatment resulted in amplification of 
non-specific products, likely due to excessive fragmentation of the mitochondrial 
genome. The second concern of the LR-qPCR assay is the difficulty in assessing the 
CT values accurately with a low reaction efficiency due to the size of the amplicons. 
Thirdly, the DNA intercalating dye SYBR Green I is known to inhibit DNA polymerase 
progression and confound melting curve analysis (Gudnason et al., 2007), making its 
use unsuitable for qPCR analysis of long amplicons. Due to these reasons, I decided to 
investigate the question of whether Tdp1 plays a role in overall mitochondrial genome 
stability by measuring the mtDNA copy numbers.  
The observation that Tdp1 promotes mtDNA stability in the unperturbed state could be 
explained in several ways: 1) that Tdp1 plays a role in mitochondrial biogenesis; 2) that 
it prevents accumulation of protein-DNA adducts, specifically of TOP1mt-cc that can 
lead to large-scale loss of mtDNA molecules; or 3) that TDP1 regulates activity of 
mitochondrial transcription A (TFAM), which has been shown to positively correlate 
with mtDNA number (Ekstrand et al., 2004;  Pohjoismäki et al., 2006;  Lu et al., 2013;  
Mei et al., 2015). The first hypothesis conflicts with our Mitotracker data, which showed 
that Tdp1-/- cells exhibited increased mitochondrial mass. The second hypothesis is 
supported by the 3’-phosphotyrosine-specific activity of TDP1 in the mitochondria (Das 
et al., 2010), as well as the observation that overexpression of a toxic form of TOP1mt 
that is converted to TOP1mt-cc causes significant loss of mtDNA without loss of 
mitochondrial mass (Dalla Rosa et al., 2014). To confirm this, the use of biochemical 
assays to show accumulation of TOP1mt-cc in the absence of Tdp1 would be 
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important. The third hypothesis is partially related to the second hypothesis, as 
TOP1mt has been shown to physically associate with TFAM, and TOP1mt itself 
negatively regulates mitochondrial transcription (Sobek et al., 2013). The latter two 
hypotheses will be addressed in the next chapter. 
In the long-term, persistent high endogenous ROS level coupled with loss of mtDNA 
and/or inhibition of mtDNA replication and transcription can affect overall mitochondrial 
function. This is demonstrated in Tdp1-/- cells overexpressing hSOD1G93A, which 
showed increased proportion of dysmorphic and dysfunctional mitochondria 
characterised by increased superoxide production (Cassina et al., 2008). This 
dysfunction may have pathophysiological relevance in determining cell survival in 
tissues with high endogenous ROS load.  
In summary, my findings support the hypothesis that Tdp1 plays a protective role in 
response to oxidative stress, through its role in the repair of nuclear TOP1-cc, as well 
as its role in maintaining mitochondrial function in a high endogenous ROS 
background. The exact mechanism of its action in the mitochondria is unclear, but 
possibly linked to the removal of TOP1mt-cc. This hypothesis was further investigated 
and will be presented in the next chapter. 
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                 CHAPTER 6 
Human TDP1 promotes mitochondrial DNA 
transcription and Redox homeostasis 
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6.1 Introduction 
In the previous chapter, I described the use of the SOD1G93A overexpression system to 
investigate the effects of high levels of endogenous ROS on Tdp1-/- MEFs. My findings 
so far indicate that Tdp1 promotes cellular resistance against oxidative stress, through 
its role in maintaining mitochondrial DNA biogenesis and the overall health of the 
mitochondria. 
In this chapter, I will describe the use of a human inducible cell line system to 
investigate the role of human TDP1 on mitochondrial DNA metabolism, primarily on its 
functional interaction with mitochondrial TOP1 (TOP1mt).  
My primary hypothesis was that TDP1 plays a role in the removal of excess TOP1mt-cc 
in the presence of high oxidative stress, in a similar manner as in the nucleus, thus 
promoting restoration of mtDNA integrity, replication and transcription in response to 
oxidative stress.  
6.1.1 Mitochondrial DNA structure and metabolism  
The mitochondrial genome is organized in structures on the inner membrane known as 
nucleoids, each consisting of 2 – 10 copies of double-stranded circular mtDNA 
molecules that closely associate with regulatory proteins, such as mitochondrial 
transcription factor A (TFAM) (Spelbrink, 2010).  
Each human mtDNA molecule contains intron-less coding sequences for 13 proteins of 
the electron transfer chain (ETC) subunits, interspersed with 22 tRNA’s, and 2 
ribosomal RNA (rRNA) subunits, 12S and 16S (Fig. 6.1). Seven of the 14 subunits of 
ETC complex I (NADH dehydrogenase) are encoded by mitochondrial genes ND1, 
ND2, ND3, ND4L, ND4, ND5 and ND6. The mitochondrial subunit of complex III 
(cytochrome bc1) is encoded by Cyt b. Complex IV (cytochrome c oxidase) subunits 
are encoded by COX1, COX2, and COX3 in the mitochondria. Complex V (ATP 
Figure 6.1 Organisation of human mitochondrial genome and TOP1mt binding site. The
mtDNA molecule contains a GC-rich heavy strand (H-strand) (outer circle) and light strand (L-
strand) (inner circle) encoding 13 genes for the respiratory complexes I, III, IV, V, 12S and 16S
rRNA’s, and 22 tRNA’s. The non-coding region (NCR) contains the L-strand promoter (“LSP”),
the two H-strand promoters (“HSP”), and the H-strand replication origin (“OH”). The D-loop
represents a three-strand structure of 908 bp containing a short transcript from LSP as primer
for replication of the H-strand leading strand. Orange bar denotes position of TOP1mt* ChIP-
qPCR sequence (position 15872-15972) (related to Figure 7.17). Figure drawn with
OrganellarGenomeDRAW: http://ogdraw.mpimp-golm.mpg.de/cgi-bin/ogdraw/pl. Annotation
adapted from Taanman, 1999; Dalla Rosa et al., 2014.
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synthase) subunits are encoded by ATP6 and ATP8. With the exception of ND6, all the 
protein-coding genes are located on the guanine-rich heavy chain. 
Transcription of mtDNA initiates at three promoter sites: HSP1, for the transcription of 
the 2 rRNA’s (encoded by MT-RNR1 and MT-RNR2, respectively); HSP2, for 
transcription of a long polycistronic mRNA of the protein-coding genes and t-RNA’s; 
and LSP, for transcription of a polycistronic mRNA of the ND6 gene and 8 tRNA’s 
(Falkenberg et al., 2007). Nuclear-encoded mitochondrial RNA polymerase (POLRMT) 
and transcription factors TFAM, transcription factor B1 (TFB1M) and transcription factor 
B2 (TFB2M) form part of the transcription machinery (Falkenberg et al., 2002;  
McCulloch et al., 2002). Termination of transcription, post-transcriptional processing, 
and intra-mitochondrial translation all require import of nuclear-encoded factors. 
Replication of mtDNA is intrinsically coupled to transcription since replication initiation 
of the heavy chain depends on transcription from the LSP site and the short transcript 
serves as a primer for DNA synthesis (Chang and Clayton, 1985;  Chang et al., 1985;  
Clayton, 1991). Replication of the heavy chain then frequently stalls ~ 650 bp 
downstream of the origin (OH), forming a displacement loop (D-loop) (Clayton, 1991). It 
is believed that D-loop plays a role in regulating the transition from transcription to 
replication by interacting with nuclear-encoded regulating factors such as TFAM and 
single-stranded-DNA-binding protein (mtSSB) that determine whether replication re-
initiates and continues to completion for the heavy chain strand (Takamatsu et al., 
2002). Around two-thirds of the way relative to the OH, replication of the light chain 
initiates in the opposite direction, apparently utilizing the elongating daughter strand of 
the heavy chain as the priming sequence. Like transcription, mtDNA replication 
elongation requires the concerted activities of nuclear-encoded DNA polymerase 
gamma (Polγ) (Hance et al., 2005), mitochondrial helicase TWINKLE (Tyynismaa et al., 
2004), POLRMT (Wanrooij et al., 2008), mitochondrial single-stranded DNA-binding 
protein (mtSSB) (Korhonen et al., 2004), RNAse H1 (Cerritelli et al., 2011), DNA Lig3 
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(Simsek et al., 2011) and topoisomerases (Zhang and Pommier, 2008;  Sobek and 
Boege, 2014). 
6.1.2 Mitochondrial TOP1 (TOP1mt) 
The circular nature of mitochondrial DNA requires topoisomerases for its replication 
and transcription. In vertebrates, TOP1mt is the only topoisomerase specifically 
evolved for handling mitochondrial DNA (Rosa et al., 2009). Encoded by a nuclear 
gene duplicated from that of nuclear TOP1, the TOP1mt transcript has a shorter N-
terminus domain, which contains the mitochondrial targeting sequence (MTS) instead 
of nuclear localization sequence (NLS) (Zhang et al., 2001). TOP1mt also has a highly 
similar mode of action of cleavage and religation of ssDNA’s as nuclear TOP1 (Zhang 
et al., 2007). However, TOP1mt activity is restricted to mtDNA, and is unable to interact 
with nuclear DNA (Rosa et al., 2009). It appears that TOP1mt is specialised to be most 
active in an alkaline environment, in the presence of divalent cations (Ca2+, Mg2+), 
consistent with the conditions of the mitochondrial matrix (Burke and Mi, 1994;  Zhang 
et al., 2001).  
It has been proposed that TOP1mt plays a role in DNA replication and transcription in 
the mitochondria, although there is likely functional overlap between TOP1mt and 
mitochondrially localised TOP2β and TOP3α (Sobek and Boege, 2014).  It is therefore 
intriguing to understand what requirement drove the conservation of the TOP1mt gene 
in vertebrates. Understanding this may provide novel druggable targets for modulating 
mitochondrial-mediated apoptosis and DNA repair pathways in cancer therapy.  
MEFs derived from Top1mt-/- mice display defective OXPHOS, as reflected by 
increased ROS production and activation of glycolysis; as well as compensatory 
responses to oxidative stress such as increased mitochondrial fusion, retrograde 
nuclear signaling, activation of the DNA damage response, and autophagy (Douarre et 
al., 2012). A similar pattern of mitochondrial dysfunction was induced in Top1mt-/- mice 
cardiomyocytes after treatment with doxorubicin, a TOP2 inhibitor used in cancer 
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therapy (Khiati et al., 2014). TOP1mt has also been shown to be necessary for mtDNA 
replication in mice hepatocyte regeneration after carbon tetrachloride (CCl4) damage, a 
potent hepatotoxin that induces excessive lipid peroxidation (Khiati et al., 2015). 
At the molecular level, TOP1mt binds predominantly at the non-coding region (NCR) 
which contains the two promoters for the light and heavy strands and the replication 
origin of the heavy strand (Fig. 6.1) (Zhang and Pommier, 2008;  Dalla Rosa et al., 
2014), which supports its involvement in resolving negative supercoils that arise from 
bidirectional transcription and replication (Zhang et al., 2014). TOP1mt also physically 
interacts with mitochondrial RNA polymerase and transcription factor TFAM, 
suggesting its localization to active transcription sites (Sobek et al., 2013). Surprisingly, 
in contrast to its nuclear counterpart, TOP1mt appears to inhibit mitochondrial 
transcription, independent of retrograde nuclear signalling (Sobek et al., 2013). Both 
depletion and overexpression of TOP1mt induced mitochondrial respiratory dysfunction 
(Douarre et al., 2012;  Sobek et al., 2013).  
Taken together, it is plausible that TOP1mt maintains mitochondrial health by adjusting 
the level of basal topological tension required for optimal transcription and replication. 
The expression level of TOP1mt is regulated by c-Myc, which also regulates the 
expression of many nuclear-encoded mitochondrial proteins (Zoppoli et al., 2011).   
6.1.3 Mitochondrial bioenergetics 
Numerous cellular processes that expend energy require ATP, which is produced by 
phosphorylation of ADP in the mitochondria. In mammalian cells, more than 80% of 
ATP production is coupled to oxidative phosphorylation (OXPHOS) (Papa et al., 2012), 
a process whereby electrons are transported from NADH to oxygen through a series of 
reduction/oxidation (Redox) reactions along the electron transport chain (ETC). The 
ETC is made up of protein complexes I – V located on the inner membrane, coupled 
with release of protons into the intermembrane space (IMS) (Fig. 6.2) (Hatefi, 1985). 
The potential energy from the proton gradient generated between the IMS and the 
Figure 6.2 Mitochondrial bioenergetic pathways. NADH, generated in the tricarboxylic acid
(“TCA”) cycle, is oxidised by complex I, producing electrons that are transferred to ubiquinone
(“UQ”), coupled with translocation of protons (“H+”) to the Inter-membrane space (“IMS”).
Similarly, oxidation of succinate to fumarate as part of the TCA cycle generates electrons that
are transferred to UQ and translocation of H+ to the IMS. In complex III, electrons from
reduced UQ are transferred to cytochrome c (”Cyt C”), coupled with H+ translocation.
Complex IV then accepts the electrons from Cyt C to reduce O2 to H2O, coupled with more H+
translocation. Finally the proton gradient, or membrane potential (“ψm”) then drives the
molecular motor ATP synthase, or complex V, to generate ATP from ADP. In the cytoplasm,
anaerobic respiration is carried out by metabolising glucose to pyruvate, generating ATP and
lactate as by-products. Deamination of amino acids also produces ATP. Anaerobic respiration
is less efficient in ATP production and also promotes lactic acidosis, thus increasing
extracellular acidification rate (ECAR). Adapted from Lemarie & Grimm, 2011.
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matrix (also known as “membrane potential”) is then used to drive ATP production by 
phosphorylation of ADP (Lemarie and Grimm, 2011). At resting state, where 
mitochondrial concentration of ADP is low, OXPHOS efficacy is low, as reflected by the 
oxygen consumption rate (OCR) (Brand and Nicholls, 2011). While under condition of 
high ATP demand, the influx of ADP into the mitochondria triggers proton flow through 
Complex V to generate ATP; the decrease in proton gradient facilitates electron flow 
through the ETC, thus increasing the OCR (Klingenberg, 2008). Thus, OCR is a 
measure of both ATP demand and efficacy of the ETC.  
To assess the two components independently, inhibitors of the ETC and ATP synthase 
can be used, as summarized in Fig. 6.3. Inhibition of ATP synthase (Complex V) by 
oligomycin prevents the majority of protons from re-entering the matrix and greatly 
reduces the efficacy of the ETC (termed “oligomycin-sensitive respiration” or “coupled 
respiration”). A small proportion of protons re-enter the matrix through uncoupling 
proteins, a process known as “proton leak” or “uncoupled respiration” (Brand and 
Nicholls, 2011). Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) acts as 
an uncoupling agent that temporarily increases the concentration of protons in the 
matrix independent of Complex V that drives electron flow through the ETC at the 
maximum rate (Benz and McLaughlin, 1983). The FCCP-induced OCR is a measure of 
the maximum capacity of the ETC (also termed the “spare respiratory capacity”) utilized 
in response to a sudden increase in ATP demand. Lastly, inhibition of Complexes I and 
III by rotenone and antimycin A, respectively, disrupts electron flow through the ETC, 
greatly reducing the efficiency of OXPHOS and mitochondrial OCR, and increasing 
leakage of electron to attack oxygen molecules, forming superoxide anions (O2-) 
(Turrens and Boveris, 1980;  Sugioka et al., 1988).  
Figure 6.3 ETC dysfunction, ROS generation and detoxification. Rotenone and antimycin
A inhibit reduction of UQ by complexes I and III, respectively, thus disrupt the ETC, reduce H+
translocation and increase superoxide (“O2-”) formation in the matrix, IMS, and into the
cytoplasm. Superoxide dismutases (“SOD2” in the matrix and “SOD1” in the IMS and
cytoplasm) transform O2- into less reactive hydrogen peroxide (”H2O2”), which is further
neutralised to H2O and O2 by glutathione peroxidase (“GPX”) and catalase. In the absence of
these ROS scavengers, or in the presence of ferrous cations (“Fe2+”), excess H2O2 can
diffuse out of the mitochondria or disintegrate into highly reactive hydroxyl radicals (“•OH”),
which can react with another •OH molecule to form more H2O2, or more commonly, attack
lipid polymers (”RH”) to form lipid peroxyl radicals (“ROOH”), which rely on GPX, catalase and
vitamin C (“Vit. C”) for neutralisation. FCCP and oligomycin inhibit ATP production by
promoting proton leak, disrupting the proton gradient and thus uncoupling ATP production with
OXPHOS, eventually shutting down the ETC. Adapted from Lemarie & Grimm, 2011.
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6.2 Method 
To investigate whether TDP1 plays a role in the mitochondria in removal of excess 
TOP1mt-cc in the presence of high oxidative stress, the Tdp1-/- MEFs could be used 
again to overexpress a toxic form of TOP1mt (TOP1mtT546A,N550H), published by the 
Pommier group (Dalla Rosa et al., 2014), with a propensity to forming stable TOP1mt-
cc . The N550H mutation enhances the DNA nicking reaction, while the T546A 
mutation inhibits the re-ligation reaction. There are several advantages of using the 
toxic TOP1mt (abbreviated as “TOP1mt*” hereafter) over TOP1 poisons such as CPT 
or topotecan (TPT). Firstly, it is mitochondria specific, without the associated nuclear 
DNA damage that make CPT and TPT highly cytotoxic. Secondly, uptake across the 
mitochondrial outer membrane is limited for hydrophobic small molecules. Thirdly, the 
alkaline environment of the mitochondrial matrix can readily inactivate these drugs.  
However, there were several concerns of using the MEFs to study mitochondrial 
functions:  
• The wildtype and Tdp1-/- MEFs were not isoclonal, so were the wildtype and Tdp1-/- 
cells overexpressing hSOD1 or hSOD1G93A. Given the high heterogeneity between 
MEF cell lines, an observed functional phenotype in Tdp1-/- MEFs could be due to 
Tdp1-independent factors; 
• To obtain isoclonal MEFs, Tdp1-/- cells complemented with hTDP1 was generated. 
However, expression of hTDP1 was gradually suppressed over one month, 
indicating perhaps cytotoxicity or survival disadvantage; 
• Although immortalised by transformation, MEFs seem to retain sensitivity to 
atmospheric oxygen and require maintenance in low oxygen incubators, to which 
our lab lacked access at the time of the project. 
The alternative of using an existing TDP1 knockdown MRC5 cell line posed several 
problems as well: 
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• TDP1 silencing using siRNA was not consistent and efficient enough for clonogenic 
survival and comet assays; 
• Attempts to generate stable knockdown cell lines using shRNA were unsuccessful 
due to cytotoxicity. 
Additionally, from a biological point of view, it would be interesting to see if the role of 
TDP1 in the mitochondria is comparable between human and mouse, as there was no 
strong evidence in the literature at that time. For these reasons, I generated an 
inducible cell line for TDP1 depletion in human HEK293 cells using the commercially 
available Flp-In T-Rex 293 cell line from Life Technologies (R780-07), which has the 
major advantage of allowing simultaneous, inducible silencing of TDP1 and 
overexpression of exogenous proteins of interest, such as TOP1mt or SOD1G93A.  
In this chapter I will outline the method I used to establish the cell lines, validate the 
known functional phenotypes of TDP1 depletion, and characterise the mitochondrial 
functional phenotype of these cell lines. 
6.2.1 The Flp-In T-Rex 293 system 
The commercially available Flp-In T-Rex 293 (Flp-In) cell lines are engineered to 
contain a single Flp recombination target (FRT) site in a transcriptionally active region 
of the genome. The FRT site allows binding of exogenously expressed Flp 
recombinase (originally derived from S. cerevisiae) and exchange of genetic 
sequences flanked by the FRT site (O'Gorman et al., 1991). The host genomic FRT 
site has a hygromycin resistance gene downstream which is only activated after 
successful Flp-mediated recombination event. This allows for selection of clones that 
have stably integrated the gene of interest between the FRT sites. The rationale behind 
the use of the exogenous system of genomic recombination is to ensure controlled, 
specific genome editing, and a homogenous expression from a single copy genomic 
insert across the whole cell population. In addition, the Flp-In T-Rex system allows for 
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tetracycline/doxycycline induction of expression of the gene of interest, thus 
circumventing some of the problems of cytotoxicity associated with constitutive gene 
expression/deletion. The Flp-In T-Rex cells stably express the tetracycline repressor 
(TetR), which binds to the two Tet operator 2 (TetO2) sequences within the CMV 
promoter upstream of the gene of interest in the absence of tetracycline. When 
tetracycline is present, it interacts with TetR and sequesters it from the TetO2 sites, 
subsequently inducing transcription of the gene of interest. Fig. 6.4 summarizes the 
principle of the system. 
For the purpose of my project, the Flp-In T-Rex 293 cells have some technical 
limitations: 
• The parental HEK293 cell line is genetically highly transformed, making the 
homogenous expression of a single copy gene across the whole cell population 
presumably less reliable, especially in continually cultured cells; 
• They are not strongly adherent cells, making assays that rely on high plating 
efficiency such as clonogenic survival assays, immunofluorescence, and the 
Seahorse assay technically more difficult.  
• They have a large nuclear:cytoplasmic ratio, making fluorescence microscopic 
imaging of the mitochondrial network more challenging. 
The measures that I have taken to address these problems include: 
• Work with single clones instead of mixed population after establishment of a cell 
line; monitor homogeneity of GFP expression before each experiment. 
• For monitoring cell killing after genotoxic stress, measure viability in a cell 
population after 72 hours of continuous drug treatment by fluorescence readout, 
instead of formation of single colonies after a bolus dose of treatment. This would 
circumvent the need for high plating efficiency, although cell viability does not 
always correlate with colony-forming (replicative) capacity. 
Figure 6.4 Scheme for generating Flp-In T-Rex 293 cells with concomitant RNAi-
mediated knockdown of TDP1 and overexpression of various fusion proteins. (A) Host
cell with two FRT sequence sites (“FRT”), tetracyline repressor (“TetR”), and blasticidin
resistance gene (“Blasticidin”) was co-transfected with (B) pcDNA5-FRT vector encoding
EmGFP-tagged fusion protein (“cDNA”) and micro RNA sequence (“miRNA”) and pGKFLP
vector encoding Flp recombinase. The transformants were selected with 100μg/ml hygromycin
for 3 weeks. (C) In the absence of tetracycline/doxycyline, the TetR binds the CMV/TetO2
hybrid promoter (“PCMV/TetO2”) to inhibit downstream transcription. After addition of tetracycline
or doxycyline, the repressor is removed and transcription of the cDNA-miRNA sequence is
initiated. Upon RNA transcription, excision of the miRNA hairpin by Drosha results in RNAi-
mediated knock-down of TDP1, while non-excision results in translation of the recombinant
protein.
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• For immunofluorescence assays, use of polymer-based coating such as D-poly-
lysine on coverslips would reduce loss of cells during washing steps. 
• Instead of measuring mitochondrial membrane potential by fluorescence 
microscopy, use FACS analysis of live cells, and the Seahorse Bioanalyser to 
measure mitochondrial respiratory functions. 
• Use of Cell-Tak, as recommended by Seahorse Bioscience, to adhere cells to the 
Seahorse Analyser microplate. 
6.3 Results 
6.3.1 Generation of stable Flp-In T-Rex 293 cell lines 
For the purpose of studying the effect of TDP1 deficiency on mitochondrial functions, 
two miRNA sequences targeting nucleotides 28 – 48 (amino acids 10 – 16) and 
nucleotides 259 – 279 (amino acids 87 – 93) of the human TDP1 mRNA sequence 
(NM_001008744.1), were inserted into mammalian expression vector pcDNA6.2-GW-
EmGFP, which contains specific flanking sequences to allow processing of the miRNA 
in vivo, as well as an EmGFP tag for monitoring expression. The miRNA-EmGFP 
fragment was then sub-cloned into the Flp-In system expression vector pcDNA5-FRT, 
which contains the CMV/TetO2 promoter, the FRT site for integration into the host 
genome, and hygromycin resistance gene, to generate the pcDNA5-FRT-miTDP1 
plasmid. Similarly, scrambled miRNA sequence was sub-cloned into pcDNA5-FRT to 
generate pcDNA5-FRT-miScr. For each of these plasmids, full-length cDNA sequences 
of SOD1G93A (NM_000454), TOP1mt (NM_001258446.1), TOP1mtT554A,N558H, or RNAi-
resistant TDP1 (silent mutations at all the amino acids residues) minus the stop codon 
were sub-cloned 5’ of and in frame with the EmGFP tag. Flp-In T-Rex 293 cells were 
then transfected with the generated constructs, together with the Flp recombinase-
expressing plasmid pPGKFLP, and stable clones were selected with hygromycin for 
three weeks to generate the following cell lines expressing: 
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1. Control microRNA (“miScr”) 
2. TDP1 microRNA (“miTDP1”) 
3. TDP1 microRNA with targeting-resistant TDP1 cDNA complementation 
(“TDP1 + miTDP1”) 
4. Control microRNA with SOD1G93A overexpression (“SOD1G93A + miScr”) 
5. TDP1 microRNA with SOD1G93A overexpression (“SOD1G93A + miTDP1”) 
6. Control microRNA with TOP1mt overexpression (“TOP1mt + miScr”) 
7. TDP1 microRNA with TOP1mt overexpression (“TOP1mt + miTDP1”) 
8. Control microRNA with TOP1mtT554A,N558H overexpression (“TOP1mt* + miScr”) 
9. TDP1 microRNA with TOP1mtT554A,N558H overexpression (“TOP1mt* + miTDP1”) 
The inclusion of target-resistant TDP1 complementation of miTDP1 cell line is an 
important control, as in a miRNA system, the structure of the synthetic miRNA may 
mimic an endogenous miRNA, and may cause tissue-specific off-target effects different 
from siRNA or shRNA transfected cells. Therefore, if a phenotype is observed in 
miTDP1 cells and is rescued by TDP1 complementation, the phenotype is more likely 
to be TDP1-specific.   
To assess the functional interaction between TDP1 and TOP1mt, instead of depleting 
TOP1mt, I opted to overexpress either wildtype TOP1mt or the toxic mutant TOP1mt*. 
The rationale was that assessment of the depletion of endogenous TOP1mt from WCE 
by immunoblotting depended on a highly sensitive and specific antibody (which was 
not commercially available at the time of the project), and the residual TOP1mt may be 
sufficient to compensate like in the case of nuclear TOP1. Interestingly, overexpression 
of TOP1mt has a known phenotypic defect (Sobek et al., 2013), which can be 
monitored to detect the effect of TDP1. The use of TOP1mt* would give more insight 
on the molecular mechanism by which TOP1mt negatively regulates mitochondrial 
transcription, as well as the role of TDP1 on this regulation. Furthermore, the use of an 
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overexpression system instead of miRNA-mediated knock-down would circumvent the 
need to establish functional assays to rule out off-target effects of the miRNAs. 
To induce miRNA and protein expression, 1 µg/mL doxycycline was added to the 
growth medium for 24 hours, cells were lysed and protein expression for each sample 
was analysed by immunoblotting. Fig. 6.5 shows depletion of endogenous TDP1 
specific to doxycycline induction. There was some leaky expression of the targeting-
resistant EmGFP-TDP1 in the absence of doxycycline, but more importantly, the 
control miRNA (“miScr”) did not affect the expression level of endogenous TDP1.  
6.3.2 Validation of functional phenotype of TDP1 depletion in Flp-In cell lines 
Using an in vitro TDP1 enzymatic assay, it was confirmed that miTDP1 cell lysates had 
reduced TDP1 activity, while complementation with the target-resistant EmGFP-TDP1 
increased TDP1 activity level (Fig. 6.6). miTDP1 cells accumulated ~ 2-fold more CPT-
induced chromosomal breaks as measured by alkaline comet assay (Fig. 6.7, 
p < 0.01; Student’s t-test) and 53BP1 foci formation (Fig. 6.8, p < 0.05; Student’s t-
test), and reduced survival after CPT (Fig. 6.9A). miTDP1 cells did not show a 
difference in viability from TDP1 + miTDP1 cells in response to oxidative damage by 
TBH (Fig. 6.9B). Bearing in mind that the doxycycline used to induce TDP1 
expression/knockdown could inhibit TDP1 activity (Pommier, 2006), the viability assays 
were carried out after withdrawal of doxycycline. In both miTDP1 and TDP1 + miTDP1 
cells the difference in TDP1 activity levels were maintained up to 72 hours after 
doxycycline withdrawal (Fig. 6.9C,D), suggesting that the lack of TBH sensitivity in 
miTDP1 cells was not due to loss of TDP1 knockdown.  
Nevertheless, as measurement of survival in terms of viability assays do not 
necessarily correlate with clonogenic assays, and as the nuclear DNA repair assays 
indicated a TDP1 deficient phenotype, I decided to investigate the role of TDP1 in the 
mitochondria using the Flp-In T-rex system as planned. 
Figure 6.5 Doxycycline induction of TDP1 depletion and complementation in Flp-In T-
Rex 293 cells. 5 x 105 cells selected in 100 μg/ml hygromycin B and 10 μg/ml blasticidin for 3
weeks were incubated in 1 μg/ml doxycyline for 24 hours, then harvested. 75 μg of WCE was
fractionated by SDS-PAGE and immunoblotted using antibodies against human TDP1 and β-
tubulin. “miScr” denotes cells expressing scrambled (control) miRNA, “miTDP1” denotes cells
expressing TDP1-targeting miRNA, “TDP1 + miScr” denotes cells overexpressing targeting-
resistant TDP1 and control miRNA, and “TDP1 + miTDP1” denotes cells overexpressing
targeting-resistant TDP1 and TDP1-targeting miRNA. The number at the end of each cell line
denotes clone number. “- Dox” indicate no doxycyline treatment, “+ Dox” indicates treatment
with doxycyline.
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Figure 6.6 In vitro TDP1 enzymatic activity of Flp-In T-Rex 293 cell lines. (A) Diagramme
of the TDP1-specific substrate consisting of a 13-mer oligonucleotide with tyrosyl residue
conjugated to the 3’ end and a fluorophore Cy5.5 molecule conjugated at the 5’ end, annealed
to a 14-mer complementary oligonucleotide. Arrow indicates cleavage of the phosphotyrosine
bond by TDP1. (B) 5 x 105 Flp-In T-Rex 293 cells selected in 100 μg/ml hygromycin B and
10 μg/ml blasticidin for 3 weeks were incubated in 1 μg/ml doxycycline for 24 hours, then
harvested and total proteins extracted. The indicated amount of WCE was incubated with
25 nM of TDP1 substrate at 37ºC for 1 hour, then resolved with a 20 % 7.5 M urea SequaGel
by electrophoresis. “Buffer” denotes sample with lysis buffer but no WCE. “miScr” denotes
cells expressing scrambled (control) miRNA, “miTDP1” denotes cells expressing TDP1-
targeting miRNA, and “TDP1 + miTDP1” denotes cells overexpressing targeting-resistant
TDP1 and TDP1-targeting miRNA. The number at the end of each cell line denotes clone
number.
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Figure 6.7 Flp-In T-Rex 293 cells with TDP1 knockdown accumulate more CPT-induced
chromosomal DNA breaks. 3 x 105 Flp-In T-Rex 293 cells were incubated in 1 μg/ml
doxycycline for 24 hours, then treated with 50 μM CPT or DMSO (“Mock”) for the indicated
time periods at 37°C. DNA strand breaks induced were measured using the alkaline comet
assay. Average tail moments from 50 cells were quantified using the Comet Assay IV
software. Data are the mean of 3 independent experiments and error bars represent ±1 S.E.M.
p values were derived from one-tailed Student’s t-test , whereby * denotes p < 0.05 and
** denotes p < 0.01.
Figure 6.8 Flp-In T-Rex 293 cells with TDP1 knockdown accumulate more CPT-induced
DSBs. 5 x 104 cells plated on poly-D-lysine-coated coverslips were induced with 1 μg/ml
doxycyline for 24 hours, then treated with 1, 5 or 10 μM CPT or DMSO (“Mock”) for 1 hour at
37°C, the media was then removed. The cells were washed twice with PBS then incubated in
normal growth media for the indicated time periods. Cells were then fixed in 4% PFA for 15
minutes at room temperature, permeated with 0.2 % Triton-X100, then washed with PBS.
Cells were then immunostained with antibodies against 53BP1 (red) and GFP (green) for 1
hour at room temperature, and DAPI (blue) for 10 minutes. (A) Example of images taken from
TDP1+miTDP1-8 cells after CPT. Distinct 53BP1 foci were manually counted. (B)
Quantification of average 53BP1 foci number per cell from 100 cells. (C) Doxycyline-induced
cells were treated with 1 μM CPT or DMSO (“Mock”) for 1 hour, washed twice with PBS, then
recovered in normal growth media for the indicated time periods. Average number of 53BP1
foci per cell from 100 cells were calculated. Data are the mean from 3 independent
experiments and error bars denote +1 S.E.M. p values were derived from one-tailed Student’s
t-test, whereby * denotes p < 0.05.
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Figure 6.9 TDP1 depletion in Flp-In T-Rex 293 cells reduced viability after CPT but not
TBH treatment. (A, B) Cells induced with doxycycline were seeded at densities of 2000-
20000 cells/100 μl, and treated with the indicated concentrations of CPT or TBH in the
absence of doxycycline for 72 hours. 20 μl of CellTiter-Blue reagent was then added to the
cells and incubated at 37°C for 1 hour. The fluorescence intensity was measured using a BMG
FLUORstar Omega microplate reader with filters of EX544/EM590-10. Data are the mean of 3
independent experiments and error bars represent ±1 S.E.M. (C) Scheme of doxycycline
induction and CPT or TBH treatment (in hours) Cells were treated with 1 μg/ml doxycycline for
24 hours, followed by treatment with the indicated concentrations of CPT in (A) for 2 hours at
37°C or TBH in (B) for 1 hour at 37°C. Cells were subsequently incubated in media with
1 μg/ml doxycycline for up to 72 hours (+0, +24, +48, +72) or without doxycycline for the
indicated hours (-24, -48, -72). (D) Cells from (C) were harvested and lysed. 40 ng of WCE
was incubated with 25 nM of TDP1 substrate at 37ºC for 1 hour, then resolved with a 20 %
7.5 M urea gel by electrophoresis. “Buffer” denotes sample with lysis buffer but no WCE.
“TDP1 + miTDP1” denotes cells overexpressing targeting-resistant TDP1 and TDP1-targeting
miRNA, “miTDP1” denotes cells expressing TDP1-targeting miRNA. The number at the end of
each cell line denotes clone number.
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6.3.3 Overexpression of SOD1G93A in TDP1-depleted cells increased H2O2-induced 
chromosomal breaks 
In order to compare the role of TDP1 in the mitochondria between human and mouse, I 
generated Flp-In cell lines concomitantly depleted of TDP1 and overexpressing 
SOD1G93A (“SOD1G93A + miTDP1”). However, after 24-hour doxycycline induction, the 
SOD1G93A-EmGFP signal was only present in < 5 % of the cell population in 4 out of 5 
clones screened by FACS, compared to ~ 15 % of the TDP1-proficient cell population 
overexpressing SOD1G93A (Fig. 6.10A). This was not due to reduced level of overall 
transcription or translation in TDP1-depleted cells, as wildtype SOD1 was expressed in 
~ 30 % of TDP1-depleted cells (“SOD1 + miTDP1”) (Fig. 6.10A). Using 
immunoblotting, I further confirmed that the expression level of SOD1G93A in TDP1-
depleted cells declined between 8 – 16 hours of induction. In contrast, in 
SOD1 + miTDP1 cells, the overexpression level of SOD1 was unaffected by TDP1 
depletion (Fig. 6.10B). This could be due to downregulation of SOD1G93A expression to 
ensure survival of TDP1 deficient cells. Nevertheless, even with low level expression of 
SOD1G93A, SOD1G93A + miTDP1 cells showed ~ 30 % higher level of chromosomal 
breaks after 10 minutes of H2O2 treatment compared to wildtype, although the 
subsequent repair of these breaks was independent of TDP1 (Fig. 6.11, p < 0.05; 
Student’s t-test). This is consistent with the finding in MEFs as described in 
Section 5.2.7. 
6.3.4 Validation of functional phenotypes of TOP1mt and TOP1mt* 
overexpression in Flp-In cell lines 
To further investigate the role of human TDP1 in the mitochondria, and possible 
functional interaction with TOP1mt, I generated Flp-In cell lines that overexpress 
TOP1mt-EmGFP in TDP1-proficient or -deficient backgrounds (“TOP1mt + miScr” and 
“TOP1mt + miTDP1”, respectively). In addition, to mimic the increase in TOP1mt-cc 
due to oxidative stress, I also established cell lines that overexpress the toxic mutant 
TOP1mt*-EmGFP in the presence or absence of TDP1 knockdown (“TOP1mt + miScr” 
Figure 6.10 SOD1G93A overexpression is attenuated in Flp-In T-Rex 293 cells with TDP1
depletion. 5 x 105 cells were incubated in 1 μg/ml doxycycline for 24 hours (“+Dox”), then
fixed with 70 % ethanol for 4 hours. Percentage of cells expressing GFP was analysed by
FACS. (B) 5 x 105 cells were incubated in 1 μg/ml doxycycline for the indicated time periods,
then harvested. 75 μg of WCE was fractionated by SDS-PAGE and immunoblotted using
antibodies against human TDP1 and SOD1. “SOD1 + miTDP1” denotes cells expressing
TDP1-targeting miRNA and SOD1. “SOD1G93A + miScr” denotes cells expressing scrambled
miRNA and SOD1G93A, while “SOD1G93A + miTDP1” denotes cells expressing TDP1-targeting
miRNA and SOD1G93A. The number at the end of each cell line denotes clone number.
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Figure 6.11 Flp-In T-Rex 293 cells expressing SOD1G93A accumulate more SSBs after
H2O2 treatment. 3 x 105 cells from the Flp-In T-Rex 293 stable cell lines were incubated in
1 μg/ml doxycyline for 8 hours, treated with 10 μM H2O2 or PBS (“Mock”) for 10 minutes on
ice, then incubated in drug-free medium for the indicated time periods. SSBs induced were
measured using the alkaline comet assay. Average tail moments from 50 cells were quantified
using the Comet Assay IV software. Data are the mean of 3 independent experiments and
error bars represent ±1 S.E.M. p values were derived from two-tailed Student’s t-test ,
whereby * denotes p < 0.05 and ** denotes p < 0.01.
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and “TOP1mt + miTDP1”, respectively). I confirmed the levels of protein expression by 
immunoblotting (Fig. 6.12A), mitochondrial localization of TOP1mt-EmGFP and 
TOP1mt*-EmGFP (Fig. 6.12B), and enzymatic activity of TDP1 in the mitochondria 
(Fig. 6.12C). Interestingly, TDP1 catalytic activity appeared to be upregulated by 
~ 20 % in both TOP1mt- and TOP1mt*-overexpressing cells (Fig. 6.12D).  
As an initial validation of the functional phenotype of TOP1mt overexpression, I 
designed primers for five peptide-coding transcripts encoded by the mitochondrial 
genome (Table 2.9) and confirmed the specificity of the primers for PCR amplification 
of a cDNA library prepared from whole cell RNAs (Fig. 6.13A). Since the mitochondrial 
encoded genes are intronless, the primers would also amplify any contaminating 
mtDNA. With the DNAse treatment, I confirmed that mtDNA was not detectable by 
PCR in the non-reverse transcribed RNA preparations (Fig. 6.13B). I then quantified 
the levels of the transcripts by RT-qPCR in each cell line. After 24-hour doxycycline 
induction, TOP1mt overexpression markedly reduced levels of the mitochondrial 
transcripts by ~ 80 % compared to control cells (Fig. 7.13C, p < 0.001; Student’s t-
test), consistent with published data (Sobek et al., 2013).  
I then validated the phenotype of TOP1mt* overexpression published by Pommier and 
coworkers (Dalla Rosa et al., 2014) by quantifying TOP1mt-cc using caesium chloride 
(CsCl) fractionation (Fig. 6.14A) (Hartsuiker, 2011). Due to the non-specificity of the 
TOP1mt antibody on immunoblotting of WCE (Fig. 6.15) and CsCl fractions 
(Fig. 6.14B), I used purified mitochondrial extracts instead of WCE for CsCl 
fractionation, and immunoblotted the fractions using anti-GFP antibody, which would 
detect EmGFP-tagged TOP1mt and TOP1mt*. Non-specific signals were now absent 
from the free DNA fractions (Fig. 6.16A,B). Interestingly, in the absence of exogenous 
stress or topoisomerase poisons, overexpression of wildtype TOP1mt did not induce 
more endogenous TOP1mt-cc than in control miScr cells, (Fig. 6.16A). Overexpression 
of TOP1mt*, however, induced ~ 6.5 fold more TOP1mt-cc compared to 
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Figure 6.12 Overexpression of TOP1mt or TOP1mt* with concurrent TDP1 depletion in
Flp-In T-Rex 293 cells. (A) 106 cells were incubated in 1 μg/ml doxycycline for 48 hours, then
harvested. 75 μg of WCE was fractionated by SDS-PAGE and immunoblotted with antibodies
against TDP1, GFP, and β-tubulin. (B) 2 x 107 cells were incubated in 1 μg/ml doxycycline for
48 hours, then harvested. Mitochondria were extracted, purified with proteinase K, and lysed.
5 μg total proteins were fractionated by SDS-PAGE and immunoblotted with antibodies
against GFP. (C) 100 ng of mitochondrial lysate from (B) was mixed with 25 nM of TDP1
substrate at 37ºC for 1 hour, then resolved with a 20 % 7.5 M urea gel by electrophoresis. The
substrate and product were detected with the ChemiDoc MP (Bio-Rad) gel imaging system
using the Cy5.5 filter. (D) Quantification of TDP1 catalytic activity from (C) using Image
Studio Lite. TDP1 activity was calculated from the ratio of 3’-P product signal intensity to the
total intensity of 3’-P and 3’-PY. Relative TDP1 activity is expressed as TDP1 activity
normalised to that of the control miScr cells. “Buffer” denotes sample with lysis buffer but no
lysate. “3’-PY” denotes oligonucleotide substrate with 3’-phosphotyrosyl end, “3’-P” denotes
oligonucleotide product with 3’-phosphate end, “miScr” denotes cells expressing scrambled
miRNA, “TDP1 + miTDP1” denotes cells overexpressing targeting-resistant TDP1-EmGFP
and TDP1-targeting miRNA, “miTDP1” denotes cells expressing TDP1-targeting miRNA.
“TOP1mt + miScr” denotes cells overexpressing TOP1mt-EmGFP and scrambled miRNA,
and ”TOP1mt + miTDP1” denotes cells overexpressing TOP1mt and TDP1-targeting miRNA.
Data are the mean of 3 independent experiments and error bars represent ±1 S.E.M. p values
were derived from two-tailed Student’s t-test , whereby * denotes p < 0.05.
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Figure 6.13 Overexpression of TOP1mt reduces abundance of mitochondrial
transcripts in Flp-In T-Rex 293 cells. (A) 106 cells were incubated in 1 μg/ml doxycyline for
24 hours then harvested. The RNA contents were extracted and 5 μg was reverse-
transcribed. PCR was carried out on the cDNA and non-reverse transcribed RNA extract to
test the specificity of primers to amplify five of the mitochondrial genes. β-actin was used as
positive control and H2O was used as non-template control (NTC). (B) cDNA and non-reverse
transcribed RNA extract from (A) was used to test PCR amplification of GAPDH, using ND1
as positive control and H2O as NTC. (C) RT-qPCR quantification of transcript abundance of
five mitochondrial genes normalised against GAPDH from cells overexpressing TOP1mt,
relative to the abundance of the mitochondrial transcripts miScr control cells. Data are the
mean of 3 independent experiments and error bars represent ±1 S.E.M. p values were
derived from one-tailed Student’s t-test. whereby *** denotes p < 0.001 and **** denotes
p < 0.0001.
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Figure 6.14 Detection of TOP1mt-cc in Flp-In cells by caesium chloride fractionation (A)
2 x 106 Flp-In cells were incubated in 1 μg/ml doxycycline for 48 hours, then harvested and
lysed. 1 % of the lysate was treated with RNAse A and Proteinase K, then the gDNA
concentration was measured by pico-green fluorescence. The remaining lysates were
fractionated by caesium chloride (“CsCl”) gradient centrifugation for 24 hours. (B) 10 equal-
volume fractions were collected, starting from the bottom of the tube, and slot-blotted onto
nitrocellulose membrane. The volumes loaded were normalised to the gDNA concentration
and the equivalent of 7 μg gDNA were loaded in each slot across the cell lines. TOP1mt–cc
were detected by immunoblotting with GFP antibodies and visualised by chemiluminescence.
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Figure 6.15 Titration of TOP1mt antibodies on WCE of Flp-In T-Rex 293 cells
overexpressing TOP1mt-EmGFP. (A) 106 cells were incubated in 1 μg/ml doxycycline for 48
hours, then harvested. 75 μg of total proteins from the WCE was fractionated by SDS-PAGE
and immunoblotted with antibodies against TOP1mt or GFP at the indicated dilutions and
visualised by chemiluminescence.
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Figure 6.16 TDP1 depletion promotes accumulation of TOP1mt-cc. (A, B) 2 x 107 Flp-In
cells were incubated in 1 μg/ml doxycyline for 24 hours, then harvested. The mitochondria
were extracted then lysed. 1 % of the lysate was treated with RNAse A and Proteinase K,
then the gDNA concentration was measured by pico-green fluorescence. The remaining
lysates were fractionated by caesium chloride (“CsC”)l gradient centrifugation for 24 hours.
Ten equal volume fractions were collected, starting from the bottom of the tube, and slot-
blotted onto nitrocellulose membrane. The volumes loaded were normalised to the gDNA
concentration and the equivalent of 7 μg gDNA were loaded in each slot across the cell lines.
TOP1mt–cc were detected by immunoblotting with GFP antibodies and visualised by
chemiluminescence. Quantification of total signal intensity of TOP1mt-cc (fractions 4-7) was
carried out using Image Studio Lite and normalised to the total intensity from TOP1mt + miScr
cells. (C) CsCl fractions from B were immunoblotted with antibodies specific to TOP1-DNA
complex.
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overexpression of wildtype TOP1mt, as detected by antibodies against GFP 
(Fig. 6.16B) as well as TOP1-DNA covalent complexes (Fig. 6.16C), confirming the 
propensity of the toxic mutant to form DNA cleavage complexes.  
6.3.5 TDP1 removes TOP1mt*-cc in the mitochondria 
Having established the expected functional phenotypes of the Flp-In cell lines 
overexpressing TOP1mt or TOP1mt*, I then explored the effect of TDP1 depletion in 
these cell lines. Figure 6. 16B shows that depletion of TDP1 increased the level of 
TOP1mt-cc by 6.6 fold, and a further 1.6 fold in the case of TOP1mt* (i.e. ~ 10.7 fold 
more than TOP1mt overexpression), suggesting that TDP1 plays a role in removing 
TOP1mt*-cc’s. To further confirm this, I quantified mtDNA covalently linked to TOP1mt* 
in the presence or absence of TDP1 using qPCR following chromatin 
immunoprecipitation (ChIP-qPCR) using GFP-Trap® beads. Primers targeting the 
putative TOP1mt*-EmGFP binding site (position 15873 – 15972) of the mtDNA 
(Fig. 6.1, Table 2.8) (Dalla Rosa et al., 2014) were tested for specificity, along with 
primers for quantifying mtDNA copy number (Fig. 6.17A, Table 2.8).  The input 
materials were first analysed for the mtDNA copy numbers, which were comparable 
amongst the cell lines (Fig. 6.17B). I then quantified the amount of TOP1mt*-linked 
mtDNA by qPCR. The CT values of the ChIP samples were normalised to that of the 
corresponding input samples and expressed as percentage input, which was 
normalised against its relative mtDNA copy numbers. As expected, TOP1mt* 
overexpressing cells showed > 2-fold more ChIP material specific to the TOP1mt 
binding site than the negative control cells overexpressing EmGFP alone (“miScr”); and 
TDP1 depletion further increased the pull-down material by ~ 4 fold (Fig. 6.17C, 
p < 0.05; Student’s t-test). Thus, TDP1 inhibits accumulation of TOP1mt-cc 
detectable by qPCR without topotecan treatment. 
Figure 6.17 TDP1 depletion promotes stalling of TOP1mt* at H-chain replication origin.
(A) 5 x 106 cells were incubated in 1 μg/ml doxycycline for 48 hours, then harvested. The
gDNA contents were extracted. Left panel: TOP1mt binding site (“15873”, denotes region
from position 15873 – 15972 of mitochondrial chromosome) was PCR-amplified to test for
primer specificity. “B2M” and “ND1” denotes nuclear- and mitochondrial-encoded genomic
regions, respectively, used for quantification of mtDNA copy number. Right panel: repeat PCR
of B2M using a range of annealing temperatures. (B) qPCR quantification of mtDNA copy
calculated by: 2 x 2(ΔCT) whereby ΔCT = B2M average CT – ND1 average CT. Data from 3
independent experiments are shown. (C) 2 x 107 cells were incubated in 1 μg/ml doxycyline
for 48 hours then harvested. Cells were lysed in ChIP lysis buffer and sonicated to yield
chromatin length of average ~ 300 bp. 10 % volume was set aside as input, while the
remaining lysates were immunoprecipitated using GFP-conjugated agarose beads. The pull-
down material was washed and eluted. The eluent was treated with RNAse A and Proteinase
K, then used for qPCR quantification of TOP1mt binding site. The % input was calculated as:
10 x 2(adjusted Input CT – IP CT), whereby adjusted Input CT = Input CT –3.32. The % Inputs for each
cell line were then normalised against the respective mtDNA copy numbers of the cell line.
Data are the mean of 3 independent experiments and error bars represent ±1 S.E.M. p values
were derived from one-tailed Student’s t-test , whereby * = p < 0.05 and ** = p < 0.01.
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6.3.6 TDP1 promotes mitochondrial transcription 
Having established the molecular mechanism of TDP1 interaction with TOP1mt, I then 
investigated whether depletion of TDP1 has an impact on TOP1mt-regulated 
transcription. Overexpression of TOP1mt led to marked reduction of five of the 
mitochondrial mRNA transcripts examined by RT-qPCR (Fig. 6.13C, p < 0.001; 
Student’s t-test). Depletion of TDP1 led to ~ 50 % reduction of all transcripts tested, 
which was partially rescued by complementation with human TDP1 (Fig. 6.18A, 
p < 0.01; Student’s t-test). Interestingly, depletion of TDP1 in cells overexpressing 
wildtype TOP1mt did not further suppress transcription (Fig. 6.18B). In striking contrast 
to wildtype TOP1mt, overexpression of TOP1mt* led to ~ 2-fold increase in 
mitochondrial gene transcription, which was largely dependent on TDP1 (Fig. 6.18C, p 
< 0.05; Student’s t-test). Given the observed role of TDP1 in processing TOP1mt-cc, 
the increase in transcription could be due to a compensatory upregulation of TDP1 
catalytic activity. This is consistent with the ~ 25 % increase in mitochondrial TDP1 
activity in cells overexpressing TOP1mt* observed in Fig. 6.12C&D. Together, these 
data suggest a role for TDP1 in promoting mitochondrial gene transcription by 
resolving TOP1mt-cc. In addition, there appears to be a second distinct mechanism by 
which TOP1mt suppresses transcription independent of TOP1mt-cc formation or TDP1.  
6.3.7 TDP1 promotes proper assembly of the ETC complex 
Since transcription of mtDNA-encoded genes is essential for synthesis of major 
subunits of all the ETC complexes of the OXPHOS system except complex II, I next 
assessed the abundance of these complexes in purified mitochondria, by probing for 
the subunits that are particularly labile when the complexes are not correctly 
assembled (Fig. 6.19A). As expected, neither overexpression of TOP1mt or TOP1mt*, 
nor depletion of TDP1 had a significant effect on the nuclear-encoded complex II 
subunit, SDHB, at protein (Fig. 6.19C) or mRNA levels (Fig. 6.19G). Nor was there 
significant alterations in stability of complexes I, IV or V (Fig. 6.19B,E,F). The most 
Figure 6.18 TDP1 depletion negatively regulates mitochondrial transcription in a
TOP1mt*-dependent manner. 106 cells were incubated in 1 μg/ml doxycycline for 48 hours,
then harvested. Total RNA was extracted and 5 μg was reverse transcribed. RT-qPCR
quantification of transcript abundance of five mitochondrial genes normalised against GAPDH
from cells depleted of TDP1 with or without TDP1 complementation (A), overexpressing
TOP1mt with or without TDP1 depletion (B), and overexpressing TOP1mt* with or without
TDP1 depletion (C), relative to the abundance of the mitochondrial transcripts in control miScr
cells. Data are the mean of 3 independent experiments and error bars represent ±1 S.E.M. p
values were derived from two-tailed Student’s t-test, whereby * denotes p < 0.05, ** denotes
p < 0.01 and *** denotes p < 0.001.
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Figure 6.19 TDP1 facilitates assembly of ETC complex III. (A) Left: Immunoblotting of
mitochondrial lysates from doxycycline-induced Flp-In T-Rex 293 cells using antibody
cocktails against human OXPHOS proteins NDUFB8 (complex I), SDHB (complex II),
UQCRC2 (complex III), COX-II (complex IV), and ATP5A (complex V). Right: Immunoblotting
using specific UQCRC2 antibody. (B-F) Protein expression levels of the labile subunit from
the indicated complexes relative to those of control miScr cells, after normalisation to levels of
the mitochondrial loading control, VDAC1. (G) RT-qPCR quantification of SDHB transcript
abundance using total RNA extracted from cells in (A) and GAPDH as internal control.
Expression levels were then normalised to miScr cells. Data are the means of 3 independent
experiments and error bars indicate +1 S.E.M. p values were derived from two-tailed
Student’s t-test. ** = p < 0.01 and ns = non-significant.
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noticeable difference was detected with complex III. When normalised to the 
mitochondrial structural protein VDAC1 (porin), the level of UQCRC2 in complex III was 
reduced by ~ 40 % when TDP1 was depleted (Fig. 6.19D, p < 0.01). Surprisingly, 
overexpression of TOP1mt in the presence of TDP1 was not associated with complex 
III instability, despite a marked reduction in mitochondrial transcription (Fig. 6.18A). 
Overexpression of TOP1mt* alone had the same effect as TDP1 depletion, and 
concomitant TDP1 depletion did not further decrease the protein level (Fig. 6.19C). 
These results suggest that TDP1 plays a role in maintaining the integrity of complex III 
in TOP1mt-overexpressing cells in the face of lower of mitochondrial encoded ETC 
subunits. In contrast, TDP1 is unable to compensate for complex III structural instability 
as a result of excess mitochondrial subunits in TOP1mt*-overexpressing cells.   
6.3.8 TDP1 promotes mitochondrial OXPHOS 
Next I examined whether dysregulation in mitochondrial transcription and complex III 
assembly would have an impact on mitochondrial function in terms of OXPHOS and 
ATP production. Real-time measurement of mitochondrial OCR in response to 
oligomycin, FCCP, rotenone and antimycin A was performed using the Seahorse 
bioanalyzer (Fig. 6.20A). Under basal condition, mitochondrial respiration rate was 
~ 25% lower in TDP1-depleted cells compared to control cells (Fig. 6.20B, left panel, 
p < 0.01; Student’s t-test). Overexpression of TOP1mt reduced basal mitochondrial 
respiration by ~ 20%, and depletion of TDP1 in these cells further reduced basal 
respiration by an additional 8%, but this decrease was not statistically significant 
(Fig. 6.20B, middle panel). Overexpression of TOP1mt* reduced basal respiration by 
~ 30%, and depletion of TDP1 in these cells had no further effect on basal respiration 
(Fig. 6.20B, right panel, p < 0.05; Student’s t-test). I then examined if the mild basal 
respiratory defect was due to a switch to non-aerobic respiration by glycolysis, which is 
accompanied by acidosis. The extracellular acidification rate (ECAR) measured was 
comparable amongst all the tested cell lines under basal and stressed conditions 
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Figure 6.20 TDP1 depletion negatively regulates mitochondrial respiration. (A) 106 cells
were incubated in 1 μg/ml doxycycline for 48 hours, then harvested. 6.5x104 cells/well were
plated in Cell-Tak pre-coated XF24 cell plate in triplicates and three basal readings of oxygen
consumption rate (“OCR”) were taken. Cells were then subjected to sequential treatments
with 1 μM oligomycin, 1 μM FCCP, and 1 μM rotenone and antimycin A during which three
repeat OCR readings were taken. (B) Mitochondria respiration was calculated by subtracting
average rotenone/antimycin A OCR from average basal OCR. Data are the mean of 3
independent experiments and error bars represent ± 1 S.E.M. p values were derived from
two-tailed Student’s t-test. * = p < 0.05, ** = p < 0.01, and ns = non-significant.
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(Fig. 6.21A&B). Interestingly, the respiratory (OCR/ECAR) ratio was decreased in 
TOP1mt+miScr, TOP1mt*+miScr, and TOP1mt*+miTDP1 cells in similar pattern as 
basal OCR (Fig. 6.21C), suggesting that the defect in basal OCR was specific to the 
OXPHOS pathway. Inhibition of ATP-coupled OXPHOS by oligomycin revealed no 
significant changes in uncoupled respiration (“proton leak”) amongst the cell lines that 
could account for the lower basal OCR (Fig. 6.22A). In contrast, the oligomycin-
sensitive OCR (i.e. ATP-coupled respiration) were reduced by ~ 30 % in all cell lines 
depleted of TDP1 (Fig. 6.22B, p < 0.05), although in TOP1mt*-overexpressing cells no 
further reduction was seen by loss of TDP1. Finally, upon induction of maximal 
respiration by FCCP, mimicking the state of high ATP demand, TDP1-depleted cells 
showed a ~ 25 % reduction in spare respiratory capacity (SRC) compared to wildtype 
cells (Fig. 6.22C, left panel, p < 0.01; Student’s t-test). In TOP1mt-overexpressing 
cells, TDP1 depletion reduced SRC by ~ 50 % (Fig. 6.22C, middle panel, p < 0.05; 
Student’s t-test). Strikingly, TOP1mt*-overexpressing cells had the lowest SRC, at 
< 10 % compared to wildtype cells (Fig. 6.22C, right panel, p < 0.05; Student’s t-
test). Depletion of TDP1 partially rescued this defect to ~ 50 % of wildtype level. Taken 
together, the mitochondrial respiration profiles showed that TDP1 promotes OXPHOS 
under both basal and high ATP demand conditions. Transient overexpression of 
wildtype TOP1mt has the mildest OXPHOS degree of dysfunction; while 
overexpression of TOP1mt* has the worst, with reduction of both basal and maximal 
respiration in a TDP1 dependent manner. These findings do not entirely correlate with 
the protein expression data of the ETC complexes, suggesting there are other dynamic 
factors mediating OXPHOS efficiency. 
6.3.9 TDP1 promotes mitochondrial metabolic activity  
To find out if the role of TDP1 in resolving TOP1mt-cc and maintaining mitochondrial 
transcription is important for non-OXPHOS metabolic activity as well, I incubated 
doxycycline-induced Flp-In cells with CellTiter-Blue (resazurin) reagent, which relies on 
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Figure 6.21 TDP1 depletion does not impact on anaerobic mitochondrial respiration.
(A) Extracellular acidification rate (ECAR) under basal condition in cells from Figure 7.18. (B)
ECAR after treatments with oligomycin and FCCP. (C) Respiratory ratio an indicator of
cellular aerobic respiration activity, derived from basal mitochondrial respiration OCR divided
by basal ECAR. Data are the mean of 3 independent experiments and error bars represent
±1 S.E.M. p values were derived from two-tailed Student’s t-test. * = p < 0.05, and ns = non-
significant.
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Figure 6.22 TDP1 depletion reduces efficiency of OXPHOS-coupled ATP production. (A)
Proton leak calculated by subtracting average oligomycin OCR from average mitochondrial
respiration OCR. (B) Oligomycin sensitive OCR derived by subtracting average proton leak
OCR from average mitochondrial respiration OCR. (C) Spare respiratory capacity derived by
subtracting average basal OCR from maximum OCR after FCCP. Data are the mean of 3
independent experiments and error bars represent ±1 S.E.M. p values were derived from two-
tailed Student’s t-test. * = p < 0.05, ** = p < 0.01, and ns = non-significant.
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the dehydrogenases in the mitochondria and cytoplasm to be metabolized to a highly 
fluorescent product, resorufin. The mitochondrial metabolic activity then can be read 
out as a function of fluorescence intensity normalised to cell numbers. TDP1 depletion 
reduced the metabolic activity with or without TOP1mt overexpression, while TOP1mt* 
overexpression alone reduced the metabolic activity, with no further reduction when 
TDP1 was depleted (Fig. 6.23, p < 0.05; Student’s t-test). The results closely reflect 
the OXPHOS profiles obtained by the Seahorse assay, suggesting TDP1 plays a role 
in the overall functioning of the mitochondria.  
6.3.10 Overexpression of TDP1 in the mitochondria negatively impacts 
mitochondrial  function 
Interestingly, TDP1-depleted cells overexpressing RNAi-resistant TDP1 showed a 
similar pattern of mitochondrial bioenergetics profile (Fig. 6.19 – 6.22) and metabolic 
activity (Fig. 6.23) as miTDP1 cells. As TDP1-EmGFP was detectable in the 
mitochondria by immunoblotting (Fig. 6.24) and clearly had an opposing effect on 
mitochondrial transcription compared to miTDP1 cells (Fig. 6.18A), I reasoned the 
observed defect in mitochondrial respiration could be due to overexpression of 
exogenous TDP1, possibly explaining the suppression of hTDP1 expression in Tdp1-/- 
MEFs.   
6.4 Discussion 
In this chapter I have presented data generated from the inducible human Flp-In T-Rex 
293 cell lines. First I have demonstrated that the miRNA-mediated TDP1 depletion 
(Fig. 6.5) is specific in terms of its catalytic activity (Fig. 6.6) and nuclear DNA repair 
activity (Fig. 6.7, 6.8). The viability defect after CPT treatment was not 
statistically significant from the control cells (Fig. 6.9A), which was not due to 
compensatory increase in enzymatic activity of the residual TDP1 expressed 
(Fig. 6.6B), nor inhibition of TDP1 activity in control cells by doxycycline (Fig. 6.9D). 
It was also observed that TDP1 depletion did not cause a viability defect from ROS 
damage (Fig. 6.9A). 
Figure 6.23 TDP1 promotes cellular metabolic activity. 2 x 106 Flp-In cells were incubated
in 1 μg/ml doxycycline for 48 hours, then re-plated at 105 cells/100μl for 72 hours. 20 μl of
CellTiter Blue reagent was then added to the cells and incubated at 37°C for 1 hour. The
fluorescence intensity emitted by the metabolite resorufein was measured using a fluorescent
microplate reader with filters of EX544/EM590-10. Fluorescence intensity was normalised
against that of miScr cells. Data are the mean of 3 independent experiments and error bars
represent ±1 S.E.M. p values were derived from two-tailed Student’s t-tests. * = p < 0.05.
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Figure 6.24 TDP1-EmGFP is localised in the mitochondria. 2 x 107 Flp-In TDP1 + miTDP1
cells were incubated in 1 μg/ml doxycycline for 48 hours, then harvested. Mitochondria were
isolated and quantified using Bradford assay. The mitochondrial pellets were resuspended in
homogenisation buffer and treated with or without 20 ng Proteinase K per 5 μg mitochondria
on ice for 30 minutes, then washed in homogenisation buffer containing 1 mM
phenylmethanesulfonyl fluoride (PMSF) to stop the digestion. The mitochondrial and nuclear
fractions were lysed in Laemmli buffer and serially diluted. The nuclear and mitochondrial
proteins were then fractionated by SDS-PAGE. The purity of the nuclear (“Nucl.”) and
mitochondrial (“Mito.”) fractions were assessed using antibodies against the nuclear protein
phospho-XRCC1(S475, T488), and mitochondrial protein COX IV, respectively, and detected
using chemiluminescence. TDP1-EmGFP is detectable inside the mitochondria (“Mito. +
Prot K”) after long exposure.
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As cell viability does not necessarily reflect the amount of DNA damage sustained 
and the repair capacity of the cells, I quantified these using the alkaline comet 
and 53BP1 immunofluorescence assays, and confirmed a transient defect in TDP1 
depleted cells (Fig. 6.7, 6.8).  Alkaline comet assay using H2O2 showed similar 
pattern of early accumulation of chromosomal DNA breaks in TDP1-deficient 
cells expressing SOD1G93A as observed in MEFs (Fig. 6.11), although the expression 
level of SOD1G93A tolerated in TDP1-deficient Flp-In cells was much lower than in 
Tdp1-/- MEFs. This could point to a higher dependence on TDP1 to reduce 
SOD1G93A-induced toxicity in these cells. 
To investigate the functional interaction between TDP1 and TOP1mt, I next induced 
TOP1mt overexpression in TDP1-proficient and -deficient cells. Interestingly, when 
TDP1 was depleted, enrichment of a higher molecular weight species (~ 15 kDa) was 
observed (Fig. 6.12A), particularly in the mitochondria (Fig. 6.12B). TOP1mt has two 
isoforms: isoform 1 has a 50 amino acids mitochondrial localisation sequence at the 
start of the N-terminus, which is cleaved off upon binding the mitochondrial outer 
membrane, giving rise to isoform 2 (Zhang et al., 2001). As the cDNA sequence of 
isoform 2 was introduced into the host genome, the higher molecular weight species 
that was also present inside the mitochondria could not be due to isoform 1, but more 
likely a covalent modification of TOP1mt. Furthermore, the same pattern of enrichment 
of the higher molecular weight species was also observed when TOP1mt* was 
overexpressed in TDP1-depleted cells, although at a lower abundance (Fig. 6.12A). 
This could suggest a TDP1-mediated regulation of TOP1mt by post-translational 
modifications such as de-ubiquitination and de-SUMOylation. The nature of the higher 
molecular weight species compared to the lower band TOP1mt can be confirmed by 
mass spectrometric analysis.  
The proximity of the mtDNA to the ETC complexes predisposes it to higher levels of 
oxidative damage (Yakes and Van Houten, 1997) that can stall TOP1mt and disrupt 
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transcription and replication (Medikayala et al., 2011). I confirmed that overexpression 
of the toxic TOP1mt* mutant indeed generates more TOP1mt-cc detectable by 
immunoblotting and qPCR (Fig. 6.16, 6.17). I also demonstrated that these lesions are 
dependent on TDP1 for repair. Interestingly, transient (up to 48-hour) overexpression 
of TOP1mt in TDP1-proficient cells in the absence of topoisomerase poisons does not 
lead to accumulation of TOP1mt-cc, suggesting there is a fundamental difference in 
steady-state levels of TOP1mt-cc between cells expressing the two versions of 
TOP1mt.  
As TOP1mt-cc at the NCR region has been implicated in mtDNA replication (Dalla 
Rosa et al., 2014), and Tdp1-/- MEFs have reduced mtDNA copy number (Fig. 5.7), it 
would be interesting to examine its role in mitochondrial transcription as well. The 
measurement of transcript abundance by RT-qPCR usually indicates transcript 
turnover, which is a product of both transcription rate and transcript stability. In the 
context of mitochondrial genes, which are translated in organello, defective mRNA 
transportation that can lead to transcript accumulation can be ruled out. In terms of 
transcription elongation, Top1mt-/- MEFs do not appear to accumulate mitochondria 
transcripts of aberrant lengths (Sobek et al., 2013), arguing against an essential role of 
TOP1mt in transcription elongation. Furthermore, the high concentration of TOP1mt in 
the NCR containing the two promoter sites strongly suggests its involvement in 
transcription initiation (Zhang and Pommier, 2008), which is the main rate-limiting factor 
in determining transcript abundance. Lastly, I analysed multiple sites along the 
polycistronic heavy chain transcript, from the 5’ end RNR1 gene to the 3’ end CYTB 
gene, to allow detection of primary transcripts of different lengths.  Taking together 
these considerations, it is highly likely that in this context, transcript abundance 
measured by RT-qPCR predominantly reflects the transcription rate.  
TOP1mt overexpression in TDP1-proficient cells led to marked reduction of 
mitochondrial mRNA transcripts, which is consistent with earlier reports (Sobek et al., 
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2013;  Kolesar et al., 2013). In contrast, overexpression of TOP1mt* resulted in higher 
transcript levels. Therefore, it appears that the steady state level of TOP1mt-cc 
positively correlates with mitochondrial transcription rate. One possible explanation 
may be through DNA damage mediated retrograde signalling, which can upregulate 
mitochondrial transcription and biogenesis (Douarre et al., 2012;  Scarpulla, 2006;  
Gong et al., 1998;  Lee et al., 2000;  Kluza et al., 2004;  Fu et al., 2008). Interestingly, 
TDP1 activity is also moderately upregulated in our cellular model, tentatively 
suggesting its involvement in the retrograde signalling response. These data also 
provide an explanation for the lack of change in mitochondrial mass following TOP1mt * 
expression in murine cells despite rapid mtDNA depletion (Dalla Rosa et al., 2014), 
further confirming the importance of the mitochondrial TDP1 pathway in repairing 
TOP1mt-cc and maintaining mitochondrial transcription. 
Although translation of mitochondrial-encoded genes occurs in organello, assembly of 
the ETC requires importation of nuclear-encoded subunits. Given that nuclear 
transcription of ETC subunits is unaffected (Fig. 6.19C), changes in levels of the 
mitochondrial subunits can potentially disrupt the nuclear:mitochondrial stoichiometry 
resulting in dysfunctional ETC. Intriguingly, although the levels of multiple mitochondrial 
transcripts are affected by the TOP1mt-TDP1 pathway, only complex III showed 
particular sensitivity to mis-assembly (Fig. 6.19D).  Complex III, also known as 
cytochrome bc1 complex, is encoded by CYTB in the mitochondria, and the remaining 
10 subunits are all encoded in the nuclear genome. The cytochrome B subunit is the 
main transmembrane subunit that anchors the complex, which could explain the 
disruption of complex III in TDP1 depleted cells with or without TOP1mt* 
overexpression. However, overexpression of TOP1mt in TDP1-proficient cells does not 
destabilise complex III, at least within the 48-hour time-frame of the observation. One 
possible explanation may be that mitochondrial transcription is constitutively 
suppressed by TOP1mt, and only activated in response to oxidative stress, when 
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increase in ETC capacity is required. Therefore, even very low level of transcription 
may be well-tolerated as other compensatory mechanisms such as mitochondrial 
fusion can facilitate pooling of essential proteins across a large number of mitochondria 
(Detmer and Chan, 2007;  Westermann, 2008). Alternatively, TDP1 may play a yet 
undefined compensatory role in maintaining ETC assembly. In any case, since 
complex III plays a crucial role in handling electron transfer, dysfunction of complex III 
is expected to increase ROS production. The effect of complex III mis-assembly on 
efficiency of the OXPHOS-ATP system was then examined.    
Transient inhibition of transcription by overexpression of TOP1mt-EmGFP minimal 
effect on mitochondrial respiration by OXPHOS. This is in contrast to the ~ 63 % 
reduction in oxygen consumption reported in human HT1080 cells constitutively 
overexpressing YFP-TOP1mt (Dalla Rosa, 2009), which also showed reduction in 
nuclear-encoded subunits of the ETC complexes. This suggests that transient inhibition 
of TOP1mt-mediated transcription without accumulation of TOP1mt-cc is not sufficient 
to alter the efficiency of the ETC system. However, depletion of TDP1 seems to 
accelerate this process, most likely through accumulation of unresolved TOP1mt-cc. 
The observation that TDP1 depletion has no further impact on basal mitochondrial 
respiration in cells overexpressing TOP1mt*, which already show a ~ 25 % reduction 
compared to control cells, suggests that the effects of TDP1 depletion and TOP1mt* 
overexpression are epistatic. However, the reduction in SRC in TOP1mt*-
overexpressing cells was striking, particularly when it is partially reversed by depletion 
of TDP1. This could suggest that excessive expression rather than suppression of 
mitochondrial-encoded proteins without corresponding change in importation of the 
nuclear-encoded counterparts is more detrimental to cellular bioenergetics, perhaps 
due to a vicious cycle that consumes ATPs.  
Surprisingly, overexpression of targeting-resistant TDP1 in TDP1 depleted cells 
showed the same mitochondrial respiratory (Fig. 6.19 – 6.21) and viability defects 
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(Fig. 6.9D) following the oxidative damage by TBH as TDP1 depleted cells, 
even though TDP1-EmGFP was detectable in the mitochondria (Fig. 6.24) and 
mitochondrial transcription was not downregulated (Fig. 6.18B). Another 
indicator that overexpression of TDP1 may be detrimental to mitochondrial 
respiratory function is that in Tdp1-/- DT40 cells, the clone that expressed high level of 
hTDP1 had a higher level of endogenous DNA radicals than the low TDP1-
expressing clone (Fig. 5.4). If this were true, it could imply that TDP1 expression 
and importation into the mitochondria could be regulated by mitochondrial OXPHOS 
homeostasis, similar to TOP1mt (Fam et al., 2013a). 
Lastly, it is worth noting that although transient overexpression of TOP1mt* did not 
alter the mtDNA copy number even with depletion of TDP1 (Fig. 6.17B), stable 
overexpression of TOP1mt* in MEFs has been reported to lead to ~ 50 % loss of 
mtDNA without change in total mitochondrial mass (Dalla Rosa et al., 2014). This 
suggests that, in contrast to mitochondrial transcription, replication stalling and 
genomic instability were not induced by an acute increase in TOP1mt*-cc. If true, this 
may have implications for clinical use of TOP1 poisons such as topotecan and TOP1mt 
poison derivatives (still to be developed) and how these drugs are administered can 
affect its adverse effects on mitochondrial function over long-term. 
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                    CHAPTER 7 
General Discussion 
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7.1 Overview 
TDP1 is an important player in the repair of TOP-mediated DNA breaks, is implicated in 
maintaining cerebellar genome stability, and is a potential therapeutic target in 
refractory cancers.  At the onset of this doctoral project, development of effective novel 
TDP1 inhibitors had reached a bottleneck; and it became apparent that a detailed 
understanding of the cellular response to TDP1 inhibition, in terms of compensatory 
upregulation of TDP1 expression or activity, DNA damage response, and impact on 
cellular proliferation, was needed.  
The main aim of this thesis is to provide insight into the molecular mechanisms of 
TDP1 functions at the cellular level, which would contribute to a long-term project of 
investigating TDP1 function (and dysfunction) at a whole organism level, with potential 
for therapeutic applications.  
7.2 Regulation of TDP1 activity by the N-terminus domain impacts cellular 
resistance to TOP1 poison 
TDP1 is conserved across eukaryotes, and the addition of the N-terminus domain 
(NTD) in higher organisms prompted me to investigate the regulatory role of the NTD in 
human.  
In chapter 3, I described the identification and characterisation of a novel post-
translational modification in the NTD, phosphorylation at S81 by the ATM and/or 
DNA-PK, that promotes TDP1 protein stability, physical interaction with Lig3α, and 
DNA repair efficiency. This was the first reported post-translational modification of the 
NTD of human TDP1, and supports the view that regulation of TDP1 expression level 
plays a significant role in the cellular response to the TOP1 poisons. In chapter 4, I 
have presented further evidence that the N-terminus domain regulates TDP1 activity 
through another post-translational modification, SUMOylation at K111. Modification by 
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SUMO1 at K111 promotes recruitment of TDP1 to sites of DNA damage at 
transcriptionally active regions of the genome. Neither post-translational modifications 
affect the catalytic activity in vitro, but nevertheless promote repair of TOP1-cc at the 
cellular level.  
7.3 Implications for novel drug combination strategies 
These results suggest that, firstly, from a drug discovery point of view, focussing solely 
on the catalytic activity may not be a reliable indicator for cytotoxicity of TDP1 
inhibitors, as the DNA repair capacity can be regulated by the N-terminus domain. 
Secondly, combination therapy using a TOP1 poison and an existing inhibitor of TDP1 
regulatory pathway could be a less time-consuming approach than developing novel 
TDP1 inhibitors. For example, inhibition of PARP1, a physical interacting partner of 
TDP1, by veliparib (ABT-888), has recently been shown to reduce TDP1 protein 
stability and recruitment to DNA damage sites (Das et al., 2014;  Murai et al., 2014). 
ABT-888 has been used with topotecan in advanced solid tumours and lymphomas in 
phases I and II clinical trials (Kummar et al., 2011;  Kunos et al., 2015). However, the 
additive effect of combination therapy was minimal, and haematological toxicity was 
the main dose-limiting factor. This is likely due to the many TOP1- and TDP1-
independent effects of PARP inhibition, such as dysregulation of DNA transcription and 
replication, DNA repair and apotosis (Weaver and Yang, 2013).  
In contrast to PARP1, inhibition of TDP1 by RNA interference and genetic inactivation 
in mice resulted in few cytotoxic effects in the absence of exogenous DNA damage 
(Hirano et al., 2007;  Katyal et al., 2007;  Guo et al., 2014). As an alternative approach 
that is more TDP1-specific, our lab has been investigating degradation of TDP1 by the 
ubiquitin-proteasome pathway. As deubiquitinating enzymes (DUBs) regulate protein 
stability, signalling pathways, cell proliferation and apoptotic response, and are heavily 
depended on by tumour cells, DUB inhibitors are attractive candidates for anti-cancer 
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treatments (D'Arcy et al., 2015). Identifying and inhibiting specific DUBs that promote 
TDP1 stability or repair of TOP1-cc by, for example, HR (Orthwein et al., 2015), can be 
potential new avenues to improve efficacy of TOP1 poisons.  
The finding that SUMOylated TDP1 promotes repair of transcription-associated SSBs 
may have implications in cancer therapy as well. Firstly, increasing evidence indicates 
that the SUMOylation pathway is upregulated in several tumour types (Mo and 
Moschos, 2005;  Mo et al., 2005;  Moschos et al., 2007;  Moschos et al., 2010;  Deng 
et al., 2011). The obligate E2 conjugating enzyme UBC9/UBE2I has been proposed as 
a cancer therapeutic target, for instance it has been demonstrated that depletion of 
UBC9 sensitised melanoma-infiltrated lymph nodes to the cytotoxic effect of cisplatin 
and paclitaxel (Moschos et al., 2007). UBC9 polymorphisms that promote TOP1 
SUMOylation have also been shown to sensitise NSCLC to irinotecan (Han et al., 
2010).  
7.4 Targeting repair of transcription-mediated DNA damage in quiescent 
cancer stem cells 
Since TOP1 SUMOylation in its catalytic domain at actively transcribed regions 
promotes recruitment of RNA processing factors and reduces R-loop formation and 
genome instability (Li et al., 2015), targeting UBC9 in tumour cells can potentially be 
achieved by understanding the molecular mechanisms underlying the specific 
interactions with TOP1, TDP1 or BRCA1 (Xu et al., 2009), and screening for small-
molecule inhibitors that disrupt the interaction sites. As TDP1 repairs transcription-
dependent protein-linked breaks (PDBs) in non-cycling cells, it could be a potential 
target in quiescent cancer stem cells (qCSCs), which are often resistant to 
conventional chemotherapy (Lyle and Moore, 2011). Several current strategies 
targeting qCSCs involve inhibition of the quiescence process (Essers and Trumpp, 
2010), but this process likely also occurs in normal adult stem cells (Li and Bhatia, 
2011;  Schuettpelz and Link, 2013), therefore this approach runs the risk of depleting 
 
148 
the normal stem cell population (Baldo et al., 2010;  Sheikh et al., 2011;  Skoetz et al., 
2015). Inhibition of TDP1 SUMOylation may therefore be useful in targeting qCSCs, 
although normal postmitotic tissues such as mature neurons (Hudson et al., 2012) and 
cardiomyocytes may be affected as well. Thus this approach may be most useful as an 
adjuvant therapy in the paediatric population, who generally have higher tissue 
regenerative potential. 
7.5 Novel anti-oxidant mechanism in vertebrates involving TOP1mt/TDP1 
functional interaction 
In chapters 5 and 6, I investigated the role of TDP1 in the mitochondria. As organelles 
implicated in many disease processes including neurodegeneration and 
tumourigenesis, the observation by several groups that TDP1 is present and active in 
the mitochondria (Das et al., 2010;  Fam et al., 2013a) warranted further investigation. 
My findings confirm that TDP1 repairs ROS-induced DNA breaks in the nucleus. I also 
demonstrated that TDP1 has a direct role on the production of ROS from the 
mitochondria, namely, by promoting transcription of mitochondria-encoded genes 
mediated by TOP1mt activity, and thereby maintaining homeostasis of mitochondrial 
oxidative phosphorylation. This, to the best of my knowledge, is the first report that 
characterises the functional interaction between human TDP1 and TOP1mt.  
7.6 Implications for targeting TOP1mt and mitochondrial TDP1 in cancer 
cells 
TOP1mt has been identified as a modulating factor in several neoplastic diseases, and 
its expression is upregulated by the proto-oncogene Myc (Goto et al., 2006;  Zoppoli et 
al., 2011). TOP1mt upregulation and mitochondrial dysfunction have also be observed 
in an ovarian cancer cell line with acquired resistance to doxorubicin (Chen et al., 
2014). TOP1mt has therefore been proposed as a novel therapeutic target in 
doxorubicin-refractory ovarian tumours. However, genetic inactivation of Top1mt in 
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mice treated with doxorubicin has been shown to exacerbate the cardiotoxicity of 
doxorubicin and increase the mortality rate (Khiati et al., 2014), thus limiting the 
usefulness of this approach.  
On the other hand, lamellarin D, an alkaloid from marine invertebrate with TOP1 
poison-like effect (Facompré et al., 2003), has been shown to induce TOP1mt-cc 
(Khiati et al., 2014) that promote ROS production and cancer cell death (Ballot et al., 
2014). Inhibition of TDP1 activity and/or its translocation to the mitochondria would 
promote accumulation of TOP1mt-cc, and would therefore be a logical combination 
with TOP1mt poisons like lamellarin D. This approach would likely be particularly 
deleterious to qCSCs that rely heavily on mitochondrial OXPHOS and have relatively 
low glycolytic capacity (Lagadinou et al., 2013). It is conceivable that the Flp-In 
TOP1mt/TDP1 cell line or an in vivo model such as transgenic zebrafish embryos could 
be utilised as positive controls in cell-based assays for development of TOP1mt 
inhibitors.  
7.7 Regulation of mitochondrial transcription in non-replicating cells 
The finding that TDP1 plays a direct role in maintaining mitochondrial function may also 
have implications in the fields of aging and neurodegeneration research. In 
differentiated postmitotic cells, regulation of mitochondrial transcription and translation 
are likely to be more crucial than mitochondrial DNA replication, as they allow more 
rapid adaptive response to mitochondrial stress. The TOP1mt-overexpressing Flp-In 
cell line may serve as a cellular model to investigate the effects of dysregulation of 
mitochondrial transcription independent of replication (Dalla Rosa, 2009). The Flp-In 
cells exhibit a high mitochondrial respiration rate both under basal and stressed 
conditions, which is reminiscent of highly aerobic cell types such as neurons. The 
tetracycline-inducible system also allows the distinction between short-term 
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mitochondria-regulated response and longer term retrograde nuclear response 
(Jazwinski, 2013).  
7.8 Future directions 
Several questions that arose from this project remain to be addressed: 
1. How does TDP1 SUMOylation promote its accumulation at sites of transcription-
mediated DNA damage? Could it be through interaction with SUMOylated TOP1, 
components of the transcription machinery, or other proteins? Mass spectroscopic 
analysis of TDP1 and TDP1K111R interacting proteins in the presence of DNA 
replication inhibitor aphidicolin could address this question.  
2. How does TDP1 translocate to the mitochondria? Does it rely on a PTM or protein-
protein interaction? Is it triggered by endogenous ROS? TDP1 does not appear to 
have a known mitochondrial targeting sequence in the NTD or mitochondrial 
isoform like many mitochondria-targeted DNA repair proteins. Although several 
groups have shown that TDP1 is present and active in the mitochondria without 
exogenously induced oxidative stress, its expression and translocation is stimulated 
by H2O2 and menadione in human fibroblasts (Fam et al., 2013). This further 
supports my findings that TDP1 functions as part of the anti-oxidant response by 
upregulating OXPHOS efficiency. SOD1G93A-overexpressing MEFs and Flp-In cells 
can be utilised to study translocation of TDP1 in response to endogenous ROS. 
Furthermore, since PTMs can regulate mitochondrial translocation of cytoplasmic 
proteins (Deng et al., 2011;  Zhang et al., 2012;  McBride et al., 2014), the 
TDP1S81A and TDP1K111R mutants can be similarly utilised.  
3. Does TDP1 interact with Lig3α in the mitochondria? If so, what role does Lig3 play 
in the function of TDP1 in the mitochondria? Our collaborator has previously shown 
that in Flp-In cells, Flag-TDP1S81E does not physically interact with endogenous 
Lig3α in the mitochondria (Meagher and Lightowlers, 2014), however the 
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interaction could be transient or abolished by the phosphomimetic mutation. 
Functional interaction could be assessed by depletion of Lig3α with or without co-
depletion of TDP1 using the Flp-In cells. 
4. Does the TDP1H493R catalytic mutation generate mtPDB’s that can contribute to loss 
of postmitotic neurons in SCAN1 patients? Flp-In cells complemented with 
TDP1H493R would be useful for initial assessment of the levels of mtTDP1-cc’s and 
mitochondrial bioenergetics profiles using protocols established in this thesis. 
Further work can be carried out in neurons reprogrammed from SCAN1 
lymphoblastoid cells or TDP1H493R knock-in neuronal cell lines using CRISPR 
technology.  
5. Does TOP1mt and/or TDP1 regulate mitochondrial transcription via R-loop 
formation? R-loop formation, especially at the OH, is intrinsically linked to regulation 
of mitochondrial transcription and replication (Brown et al., 2008;  El Hage et al., 
2014).  Nuclear TOP1 and TDP1 have both been demonstrated to reduce R-loop 
formation (El Hage et al., 2010;  Yeo et al., 2014). Given the opposing effects of 
TOP1mt and TOP1mt* on transcription in contrast to nuclear TOP1, it would be 
interesting to assess the level of mitochondrial R-loops in the Flp-In cell lines 
overexpressing TOP1mt or TOP1mt* in the presence and absence of TDP1. An 
increase in R-loops in TOP1mt-overexpressing cells in the absence of TDP1 would 
support the hypothesis that TOP1mt inhibits transcription through excessive 
relaxation of the transcription initiation region. It would also be interesting to identify 
TOP1mt*-binding protein partners at the OH in the presence or absence of TDP1 
using mass spectrometry.  
7.9 Conclusions 
To conclude, the main findings from this thesis comprise firstly of the identification and 
characterisation of novel factors involved in the regulation of TDP1 function, which can 
contribute to the rational design of combination therapies for neoplastic diseases; and 
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secondly of the characterisation of the protective role of TDP1 against oxidative stress, 
which can be utilised again in design of combination therapies for cancers, as well as 
design of novel cellular models to study the process of mitochondrial transcription in 
postmitotic cells.  
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